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 Emerging evidence has suggested that the circadian clock is a control tower 
in the regulation of behavioral and molecular processes under day/night cycle. Also, 
precise regulation of the circadian clock is crucial for maintaining whole-body energy 
homeostasis. Thus, dysregulation of the circadian clock is closely associated with 
obesity and metabolic complications. In metabolic organs, such as adipose tissue, 
muscle and liver, the circadian clocks affect various metabolic processes including 
lipogenesis, gluconeogenesis and lipid oxidation. Moreover, unsynchronized 
cooperation between the hypothalamic central clock and the peripheral clock, in shift 
workers, is prone to occur metabolic disorders. However, the pathophysiological role 
of the circadian clock and its metabolic regulatory processes have not been 
thoroughly elucidated.  
In this study, I have demonstrated that unsynchronized circadian clock 
influences hepatic glucose and lipid metabolisms without altering body weight. With 
the same amounts of caloric intake during different time periods, the expression 
patterns of peripheral circadian clock genes showed different by day time feeding and 
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night time feeding, while that of light-regulated hypothalamic circadian clock genes 
was not affected. For instance, the expression pattern of core circadian clock genes, 
such as BMAL1, CLOCK and PER2 in peripheral tissues, was altered by different 
feeding periods. In addition, hepatic expression of lipogenic genes, gluconeogenic 
genes, and fatty acid oxidation genes was also changed by feeding periods. In 
conclusion, it is likely that the amounts of food consumed might be a crucial factor 
to induce obesity compared to feeding time because feeding period restriction has no 
effects on body weight gain either normal chow diet (NCD) or high fat diet (HFD).  
In addition, I have revealed that feeding-induced CRY1 gene expression 
leads to suppression of hepatic gluconeogenesis. Given that SREBP1c is a well-
known transcriptional activator in postprandial state for activating lipogenesis, I 
found out that SREBP1c stimulated CRY1 gene expression. CRY1 was induced by 
feeding and insulin challenge. In addition, I have shown that hepatic SREBP1c 
contributed to repress gluconeogenesis through CRY1 induction. Hepatocytes 
overexpressing CRY1 inhibited hepatic gluconeogenic genes, such as PEPCK and 
G6Pase, via lowering FOXO1 protein. Furthermore, CRY1 was elevated in long term 
insulin action for sustainable suppression of hepatic gluconeogenesis. Intriguingly, 
SREBP1c-induced CRY1 accelerated FOXO1 degradation via ubiquitination. I 
discovered that CRY1 would act as a scaffold protein by binding with MDM2, an E3 
ubiquitin ligase, and FOXO1. Although SREBP1c is increased in obese diabetic 
animals, such as db/db mice and HFD fed mice, SREBP1c failed to stimulate CRY1 
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and thereby hepatic gluconeogenesis was not suppressed in obese animals. When I 
overexpressed CRY1 in the liver of db/db mice to test the CRY1 effects on 
gluconeogenesis suppression. CRY1 overexpression reduced blood glucose level as 
well as downregulated hepatic gluconeogenic gene expression. Taken together, these 
data suggest that circadian clock genes actively and dynamically regulate energy 
metabolism in the liver. Among many circadian clock genes, SREBP1c-induced 
CRY1 especially contributes to the suppression of hepatic glucose production through 
FOXO1 degradation in liver. However, body weight gain is mainly determined by the 
amounts of calorie intake rather than alteration of peripheral circadian clock gene. 
Therefore, it is likely that appropriate regulation of SREBP1c-CRY1 signaling 
pathway would be crucial for maintaining whole-body energy homeostasis.  
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1. Circadian clock and metabolic regulation 
 
(1) Circadian clock 
 
Circadian clocks control behavioral and molecular processes with the day 
and night cycle. The molecular circadian clock in mammals exists within pacemaker 
neurons of the suprachiasmatic nucleus (SCN) and peripheral tissues. The central 
SCN clock regulates standard time for peripheral tissue clock (Ramsey et al., 2007). 
Various physiological changes, such as sleep-wake cycles, body temperature, blood 
pressure, and hormone secretion, are associated with the circadian clock. Molecular 
circadian oscillation is composed of transcription-translational auto-regulatory 
negative feedback loops; BMAL1, CLOCK, PER, and CRY are key circadian 
molecules that produce rhythmic oscillations in a cell-autonomous manner (Thresher 
et al., 1998; Vitaterna et al., 1999). BMAL1 and CLOCK play key roles in inducing 
PER and CRY. Induced PER and CRY then form a transcriptional repressor complex 
to suppress BMAL1 and CLOCK, which eventually leads to negative feedback 
regulation (Figure 1). In addition, BMAL1 and CLOCK also increase the mRNA 
levels of Rev-erbα and RORα, which then compete to bind to the retinoic acid-related 
orphan receptor response elements (ROREs) in BMAL1 promoter and repress or 
activate the expression of BMAL1, respectively (Raspe et al., 2002; Tini et al., 1995). 









Figure 1. Molecular clock: circadian negative feedback loop.  
CLOCK and BMAL1, heterodimer initiates transcription of target genes such ‘period’ 
genes (PER1, PER2, and PER3) and two cryptochrome genes (CRY1 and CRY2). 
Negative feedback is achieved by PER/CRY complexes which translocate into the 
nucleus to suppress their own transcription by blocking the activity of the 
























Moreover, these auto-regulatory loops are modulated by various post-
translational modifications such as phosphorylation, sumoylation, acetylation, and 
ubiquitination. For instance, casein kinase phosphorylates the PER proteins for 
degradation via the Skp1, cullin1, F-box protein (SCF)/ B-TrCP ubiquitin ligase 
complex. Adenosine monophosphate kinase (AMPK) phosphorylates CRYs and 
leads to ubiquitin-mediated proteasomal degradation via the SCF/FBXL3 ubiquitin 
ligase complex (Lamia et al., 2009; Zheng et al., 2014). In addition, cellular NAD+ 
level regulates SIRT1 activity which participates in CLOCK protein deacetylation 
(Peek et al., 2013; Ramsey et al., 2009).   
Central SCN circadian oscillation is primarily regulated by light, whereas 
peripheral circadian oscillation is affected by food intake along with hormones such 
as insulin and glucagon (Gamble et al., 2014; Hoyle and O'Neill, 2013). These clocks 
regulate biological processes to maintain whole-body homeostasis with the 
environmental changes of light and nutrients (Figure 2). Many recent studies have 
shown that numerous aspects of metabolic regulation, such as circulating hormones, 
intracellular metabolites, and feeding behaviors, exhibit daily rhythmicity 
(Brandenberger and Weibel, 2004).  
(2) Circadian clock and metabolic regulation 









Figure 2. Light-dependent central clock and feeding-mediated peripheral clock.  
The master pacemaker within SCN, although clock genes are also expressed in other 
tissues such as liver, adipose tissue, and pancreas. Emerging evidence suggests that 





















with whole-body energy homeostasis. For example, the finding that participation of 
the orphan nuclear hormone receptors, Rev-erbα and the opposing RORα, in a short 
feedback loop by controlling BMAL1 transcription provides a direct evidence for 
metabolic input into the molecular clock (Raspe et al., 2002; Tini et al., 1995). In 
addition, peroxisome proliferator-activated receptor α (PPARα) and peroxisome 
proliferator-activated receptor gamma coactivator 1 α (PGC1α) also regulate 
BMAL1 transcription via circadian core feedback loop (Liu et al., 2007). Moreover, 
microarray analysis reveals that more than half of transcripts show rhythmic gene 
oscillation, with some variation among different tissues such as liver, skeletal muscle, 
and brown and white adipose tissue (Yang et al., 2006). The numbers of transcripts 
rhythmic oscillation are up to 20%, indicating that a large proportion of the 
transcriptomes seem to be affected by circadian genes. These oscillating genes are 
involved in biosynthetic and metabolic processes such as cholesterol and lipid 
metabolism, glycolysis and gluconeogenesis, oxidative phosphorylation, and 
detoxification pathways (Akhtar et al., 2002; McCarthy et al., 2007). Interestingly, 
most rate-limiting enzymes in these metabolic pathways are regulated by circadian 
clocks, implying that the clocks could influence on biosynthetic and metabolic 
processes whole-body metabolic homeostasis 
(3) Circadian clock and metabolic disorder 
In the aspect of clinical studies, several evidences suggest that circadian 
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disruption is associated with metabolic complications across large portions of the 
human population (Karlsson et al., 2001). Cross-sectional studies have revealed an 
increased prevalence of metabolic syndrome, such as high body mass index and 
cardiovascular events, in shift workers. These observations suggest the possibility 
that chronic disharmony between central and peripheral clocks, combined with 
light/dark and fasting/feeding, might contribute to body weight gain and metabolic 
complications (Kalra and Kalra, 2004). In addition, intriguing human behavioral 
studies propose that nocturnal feeding patterns might be related with metabolic 
diseases (Ayala et al., 2009). These findings have been recapitulated by recent rodent 
experimental studies, indicating that diet-induced obesity (DIO) with HFD may lead 
to increased energy intake only in the rest/light period and not in the active/dark 
period (Kohsaka et al., 2007). In addition, several rodent models have suggested that 
circadian clock regulation is associated with metabolic disease. For example, 
CLOCK-defective mice show increased body weight and hyperphagia with disrupted 
circadian oscillation (Turek et al., 2005). HFD-fed mice become obese and diabetic 
concomitantly with altered expression of circadian clock genes (Kohsaka et al., 2007). 
BMAL1 knockout mice show dysregulation of hepatic glucose homeostasis (Rudic 
et al., 2004). Furthermore, key metabolic genes, such as PPARα, PPARγ, and AMPK, 
are involved in the regulation of circadian genes, and the circadian clocks in turn 
modulate whole-body energy metabolism (Lamia et al., 2009; Schmutz et al., 2010; 
Wang et al., 2008a). In addition to rodent studies, the control of glucose metabolism 
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by circadian oscillation in humans is a well-known aspect of clinical diabetes 
management, and a variation of the normal cyclic pattern of glucose tolerance is an 
important indicator of type 2 diabetes (Allison et al., 2007; Tasali et al., 2008).  
Unsynchronized central and peripheral clocks caused by different regulation 
of light/dark cycle and the feeding/fasting cycle have been implicated in metabolic 
disorder, along with higher calorie intake in the case of shift-workers (Ellingsen et al., 
2007; Karlsson et al., 2001). Under physiological conditions, the central and 
peripheral clocks are synchronized by the light/dark cycle and the feeding/fasting 
cycle. However, it has been also demonstrated that disharmonious signaling by these 
two cues leads to the independent regulation of each circadian oscillation. Although 
it appears that there is a close relationship between the circadian clock and metabolic 
regulation, the effects of unsynchronized SCN and peripheral-tissue circadian clocks 
on metabolic regulation are largely unknown. In addition, it is still elusive whether 
feeding period alteration might be a key determinant of body weight change without 
change of total calorie intake.   
 
2. Hepatic lipid and glucose metabolism 
(1) Lipogenesis 
In liver, synthesis of triacylglycerides in liver is nutritionally and 
hormonally regulated. The ingestion of a high-carbohydrate diet causes a marked 
elevation of enzymes involved in key metabolic pathways, including glycolysis, 
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lipogenesis, fatty acid elongation and desaturation steps, and finally triacylglyceride 
synthesis. Especially, lipogenesis is the process that converts acetyl-CoA to fatty 
acids. Acetyl-CoA is an intermediate metabolite produced from glucose, a source of 
primary energy of living organisms. Through lipogenesis and subsequent 
triacylglyceride synthesis, the excess energy can be efficiently stored in the form of 
neutral lipid metabolites (Ferre and Foufelle, 2010). Acetyl-CoA carboxylase (ACC) 
converts acetyl-CoA to malonyl-CoA, and increased malonyl-CoA level leads to 
produce long chain fatty acids. This reaction is the controlling step in fatty acid 
synthesis and takes place in the cell cytosol. The overall synthesis of fatty acids is 
catalyzed by the fatty acid synthase (FASN) complex, a single polypeptide containing 
seven distinct enzymatic activities (Griffin and Sul, 2004).  
Sterol regulatory element binding proteins (SREBPs) including SREBP1a, 
SREBP1c, and SREBP2 belong to the basic-helix-loop-helix-leucine zipper (bHLH-
LZ) transcription factor family that regulates de novo lipogenesis and cholesterol 
biosynthetic pathway (Figure 3) (Brown and Goldstein, 1997). SREBP precursor 
consists of structurally three functional domains; an NH2-terminal domain that 
contains the bHLH-LZ region for DNA binding, two hydrophobic transmembrane 
spanning domains interrupted by a short loop which are inserted into the lumen of 
ER, and COOH-terminal domain that recruits the gene regulatory machinery (Figure 








Figure 3. Structure of SREBP isotypes.  
Sterol regulatory element binding protein (SREBP) was identified as a protein that 
bound to the sterol regulatory element (SRE). SREBPs are a family of transcription 
factors that control lipid homeostasis by regulating the expression of enzymes 
required for cholesterol, fatty acid, triacylglycerol, and phospholipid synthesis. 
SREBPs are synthetized as precursor forms bound to the endoplasmic reticulum 
membranes. Upon activation, the precursor undergoes a sequential two step cleavage 























SREBP cleavage-activating protein (SCAP) is a sensor of cholesterol, and escorts the 
SREBP from the ER to the Golgi, where there are two proteases involved in the 
cleavage (DeBose-Boyd et al., 1999; Tomita et al., 1998). In the Golgi apparatus, 
SREBP is released from the Golgi membrane through cleavage by Site-1 protease 
(S1P) and Site-2 protease (S2P). The NH2-terminal domain of SREBPs is 
translocated to the nucleus, where it stimulates target gene transcription by binding 
to sterol response elements (SREs) or E-BOX in the promoter/enhancer regions of 
various target genes (Kim et al., 1995).  
SREBP1c is the master regulator of de novo lipogenesis in fat tissue and 
liver (Shimomura et al., 1999a). Insulin, which is released from pancreatic β-cells, 
stimulates, leading to fatty acid synthesis during nutrient rich status (Kim et al., 
1998a). However, glucagon, which is released from pancreatic α-cells during fasting, 
suppresses SREBP1c mediated lipogenic action (Lee et al., 2014a). SREBP1c 
regulates lipogenic pathways by stimulating the expression of fatty acid synthase 
(FASN), stearoyl-CoA desaturase 1 (SCD1) and acetyl-coenzyme A carboxylase 
(ACC) (Kim et al., 1998a; Shimomura et al., 1999b). The level of SREBP1c falls in 
streptozotocin-treated animals by accelerating pancreatic β-cell apoptosis and 
increases after insulin injection (Shimomura et al., 1999b). Moreover, overexpression 
of nuclear SREBP1c in livers of transgenic mice prevents the reduction of lipogenic 
action in fasting (Takahashi et al., 2005). Taken together, accumulating evidences 
indicate that SREBP1c is a key player in insulin-mediated lipogenic activation in liver.  
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(2) Glucose metabolism 
During fasting, most animals maintain energy balance by shifting from 
glucose utilization to fat burning. The levels of glycogenolysis and gluconeogenesis 
are increased to provide glucose as an energy source in many organs and tissues such 
as the brain and the red blood cell compartment, which are deficient in enzymes for 
burning free fatty acids (Altarejos and Montminy, 2011; Roach et al., 2012). Fasting 
also triggers elevation of circulating free amino acids, which are also major 
precursors for hepatic glucose production. When fasting is prolonged, hepatic 
gluconeogenesis is blocked to protect against excessive muscle wasting by over-
converting protein to glucose, and liver derived ketone bodies become the primary 
energy source for the brain (Morris, 2005).  
During fasting, elevated levels of circulating pancreatic glucagon stimulate 
the gluconeogenic program through the activation of the protein kinase A (PKA) 
pathway. Increased cAMP levels activate PKA, then gluconeogenic genes such as 
phosphoenol pyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase) 
are upregulated (Montminy et al., 2004). cAMP response element binding protein 
(CREB), one of major regulators of hepatic gluconeogenesis, binds to promoters for 
the PEPCK and G6Pase genes to directly stimulate the gluconeogenic program. The 
significance of CREB in the activation of hepatic gluconeogenesis has been revealed 
by a study utilizing albumin-ACREB TG mice overexpressing a dominant negative 
CREB in liver (Herzig et al., 2001). These mice show lower blood glucose levels with 
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downregulated mRNA levels for hepatic gluconeogenic genes, indicating that CREB 
is a physiological transcriptional regulator of gluconeogenesis in vivo. 
In parallel, decrement of insulin signaling upon fasting also stimulates 
gluconeogenic gene expression through dephosphorylation and nuclear translocation 
of the forkhead box (FOXO) domain proteins (Matsumoto and Accili, 2005). FOXO1 
belongs to a subclass of the forkhead family of transcription factors which have a 
forkhead box type DNA binding domain. FOXO1 recognizes insulin response 
element (IRE) located in the promoters of PEPCK and G6Pase. Regulation of 
subcellular localization of FOXO1 is one of the important regulatory pathways to 
control its activity, which is modulated by the phosphorylation status of Ser/Thr 
residues. Insulin and PI3K signaling pathway activates AKT-dependent 
phosphorylation of FOXO1 and phosphorylated FOXO1 binds with 14-3-3 shuttle 
protein to translocate to the cytoplasm (Nielsen et al., 2008; Tzivion et al., 2011; 
Wang et al., 2006). The cytoplasm-localized FOXO1 then undergoes subsequent 
degradation by an ubiquitin-proteasome pathway. Although the translocation of 
hepatic FOXO1 from the nucleus to the cytoplasm is a well-defined mechanism 
mediating a quick decrease in glucose production by insulin, it is largely unknown 
how insulin provides a sustainable inhibition of hepatic gluconeogenesis during the 
postprandial state. 
Interestingly, SREBP1c appears to be involved in hepatic carbohydrate 
metabolism. For example, SREBP1c affects the mRNA levels of PEPCK, G6Pase, 
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and IRS-2 genes and inhibits the interaction between HNF4 and PGC1α to suppress 
gluconeogenic genes (Lee et al., 2007; Yamamoto et al., 2004). Although it has been 
reported that hepatic SREBP1c suppresses hepatic glucose production, the molecular 
mechanism(s) by which SREBP1c could repress hepatic gluconeogenesis is unclear. 
(3) Selective insulin resistance in liver 
Under nutrient rich status, pancreatic β-cell secrets insulin, which is one of 
the major anabolic hormones in human body. Insulin accelerates glucose uptake in 
fat tissue and muscle as well as inhibits hepatic gluconeogenesis for lowering blood 
glucose level (Biddinger and Kahn, 2006). Moreover, insulin elevates lipogenic 
activity to store excess energy as triacylglyceride in liver and fat tissue (Kim et al., 
1998a).  
Type 2 diabetes are closely associated with hyperinsulinemia, 
hyperglycemia, and hypertriacylglyceridemia. Insulin resistance is one of the 
characteristics of type 2 diabetes. In insulin resistant animals, increased insulin is not 
enough to lower blood glucose, and consequently hyperglycemia reveals (Saltiel and 
Kahn, 2001). In diabetic subjects, liver, muscle, and adipose tissue are the major 
insulin resistant organs and the precise contributions of each organ to hyperglycemia 
and hypertriacylglyceridemia are unclear.   
Upon feeding conditions, increased plasma insulin levels elicit two key 
actions at the level of gene expression, at least, in the liver. First, insulin activates 
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transcription factor SREBP1c which enhances transcription of genes required for 
fatty acid and triacylglyceride biosynthesis such as ACC and FASN (Kim et al., 
1998a). In liver, the newly synthesized triacylglycerides are secreted in the form of 
very low density lipoproteins (VLDL), which are delivered to adipose tissues for 
storage and to muscles for fueling. The uptake of VLDL-derived fatty acids in adipose 
tissue is facilitated by insulin, which activates lipoprotein lipase on the surface of 
endothelial cells (Bourgeois et al., 1995; Lewis et al., 1994). Second, insulin 
stimulates the phosphorylation of FOXO1, a transcription factor that activates 
gluconeogenesis (Puigserver et al., 2003; Schilling et al., 2006; Xiong et al., 2013). 
Insulin-mediated FOXO1 phosphorylation prevents FOXO1 from entering the 
nucleus, which downregulates the expression of genes required for gluconeogenesis, 
including PEPCK and G6Pase. Blocking of hepatic glucose production by insulin is 
one of the crucial pathways to maintain blood glucose homeostasis. Interestingly, in 
diabetic liver, FOXO1 pathway becomes insulin resistant whereas SREBP1c-
mediated lipogenesis shows insulin sensitive (Figure 4)  (Brown and Goldstein, 
2008). Despite extremely high insulin levels, the mRNAs of PEPCK and G6Pase 
remain high, and gluconeogenesis continues in diabetic liver. Moreover, since nuclear 
SREBP1c levels are high, fatty acid synthesis is accelerated and triacylglycerides are 
accumulated, leading to hepatic steatosis (Lee et al., 2014a). Further, elevated hepatic 
triacylglycerides are secreted via VLDL, raising plasma triacylglyceride levels in 







Figure 4. Selective insulin resistance in liver.  
(A) Normal insulin response in liver. Insulin activates SERBP1c-mediated 
lipogenesis whereas inhibits gluconeogenesis. (B) Selective insulin resistance in liver 
of type 2 diabetes. Hyperinsulinemia still activates lipogenic action while is not able 
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aggravate insulin resistant state in muscle and adipose tissue, and the net results 
become hyperglycemia, hyperinsulinemia, and hypertriacylglyceridemia in type 2 
diabetic animals (Figure 4).  
An understanding the selective insulin resistance in diabetic liver is 
important for providing appropriate approaches to type 2 diabetes. Although it has 
been reported that hepatic SREBP1c is upregulated in obese animals, it is unknown 
why increased SREBP1c appears to fail to repress hepatic gluconeogenesis. Thus, it 
is crucial that understanding the molecular mechanisms by which SREBP1c could 
modulate gluconeogenesis under physiological and pathological conditions.   
 
 
3. Purpose of this study 
Circadian clock has a close correlation with metabolic regulation. Feeding 
is a major trigger that modulates the peripheral circadian clock while light activates 
the central circadian clock. These biological clocks are synchronized and synergically 
regulates various whole-body homeostasis including metabolism, body temperature, 
and sleep/wake cycle. Emerging evidence for the roles of circadian clock in metabolic 
tissues, such as adipose tissue, liver and muscle, proposes that the circadian clock 
actively interacts with metabolic signaling pathway to maintain the whole-body 
biological clock and energy homeostasis.  
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In this study, I have focused on body weight change according to feeding 
period restriction to investigate whether the restriction of feeding periods may affect 
body weight gain upon NCD and HFD. Whether the modulated peripheral circadian 
clock or the different amounts of food intake might be the primarily cause of obesity 
in shift workers is unclear. I have demonstrated that body weight gain in mice is not 
significantly changed by restricting feeding period to daytime or to nighttime if the 
animals take same calorie intake. On the contrary, the expression of peripheral 
circadian clock genes was altered by feeding period restriction, while the expression 
of light-regulated hypothalamic circadian clock genes was unaffected by both a NCD 
and HFD. The expression of lipogenic genes, gluconeogenic genes, and fatty acid 
oxidation related genes in the liver was also altered by feeding period restriction. 
Given that feeding period restriction does not affect body weight gain with both a 
NCD and HFD, it is likely that the amount of food consumed might be a crucial factor 
in determining body weight. In the second part, I have aimed to find out the new 
target gene of SREBP1c to find the signaling pathway that suppresses the 
gluconeogenesis. Although SREBP1c suppresses hepatic glucose production, the 
underlying molecular signaling pathway is unclear. To find out missing link between 
SREBP1c and inhibition of gluconeogenesis, I discovered CRY1 as a new target gene 
of SREBP1c. With fasting and refeeding experiment, I have shown that CRY1 is 
increased by feeding and insulin, which suppresses hepatic glucose production by 
FOXO1 degradation. Taken together, I would like to propose that the interpretation 
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of the relationship between circadian clock and hepatic glucose/lipid metabolism is 
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Accumulating evidence suggests that circadian clock is closely associated 
with metabolic regulation. However, it has not been clearly understood whether 
impaired circadian clock is a direct cause of metabolic dysregulation including body 
weight gain. In this study, I demonstrate that mice body weight gain is not 
significantly changed by feeding period restriction; ad libitum, day time feeding and 
night time feeding. Expression of peripheral circadian clock genes was altered by 
feeding period restriction, while that of light-regulated hypothalamic circadian clock 
genes was not affected with either normal chow diet (NCD) or high fat diet (HFD). 
In liver, the expression pattern of circadian clock genes including BMAL1, CLOCK, 
and PER2 was changed by different restrictions of feeding period. Moreover, the 
expression of lipogenic genes, gluconeogenic genes, and fatty acid oxidation-related 
genes was also altered in liver by feeding period restriction. Taken together, these 
data suggest that restriction of feeding period would modulate expression of 
peripheral circadian clock genes, which is uncoupled from light-sensitive 
hypothalamic circadian clock genes, even though feeding period restriction might not 
be a crucial factor to affect body weight gain under NCD or HFD, implying that the 






Various physiological and behavioral oscillations such as sleep-wake cycles, 
body temperature, blood pressure, and hormone secretion are associated with 
circadian clock (Bass and Takahashi, 2010). Circadian oscillation is composed of 
auto-regulatory negative feedback loops; BMAL1, CLOCK, PER, and CRY are key 
circadian transcription factors that determine rhythmic oscillation in a cell-
autonomous manner. BMAL1 and CLOCK play a key role to induce PER and CRY. 
Then, elevated PER and CRY form a transcriptional repressor complex to suppress 
BMAL1 and CLOCK, which eventually leads to negative feedback regulation. In 
addition to the PER and CRY targets, BMAL1 and CLOCK also activate mRNA level 
of Rev-erbα and RORα, which thereafter compete for binding to the retinoic acid 
related orphan receptor response elements (ROREs) as to repress or activate 
expression of Bmal1, respectively. This alternating promoter occupancy is due to 
rhythmic expression of Rev-erbα (Green et al., 2008). In addition, these auto-
regulatory loops are modulated by various post-translational modifications such as 
phosphorylation, sumoylation, acetylation, and ubiquitination (Lamia et al., 2009; 
Nakahata et al., 2009; Shirogane et al., 2005).  
Circadian clock exists in the hypothalamic suprachiasmatic nucleus (SCN) 
as well as peripheral tissues including liver and fat (Bass and Takahashi, 2010). SCN 
circadian oscillation is primarily regulated by light signal whereas peripheral 
circadian oscillation is affected by food intake accompanied by hormones such as 
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insulin and glucagon (Green et al., 2008). Emerging evidences have suggested that 
circadian clock is deeply associated with whole-body energy homeostasis. For 
instance, CLOCK defective mice exhibit obesity and hyperphagia with disrupted 
circadian oscillation (Turek et al., 2005). High fat diet (HFD) fed wild type mice 
become obese and show altered expression of circadian clock genes with metabolic 
dysregulation (Kohsaka et al., 2007). Further, liver specific Bmal1 knockout mice 
lose their hepatic glucose homeostasis (Canaple et al., 2006). Moreover, key 
metabolic genes such as PPARα, PPARγ, and AMPK are involved in the regulation 
of circadian genes, and circadian clocks in turn modulate whole-body energy 
metabolism (Canaple et al., 2006; Lamia et al., 2009; Wang et al., 2008b). Under 
physiological conditions, SCN clock and peripheral clock are synchronized by light-
dark cycle and feeding-fasting cycle. Nonetheless, it has been also demonstrated that 
disharmonious signaling of these two cues, light-dark cycle and feeding-fasting cycle, 
independently regulates each circadian oscillation (Damiola et al., 2000). Although it 
appears that there is a close relationship between circadian clock and metabolic 
regulation, the effects of unsynchronized circadian clocks in SCN and peripheral 
tissues on metabolic regulation are largely unknown. In addition, it is unclear whether 
alteration of feeding periods would be a major determinant of body weight change 
even when there is no change of calorie intake.  
In this study, I have investigated whether the restriction of feeding periods 
may affect body weight gain upon NCD and HFD. Also, I have analyzed gene 
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expression profiles of circadian clocks from SCN and peripheral tissue under different 
feeding periods. Our data suggest that feeding period restriction would not influence 
body weight gain whereas it would differently regulate circadian oscillations in 

















Animal care and experimental protocol 
 Four-week-old male C57BL/6N mice were obtained from SAMTAKO BIO 
KOREA Co., Ltd. Mice were maintained according to the guidelines of Seoul 
National University Animal Experiment Ethics Committee. They were housed in 
individual cages for pair feeding in 12 hr light/ 12 hr dark cycles. After a minimum 
1-week stabilization period, ad libitum group mice (5 weeks old) were exposed to 
food freely, and the night time fed mice were pair fed to match the amount of food of 
day time group with NCD and 60% HFD (Research Diets, Inc.) for 4 weeks (Figure 
5). Only those pair-fed mice (night time fed) with similar body weights as those of 
day time fed mice were subjected to the procedure from 5 weeks of age to 9 weeks of 
age. Body weight and food intake were measured daily at ZT0 (7 a.m.) and ZT12 (7 
p.m.) during the experimental protocol. The average initial body weights in each 
group of mice were not different. All mice were euthanized, and dissected tissue 
specimens were immediately stored at -80C until analysis.  
 
Quantitative real-time RT-PCR analysis 
Total RNAs were isolated from liver and hypothalamus as described 
previously (Choe et al., 2007), and cDNA was synthesized using the M-MuLV reverse 
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transcriptase kit (Fermentas, Glen Burnie, MD). The primers used for the real-time 
PCR analyses were produced in Bioneer (Korea). The primer sequences used for real-
time PCR analyses are provided in supplementary Table 1. 
  
Biochemical analysis 
The levels of plasma cholesterol and triacylglycerides were measured using 
Infinity reagents (Thermo, Melbourne, Australia). Plasma glucose levels were 























 Feeding period restriction does not change body weight gain 
  To address the question whether body weight gain is sensitively altered by 
feeding behavior, accompanied with changes of circadian clock genes, I have 
investigated the effects of feeding period restriction on body weight. Restriction of 
feeding period has been designed with the following three groups: 1) ad libitum in 
which mice were freely exposed to food, 2) restriction feeding to day time (RF Day), 
in which mice could access food only in day time, and 3) pair-feeding in night time 
(PF Night), in which mice were given the same amount of food as the RF Day group 
only in night time (Figure 5). Since mice are nocturnal animals that would take most 
food at night time than during day time, I measured the amount of food intake in day 
time, and the same amount of food was given to night time feeding (PF Night) group. 
I have designed the pair-feeding group to investigate the effect of feeding period 
variation on body weight with the same amount of calorie intake. Moreover, mice 
were fed with either normal chow diet (NCD) or high fat diet (HFD) in order to test 
the effects of different nutrition sources on body weight gain upon feeding period 
restriction. 
Interestingly, I observed that RF Day and PF Night groups revealed a similar 
pattern of body weight gain, regardless of diet source (NCD or HFD) (Figure 6A, 6B, 







Figure 5. Feeding period restriction scheme for the three feeding groups in this 
study.  
The ad libitum (AL) group was freely exposed to food; the feeding restricted to day 
time (RF Day) group could access food only during daytime; and the pair-feeding at 
night (PF Night) group was given the same amount of food as the RF Day group but 
only at night. Mice were fed with a normal chow diet (NCD) or a high-fat diet (HFD). 
The light was turned on at ZT0 and turned off at ZT12. At ZT2 and ZT14, mice were 




























Figure 6.  Feeding period restriction does not change body weight gain.  
(A and B) Body weight gain or total body weight of AL, RF Day, and PF Night NCD-
fed mice. (C) Total food intake in NCD-fed AL and RF Day mice. (D and E) Body 
weight gain or total body weight of AL, RF Day, and PF Night HFD-fed mice. (F) 
Total food intake in HFD-fed AL and RF Day mice. Each bar represents mean ±SD 
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body weight gain of ad libitum group was significantly increased with either NCD 
or HFD (Figure 6A, 6B, 6D, 6E). When the amounts of cumulative food intakes 
were measured, ad libitum group gradually consumed more food than RF Day or PF 
Night group (Figure 6C, 6F). Recently, it has been reported that circadian clock is 
disrupted by HFD (Kohsaka et al., 2007). Thus, I examined food intake patterns 
during day time (ZT0-ZT12) and night time (ZT12-ZT24) time periods in ad libitum 
group. Expectedly, mice ate more food during night time period than day time 
periods (Figure 7). Interestingly, it seemed that HFD fed mice slightly, but 
substantially, consumed more food in day time period than NCD fed mice (Figure 
7). These data suggest that the amount of food intake rather than feeding periods 
would be a major determinant of body weight gain, which is both applicable in 
different nutrition sources such as NCD and HFD.   
 
Day time feeding changes the expression of circadian clock genes in liver but 
not in hypothalamus 
I next investigated the expression of circadian clock genes upon feeding 
period restriction. In order to examine the expression profiles of circadian clock genes, 
mice were sacrificed at ZT2 and ZT14, which may reflect different expression pattern 
of circadian clock genes in 12:12 light-dark cycle. Total RNAs were isolated from 









Figure 7. Ad libitum calorie intake during day and night with NCD and HFD 
feeding.  
























respectively, and analyzed by qRT-PCR. As shown in Figure 8 and 9, the expression 
patterns of circadian clock genes such as BMAL11, PER2 and CLOCK were altered 
by feeding period restrictions in liver but not in hypothalamus with either NCD or 
HFD. Overall, ad libitum group and PF Night group showed the similar expression 
patterns of circadian clock genes in liver, which would be resulted from the behavior 
of nocturnal mice that took most food during night time. In contrast, in liver, RF Day 
group revealed distinct expression pattern of circadian genes from either ad libitum 
or PF Night group. Unlike liver, the expression patterns of hypothalamic circadian 
genes were not changed by feeding period restrictions with either NCD or HFD 
(Figure 8, 9). These data strongly indicate that feeding period restriction would 
influence expression of circadian clock genes in peripheral tissues, probably via 
modulating nutritional hormones such as insulin or glucagon, which may not affect 
expression of circadian clock genes in hypothalamus.   
 
Feeding period restriction alters expression of metabolic genes and plasma 
metabolites  
It is well known that feeding is one of important factors to regulate circadian 
clock genes as well as hepatic lipid and glucose metabolism (Kohsaka et al., 2007; 
Lamia et al., 2008). Given that RF Day changed expression patterns of hepatic 
circadian clock genes, I decided to examine whether RF Day might also influence 








Figure 8. Daytime feeding changes expression of circadian clock genes in the 
liver but not in the hypothalamus in NCD.  
Hepatic and hypothalamic BMAL1, PER2, and CLOCK gene expression profiles in 
AL, RF Day, and PF Night NCD-fed mice at ZT2 and ZT14. All RNA samples are 
normalized to TBP mRNA. Each bar represents mean ±SD of each group of mice 






















Figure 9. Daytime feeding changes expression of circadian clock genes in the 
liver but not in the hypothalamus in HFD.  
Hepatic and hypothalamic BMAL1, PER2, and CLOCK gene expression profiles in 
AL, RF Day, and PF Night HFD-fed mice at ZT2 and ZT14. All RNA samples are 
normalized to TBP mRNA. Each bar represents mean ±SD of each group of mice 
















PCR from NCD (Figure 10A, 10B, 10C) or HFD (Figure 11A, 11B, 11C) fed mice at 
ZT2 and 14. In order to conjecture key metabolic changes, I have investigated 
expression of several lipid and carbohydrate metabolism genes such as SREBP1c, 
FASN, PEPCK, G6PASE, PPARα, and CPT1. Since SREBP1c is a master 
transcription factor for lipogenesis, it regulates the expression of FASN upon 
nutritional and hormonal changes (Kim et al., 1998a; Kim and Spiegelman, 1996; 
Kim et al., 1995; Kim et al., 1998b; Kim et al., 2004). Under NCD feeding, expression 
of SREBP1c mRNA was greatly suppressed in RF Day at ZT14, while it was up-
regulated at ZT14 in PF Night (Figure 10A). Despite of this, FASN did not show 
significant change at ZT2 and 14 in RF Day and PF Night, implying that it may need 
several hours to reflect SREBP1c target gene expression in vivo. Upon HFD feeding, 
FASN was increased in RF Day at ZT2, while it was not altered in PF Night (Figure 
11A). Conversely, the expression of gluconeogenic genes such as PEPCK and G6Pase, 
which are well known as fasting-induced genes, was not changed at ZT2 and 14 both 
in RF Day and PF Night in NCD (Figure 10B). When fatty acid oxidation genes such 
as PPARα and CPT1 were analyzed, their mRNA levels were not significantly 
different in RF Day and PF Night groups (Figure 10C). These data propose that 
expression of several metabolic genes might to be partly altered by feeding period 
restriction but not as much as that of circadian clock genes in liver. 
Since feeding period restriction altered expression of subset of metabolic 







Figure 10. Feeding period restriction changes the expression of metabolic genes 
in NCD fed mice.  
(A) Expression profiles of lipogenic genes such as SREBP1c and FASN in AL, RF 
Day, and PF Night NCD-fed mice at ZT2 and ZT14. (B) Expression profiles of the 
gluconeogenic genes PEPCK and G6Pase in AL, RF Day, and PF Night NCD-fed 
mice at ZT2 and ZT14. (C) Expression profiles of the fatty acid oxidation genes 
PPARα and CPT1 in AL, RF Day, and PF Night NCD-fed mice at ZT2 and ZT14. All 
RNA samples are normalized to TBP mRNA. Each bar represents mean ± SD of each 





















Figure 11. Feeding period restriction changes the expression of metabolic genes 
in HFD fed mice.  
(A) Expression profiles of lipogenic genes such as SREBP1c and FASN in AL, RF 
Day, and PF Night HFD-fed mice at ZT2 and ZT14. (B) Expression profiles of the 
gluconeogenic genes PEPCK and G6Pase in AL, RF Day, and PF Night HFD-fed 
mice at ZT2 and ZT14. (C) Expression profiles of the fatty acid oxidation genes 
PPARa and CPT1 in AL, RF Day, and PF Night HFD-fed mice at ZT2 and ZT14. All 
RNA samples are normalized to TBP mRNA. Each bar represents mean ± SD of each 

















relevant to whole-body energy state, in different feeding period restriction groups. 
Although it has been reported that serum metabolite levels are varied throughout 
feeding-fasting cycle (Morris et al., 2012), our experimental windows limited at ZT2 
and 14 did not sensitively reflect whole-body energy state. When I measured serum 
glucose, triacylglyceride (TG), and cholesterol levels at ZT2 and 14, I failed to 
observe distinct patterns of those metabolites. Nonetheless, in PF Night group, the 
levels of serum glucose, TG, and cholesterol were higher at ZT2 than at ZT14 under 
NCD, implying that there might be a correlation between peripheral circadian 
oscillation and serum metabolites (Figure 12A, 12B, 12C). On the contrary, HFD 
challenged animals exhibited disrupted serum metabolite profiles as previously 
reported (data not shown) (Hatori et al., 2012). These data indicate that feeding period 
restriction may modulate the profiles of several serum metabolites without changes 
in body weight gain, concomitant with alteration of circadian clock genes as well as 













Figure 12. Feeding period restriction changes plasma metabolites.  
(A) Serum glucose levels in AL, RF Day, and PF Night NCD-fed mice at ZT2 and 
ZT14. (B) Serum TG levels in AL, RF Day, and PF Night NCD-fed mice at ZT2 and 
ZT14. (C) Serum cholesterol levels in AL, RF Day, and PF Night NCD-fed mice at 
























Obesity is characterized by increase of adipose tissue and lipid metabolism, 
which is caused by chronic excess of energy intake than energy expenditure. Very 
recent reports have suggested that feeding period restriction would be an important 
factor to influence body weight gain, leading to obesity (Arble et al., 2009; Hatori et 
al., 2012). Since Arble et al. have reported that day time HFD-fed mice were more 
obese than night time HFD-fed mice with no differences in calorie intake and activity 
(Arble et al., 2009), it has been proposed that change of feeding behavior by shifting 
from nigh to day time would be an important factor to regulate energy metabolism 
contribute to. In accordance with this, it has been reported that night-eating syndrome 
in human might lead to weight gain as a result of excess calories consumption at night 
(Aronoff et al., 2001; Colles et al., 2007; Tholin et al., 2009). On the contrary, several 
studies have revealed that there is no correlation of night eating syndrome and body 
weight gain in human (Gluck et al., 2008; Striegel-Moore et al., 2008; Striegel-Moore 
et al., 2004). Nonetheless, it has not been clearly understood whether dysregulation 
of any circadian clock gene expression is an essential factor to alter body weight gain.  
In the present work, I have investigated the relationship between body 
weight gain and feeding period restriction by providing the same amount of food at 
either night time or day time. I observed that feeding period restriction evidently 
altered expression pattern of peripheral circadian clock genes, provably via nutrition 
sensitive hormones. However, the expression of central circadian clock genes in 
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hypothalamus was not modulated by feeding restriction regardless of NCD or HFD. 
These data implied that central circadian clock and peripheral circadian clock would 
be independently regulated, at least, at transcriptional level, upon feeding period 
restriction (Damiola et al., 2000). Furthermore, hepatic expression of metabolic genes 
including lipogenesis, gluconeogenesis, and fatty acid oxidation were modulated 
upon feeding period restriction. Similarly, the levels of serum glucose, 
triacylglyceride, and cholesterol were also adjusted by feeding period restriction. 
Despite these changes of peripheral metabolic gene expression, there were no 
significant body weight differences between RF Day and PF Night groups with NCD 
or HFD, indicating that the change of peripheral circadian clock genes may not be a 
key factor to influence body weight. Instead of feeding behavior, it appears that the 
amount of energy intake would be a crucial factor to determine body weight, which 
might be closely linked with central circadian genes. 
It has been reported that, HFD challenge disrupts behavioral and 
physiological circadian rhythms. For instance, HFD leads to alterations in the period 
of the locomotor activity and canonical circadian clock genes (Wang et al., 2008b). 
In this study, I observed that HFD fed mice exhibited distinct expression patterns of 
subset genes in liver, including circadian clock genes and metabolic genes, compared 
with NCD fed mice. In addition, ad libitum group exhibited different food 
consumption patterns depending upon nutrition source. HFD challenged mice 
consumed more food intake in day time than NCD challenged mice, implying that 
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food intake control would be dysregulated in HFD fed group. Since fasting period of 
HFD group might be shorter than that of NCD fed group under ad libitum (Kohsaka 
et al., 2007), it appears that NCD fed group might gain less body weight compared 
with HFD fed group through activation of fasting-induced signals with SIRT1 and 
AMPK, which mediated energy expenditure to burn extra energy (Canto et al., 2010; 
Kohsaka et al., 2007). Of course, I cannot rule out the possibility that physical activity 
or body temperature may contribute to compensate for body weight gain, which will 
be investigated in further study.  
Disruption of circadian clock genes is exerted by various stimuli such as 
changes of light/dark cycle and food consumption. Interference of central circadian 
clock by light time modulation affects body weight gain (Karatsoreos et al., 2011). 
For instance, 10:10 light-dark (LD) cycle leads to body weight gain compared with 
12:12 LD cycle, and 10:10 LD cycle regime increases several metabolic parameters 
such as plasma leptin, insulin, and glucose (Karatsoreos et al., 2011). Moreover, 
circadian clock defective mice such as clock gene mutant mice and HFD fed mice 
show irregular food intake pattern, accompanied with obesity due to increased food 
intake (Damiola et al., 2000; Turek et al., 2005). In contrast, Bmal1 deficient mice 
show obese phenotype during 5 weeks of HFD, whereas they are no longer obese 
with 15 weeks of HFD (Hemmeryckx et al., 2011). However, liver-specific Bmal1 




Here, I revealed that feeding period restriction selectively alters expression 
patterns of peripheral circadian clock genes without body weight gain, concomitant 
with adjusted levels of metabolic genes and plasma profiles. Therefore, it is plausible 
to speculate that central circadian clock might play a key role to regulate body weight 
through regulation of energy intake and expenditure. Consistently, it appears the 
amounts of calorie intake would be a major factor to change body weight (Figure 13). 
On the contrary, peripheral circadian clock genes sensitively respond to changes of 
metabolic alterations upon nutrients and hormones. The exact molecular mechanism 
of central circadian clock to influence body weight gain remains to be elucidated. In 
conclusion, our data suggest that feeding period restriction would selectively 
modulate peripheral circadian clocks and metabolic regulation without a significant 









































Hyperglycemia is exacerbated by dysregulation 












SREBP1c is a key transcription factor of lipogenesis to store excess energy 
in postprandial state. Although SREBP1c appears to be involved in suppression of 
hepatic gluconeogenesis, the molecular mechanism(s) by which insulin-activated 
SREBP1c could repress hepatic gluconeogenesis is not thoroughly understood. Here, 
I demonstrate that CRY1 activation by insulin-induced SREBP1c led to decrease 
hepatic gluconeogenesis through FOXO1 degradation. In accordance with these, 
SREBP1c-/- and CRY1-/- mice showed higher blood glucose than wild type (WT) mice 
during pyruvate tolerance test, accompanied with enhanced expression of PEPCK and 
G6Pase genes. Moreover, CRY1 promoted degradation of nuclear FOXO1 by MDM2, 
one of the ubiquitin E3 ligases, by enhancing binding of FOXO1 and MDM2. 
Although hepatic SREBP1c failed to upregulate CRY1 expression in db/db mice, 
overexpression of CRY1 led to attenuate hyperglycemia through reduction of hepatic 
FOXO1 protein as well as gluconeogenic gene expression. Collectively, these data 
suggest that insulin-activated SREBP1c downregulates hepatic gluconeogenesis 
through CRY1-mediated FOXO1 degradation and thereby dysregulation of 







Insulin, which is released from pancreatic β-cells, plays a key role in the maintenance 
of the whole-body energy homeostasis by actively regulating glucose and lipid 
metabolism. In the postprandial state, insulin lowers blood glucose by stimulating 
glucose uptake in adipose tissues and muscles as well as by inhibiting hepatic glucose 
production (Puigserver et al., 2003; Summers and Birnbaum, 1997). Moreover, in the 
liver, insulin stimulates the conversion of excess glucose into glycogen (glycogenesis) 
and triacylglyceride (lipogenesis) for the long term energy storage (Moller, 2001; 
Wang et al., 2013; Wong et al., 2009).  
Suppression of hepatic gluconeogenesis by insulin is an important process 
to inhibit hyperglycemia. PEPCK and G6Pase are crucial enzymes that convert 
pyruvate to glucose, and their gene expression is regulated by several transcription 
factors such as Forkhead box O1 (FOXO1), cAMP Response Element-Binding 
protein (CREB), Hepatocyte Nuclear Factor 4 (HNF4), Glucocorticoid Receptor 
(GR), and Peroxisome proliferator-activated receptor Gamma Coactivator 1-Alpha 
(PGC1α) (Mouchiroud et al., 2014; Sugden et al., 2010; Yoon et al., 2001). In the 
liver, FOXO1 is activated upon fasting and gets inactivated by feeding, which is one 
of the essential mechanisms by which insulin rapidly and efficiently represses hepatic 
glucose production during postprandial periods (Accili and Arden, 2004; Kops et al., 
1999; Lu et al., 2012). After insulin treatment, FOXO1 protein is phosphorylated by 
AKT and then moves to the cytoplasm, resulting in the decrease of gluconeogenic 
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gene expression(Matsumoto and Accili, 2005). Although the translocation of hepatic 
FOXO1 from the nucleus to the cytoplasm is a well-defined mechanism mediating a 
quick decrease in glucose production by insulin, it is largely unknown how insulin 
endows a sustainable inhibition of hepatic gluconeogenesis during the postprandial 
state. 
 On the other hand, it has been proposed that SREBP1c might be involved in 
hepatic glucose metabolism. SREBP1c is a basic-helix-loop-helix-leucine zipper 
(bHLH-LZ) transcription factor that regulates de novo lipogenesis (Brown and 
Goldstein, 1997; Fajas et al., 1999; Moon et al., 2012; Tontonoz et al., 1993; 
Yokoyama et al., 1993). Activation of SREBP1c is mediated by AKT and mTORC1 
upon insulin signaling (Laplante and Sabatini, 2010; Peterson et al., 2011). SREBP1c 
regulates lipogenic pathways by stimulating the expression of target genes such as 
those encoding fatty acid synthase (FASN), stearoyl-CoA desaturase 1 (SCD1) and 
acetyl-coenzyme A carboxylase (ACC) (Horton et al., 2003; Kim et al., 1998a; Liang 
et al., 2002). In addition, SREBP1c appears to be involved in hepatic carbohydrate 
metabolism. For example, SREBP1c affects the mRNA levels of PEPCK, G6Pase, 
and IRS-2 genes and inhibits the interaction between HNF4 and PGC1α to suppress 
gluconeogenic genes (Becard et al., 2001; Ide et al., 2004; Lee et al., 2007; Ponugoti 
et al., 2007; Yamamoto et al., 2004). Although it has been reported that hepatic 
SREBP1c is upregulated in obese animals, it is unknown how increased SREBP1c 
fails to repress hepatic gluconeogenesis. Thus, it remains crucial to understand the 
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molecular mechanisms by which SREBP1c could modulate gluconeogenesis under 
physiological and pathological conditions.   
 CRY1 is a member of the mammalian clock transcription-translation 
feedback loop that also includes CLOCK, BMAL1, PER1, PER2, and CRY2, to 
modulate rhythmic oscillations. CLOCK and BMAL1 form a heterodimer to activate 
PER and CRY genes and then elevated PER and CRY proteins act as transcriptional 
repressors that decrease the transcriptional activity of CLOCK and BMAL1 
(Miyamoto and Sancar, 1998; Thresher et al., 1998; Vitaterna et al., 1999; Ye et al., 
2014). The hepatic circadian clock is affected by food intake as well by the expression 
of hormones such as insulin and glucagon, whereas the suprachiasmatic nucleus 
circadian clock is controlled by the light-dark cycle (Green et al., 2008). Recently, it 
has been shown that hepatic circadian clock genes also contribute to glucose 
homeostasis. For example, hepatic CRY proteins modulate glucose production by 
inhibiting the glucagon receptor signaling pathway and binding to GR (Lamia et al., 
2011; Zhang et al., 2010). In addition, an agonist of CRY proteins has been reported 
to repress the expression of hepatic gluconeogenic genes, such as PEPCK and G6Pase 
(Hirota et al., 2012). Furthermore, BMAL1-/- mice exhibited disrupted hepatic glucose 
homeostasis (Rudic et al., 2004). However, the molecular mechanisms by which 
CRY1 could repress hepatic glucose production during the postprandial state remain 
to be elucidated. 
The fact that SREBP1c downregulates hepatic gluconeogenesis prompted 
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us to investigate novel target genes of SREBP1c by comparing SREBP1c+/+ and 
SREBP1c-/- mice. Here, I demonstrate that SREBP1c attenuates hepatic glucose 
production via activation of CRY1, eventually leading to degradation of the FOXO1 
protein upon insulin signaling. While hepatic FOXO1 is rapidly translocated from the 
nucleus into the cytoplasm by AKT-mediated phosphorylation triggered by insulin, 
the SREBP1c-CRY1 signaling pathway durably represses the execution of 
gluconeogenic genes by decreasing nuclear FOXO1 protein for long term insulin 
action. Additionally, in the liver of diabetic db/db mice, overexpression of CRY1 
lowers blood glucose, accompanied with attenuated gluconeogenic genes and 
FOXO1 protein. Together, our data suggest that insulin activates the SREBP1c-CRY1 
signaling pathway, resulting in FOXO1 degradation mediated by MDM2, which is 












C57BL/6 mice were purchased from SAMTACO (Seoul, South Korea) and housed in 
colony cages. db/+ and db/db mice were obtained from Central Lab (Seoul, Korea). 
SREBP1c-/- mice were generously provided from Dr. J. Horton at the University of 
Texas Southwestern Medical Center and bred in isolated cages. All animals were 
maintained under 12 h light/ 12 h dark cycle in a pathogen-free animal facility. 
Following dissection, mouse tissue specimens were immediately stored at -80 °C 
until further analysis. All experiments with mice were approved by the Institute of 
Laboratory Animal Resources at Seoul National University and the Institutional 
Animal Care and Use Committee at the University of North Carolina.  
In vivo imaging system 
C57BL/6 mice were injected with adenoviruses encoding GFP (Ad-Mock), SREBP1c 
(Ad-SREBP1c) and G6Pase luciferase (Ad-G6Pase-luc) through the tail vein. After 
5 days, adenovirus-infected mice were injected intraperitoneally with 100 mg/kg 
sterile firefly D-luciferin. After 5 min, mice were anesthetized and imaged using an 
IVIS 100 imaging system (Xenogen, Alameda, CA, USA) as described(Lee et al., 
2014b). 
Pyruvate tolerance tests 
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For the pyruvate tolerance test, mice were fasted for 16 h and then injected 
intraperitoneally with pyruvate (2 g/kg body weight for mice). Blood glucose levels 
were measured in tail vein blood samples at the indicated time points by using a Free-
Style blood glucose meter (Therasense, Sweden).   
Antibodies, chemicals and plasmids 
MG132 was purchased from Calbiochem (San Diego, CA, USA). I used antibodies 
to the following proteins in our study: MYC, HA, FOXO1, phosphor-
FOXO1(Ser256), AKT, and phosphor-AKT(Ser473) (all purchased form Cell 
Signaling Technology, Beverly, MA, USA), FLAG, ACTIN (Sigma-Aldrich, St. 
Louis, MO, USA), G6Pase, POLII, GFP (Santa Cruz Biotechnology Santa Cruz, CA, 
USA), GAPDH (LabFrontier Co., Ltd, Seoul, Korea), SREBP1 (BD Bioscience, San 
Jose, CA, USA), MDM2 (Abcam, Cambridge, MA, USA), and CRY1 (Alpha 
Diagnostic International Inc., San Antonio, Texas, USA). GFP-CRY1 was cloned into 
the pEGFP-N1 vector and FLAG-MDM2 was cloned into pCMV-3 FLAG. Mouse 
CRY1 promoter was cloned into the pGL3-basic vector.     
Cell-based ubiquitination assays 
COS-1 cells were transfected with plasmids encoding FOXO1 WT-MYC, nFOXO1 
(ADA)-MYC, GFP-CRY1 (or FLAG-CRY1), FLAG-MDM2 and Ubiquitin-HA in 
the presence of 20 µM MG132 for 4 h. Total cell lysates were prepared using the 
TGN buffer. FOXO1 WT-MYC and nFOXO1 (ADA)-MYC were 
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immunoprecipitated with an anti-MYC antibody (Cell Signaling Technology, USA), 
and after washing in the TGN buffer, proteins were separated by SDS-PAGE followed 
by western blotting analyses with an anti-HA antibody.    
ChIP assays  
Cross-linking and chromatin immunoprecipitation assays with H4IIE cells were 
performed as described previously (Sakai et al., 2003). Extracted proteins from total 
cell lysates were immunoprecipitated with anti-SREBP1 (BD Bioscience) or IgG 
(Santa Cruz) for 2 h. Precipitated DNA fragments were analyzed by PCR using primer 
sets that encompassed the proximal (-100 to +100 base pairs) region of the rat CRY1 
promoter and negative control (+9670 to +9890 base pairs) region. The sequences of 
ChIP assay primers were as follows: sense, 5′-GTCCGAGCCAGCGTAGTAAA, 
antisense, 5′- GGATAGCGCGGGCTAGAG; negative control primer sense, 5′- 
CCAGCCACTTTGCTGAAGTT and antisense, 5′-
CTAGACAAGGCTGCCCACTC.  
Preparation of recombinant adenovirus 
The adenovirus plasmid was constructed as previously described (Lee et al., 2014a). 
rat SREBP1c and mouse CRY1 cDNAs were incorporated into the AdTrack-CMV 
shuttle vector and a recombinant vector was generated using the Ad-Easy adenoviral 
vector system. Adenoviruses were amplified in HEK293A cells and isolated by 
cesium chloride density centrifugation. The GFP was co-expressed from an 
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independent promoter with inserted cDNA. For in vivo experiments, mice were 
injected with 5 × 109 PFU of adenovirus (db/db mice, 2 × 1010 PFU) in 200 µl PBS 
through the tail vein. Empty virus expressing only the gene for GFP served as the 
control (Mock).    
Mouse primary hepatocytes cultures 
Mouse primary hepatocytes were isolated as previously described (Jo et al., 2013). 
For adenoviral infection, isolated hepatocytes were incubated for 12 h with 
adenovirus at 50 PFU/cell with the serum-free medium, which was subsequently 
replaced by the 10% FBS-containing M199 medium.  
Cell lysis and immunoprecipitation 
After washing in cold PBS, cells were treated either with the TGN buffer (50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1% Tween-20 and 0.3% NP-40) or the SDS lysis 
buffer (200 mM Tris-HCl, pH 6.8, 10% glycerol and 4% SDS) supplemented with 
0.1% protease inhibitor cocktail (Roche, Basel, Switzerland). Total cell lysates were 
obtained by centrifugation at 12,000 rpm for 15 min at 4 °C, and 1–1.5 mg of lysates 
was used for immunoprecipitation. The lysates were incubated with primary 
antibodies for 2 h at 4 °C, followed by 1 h of further incubation with 50% slurry of 
protein A sepharose presaturated with the lysis buffer. After washing three times with 
the lysis buffer, the immunoprecipitated proteins were recovered from the beads by 




Transient transfection and luciferase assays 
HEK293T cells were transiently transfected with various DNA plasmids using the 
calcium-phosphate method described previously (Seo et al., 2004). After incubation 
for 36 h, transfected cells were harvested with the lysis buffer (25 mM Tris-phosphate 
pH 7.8, 10% glycerol, 2 mM EDTA, 2 mM DTT and 1% Triton X-100) and the 
activities of luciferase and β-galactosidase were measured according to the 
manufacturer’s protocol (Promega, Madison, WI, USA). The relative luciferase 
activity was normalized to β-galactosidase activity in each sample.  
RNA preparation and q-RT-PCR analyses 
RNA was prepared as previously described (Kim et al., 2010). Briefly, total RNA was 
isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Subsequently, 
equal amounts of RNA were subjected to cDNA synthesis using the RevertAid M-
MuLV reverse transcriptase (Fermentas, Canada). The relative amount of mRNA was 
evaluated by using a CFX real-time quantitative PCR detection system (Bio-Rad 
Laboratories, Hercules, CA, USA) and calculated following normalization to the 
level of TBP or cyclophilin mRNA. The primer sequences used for the real-time 










siRNA duplexes for CRY1, MDM2, and FOXO1 were purchased from the Bioneer 
Inc. (Daejeon, South Korea). Primary hepatocytes were transiently transfected with 
the Lipofectamine RNAi MAX reagent (Invitrogen, Carlsbad, CA, USA) according 
to the manufacturer’s protocol. The sequence information for siRNA is described in 
the Supplementary Table 3.  
Glucose production assays 
Glucose production by mouse primary hepatocytes was measured according to the 
manufacturer’s protocol using a glucose oxidase assay (Sigma-Aldrich, St. Louis, 
MO, USA). Briefly, the cells were incubated for 6 h at 37 °C and 5% CO2 in the 
Krebs-Ringer buffer (115 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 1.2 mM 
NaH2PO4, 2.5 mM CaCl2, 25 mM NaHCO3, 10 mM lactate and 2 mM pyruvate, pH 
7.4). The glucose production assays were performed in triplicate.  
Statistical analysis 
Data were compared using a paired Student’s t test or analysis of variance as 
appropriate and are represented as the mean ± standard deviation (SD). Values of P 





















CRY1 is promoted by feeding and insulin 
 In the liver, peripheral circadian clock genes are regulated by various 
nutritional and hormonal changes (Jang et al., 2012). Given that circadian clock genes 
are closely associated with energy homeostasis, I sought to investigate which 
circadian clock genes could affect feeding-dependent hepatic lipid and glucose 
metabolism. Since the expression of most circadian clock genes is oscillated in a time 
dependent manner, the end points of the fasting and/or refeeding experiment were 
fixed at ZT 3. Upon refeeding, the expression of most lipogenic genes including 
SREBP1c, FASN, and ACC was upregulated in the liver. In accordance with previous 
reports (McNeill et al., 1982; Oh et al., 2013; Pilkis et al., 1988), the expression of 
gluconeogenic genes such as PEPCK and G6Pase was downregulated in the 
postprandial state (Figure 14A). Interestingly, the level of hepatic CRY1 mRNA was 
selectively elevated in refed mice, while the expression of other circadian clock genes 
such as PER2, CRY2, CLOCK, and BMAL1 was not significantly altered after 
nutritional changes (Figure 14A). Moreover, the expression of the CRY1 protein was 
markedly increased in the liver of refed mice (Figure 14B). These findings prompted 
us to test whether insulin might elevate hepatic CRY1 gene expression. In primary 
hepatocytes, the level of CRY1 mRNA was increased by insulin, similar to SREBP1c 
mRNA (Figure 14C). These data indicate that hepatic CRY1 expression is 







Figure 14. CRY1 is stimulated by feeding and exposure to insulin 
(A and B) C57BL/6 mice were fasted for 24 h and then refed for 12 h. Both fasted 
and refed mice were sacrificed at ZT3.In the liver, levels of the CRY1 mRNA (A) and 
CRY1 protein (B) were determined using qRT-PCR with normalization to TBP 
mRNA levels and western blotting, respectively. Data are represented as mean ±SD, 
N=4 for each group. *P < 0.05, **P < 0.01 (Student’s t-test). (C) CRY1 gene 
expression was measured in mouse primary hepatocytes following 12 h of insulin 
exposure and in control conditions using qRT-PCR. The level of the TBP mRNA was 
used for the qRT-PCR normalization. Data are represented as mean ±SD, N=3 for 




















dependent energy metabolism. 
 
SREBP1c regulates CRY1 gene expression  
 To investigate which transcription factors regulate insulin-dependent CRY1 
gene expression, I analyzed CRY1 promoters in several species including monkey, 
cow, sheep, human, rat and mouse (Figure 16A). In the proximal CRY1 promoter, 
there are several sterol regulatory element (SRE) motifs as well as an E-BOX 
(CANNTG) motif, which is also a target motif for BMAL1 and CLOCK, the core 
circadian clock proteins (Figure 16A). Both SRE and E-BOX motifs are well known 
binding targets of SREBP1c with its dual DNA binding specificity (Griffin et al., 
2007; Kim et al., 1995). To examine whether SREBP1c could regulate CRY1 gene 
expression, SREBP1c was overexpressed in mouse primary hepatocytes. As shown 
in Figure 15A and 15B, the levels of hepatic CRY1 mRNA and CRY1 protein were 
increased by SREBP1c overexpression (Figure 15A, 15B), implying that SREBP1c 
may be a key transcription factor that upregulates hepatic CRY1 gene expression in 
the postprandial state. Next, the effect of ectopic expression of SREBP1c on the 
CRY1 promoter activity was examined. Expression of luciferase from a wild-type 
CRY1 promoter was compared with expression from a promoter with mutated SRE 
motifs (3XSRE) in HEK293T cells (Figure 16B). I observed substantial loss of 








Figure 15. SREBP1c directly activates CRY1 gene expression  
(A and B) Mouse primary hepatocytes were adenovirally infected with Ad-Mock or 
Ad-SREBP1c, as indicated. The levels of the CRY1 mRNA (A) and CRY1 protein 
(B) were determined using qRT-PCR with normalization to TBP mRNA levels and 
western blotting, respectively. Data are represented as mean ±SD, N=3 for each group. 

























Figure 16. SREBP1c binds to SRE sequence in CRY1 promoter. 
(A) SRE motifs and E-BOX sequences in the CRY1 promoter from various species. 
(B) Luciferase activity of the WT CRY1 promoter and 3XSRE mutant promoter were 
measured following co-transfection with expression plasmids encoding either 
SREBP1c or Mock in HEK293T cells. Luciferase activity was normalized by β-gal 
activity. Data are represented as mean ±SD, N=5 for each group. *P < 0.05, **P < 
0.01 (Student’s t-test). (C) HEK293T cells were co-transfected with a reporter 
plasmid containing the WT or E-BOX mutant mouse CRY1 promoter along with 
expression plasmids encoding either Mock or SREBP1c. The values represent the 















(Figure 16B, 16C). In addition, SREBP1c binding to the CRY1 promoter was 
confirmed by a ChIP assay (Figure 17). Meanwhile, consistent with previous reports 
(Becard et al., 2001; Ide et al., 2004; Lee et al., 2007), hepatic SREBP1c reduced 
G6Pase expression (Figure 15A, 15B). 
 To verify whether SREBP1c could modulate hepatic CRY1 gene expression 
in vivo, SREBP1c adenovirus was injected into mice via the tail vein and hepatic gene 
expression was investigated. As expected, hepatic SREBP1c overexpression 
increased the expression of lipogenic genes such as FASN, SCD1 and ELOVL6 
(Figure 18A). As in the case with primary hepatocytes, the level of hepatic CRY1 
mRNA was enhanced by SREBP1c in vivo (Figure 18A). Moreover, in contrast to 
SREBP1c+/+ mice, refeeding failed to increase hepatic CRY1 gene expression in 
SREBP1c-/- mice (Figure 18B). This observation indicates that SREBP1c is an 
essential factor for the upregulation of hepatic CRY1 gene expression in the 
postprandial state. 
 
SREBP1c-CRY1 pathway inhibits hepatic gluconeogenesis 
 Consistent with previous reports (Becard et al., 2001; Lamia et al., 2011; 
Zhang et al., 2010), SREBP1c overexpression decreased glucose production in mouse 
primary hepatocytes (Figure 19A). In addition, the optical in vivo imaging analysis 









Figure 17. SREBP1c directly binds to CRY1 promoter. 
ChIP assay, performed as described in Methods, showing CRY1 promoter occupancy 































Figure 18. CRY1 regulation in SREBP1c modulated mice.  
(A) C57BL/6 mice were infected with adenoviruses encoding either a Mock or 
SREBP1c (adenoviral dose of 5×109 viral particles per mouse) through the tail vein. 
Mice were sacrificed 5 days following the injection of adenoviruses and relative 
mRNA levels were determined by qRT-PCR and normalized to the TBP mRNA signal. 
Data are represented as mean ±SD, N=3-4 for each group. *P < 0.05, **P < 0.01 
(Student’s t-test). (B) SREBP1c-/- and SREBP1c+/+ mice were fasted for 24 h and then 
refed for 12 h. Both fasted and refed mice were sacrificed at ZT3. The levels of 
SREBP1c and CRY1 mRNAs were determined by qRT-PCR and normalized to TBP 
mRNA levels. Data are represented as mean ±SD, N=3-4 for each group. *P < 0.05, 





















Figure 19. SREBP1c suppresses hepatic gluconeogenesis 
(A) Mouse primary hepatocytes were adenovirally infected with Ad-Mock or Ad-
SREBP1c. Relative glucose secretion was measured using a glucose oxidase (GO) kit 
as described in Methods. Data are represented as mean ±SD, N=3 for each group. *P 
< 0.05 (Student’s t-test). (B) C57BL/6 mice were infected with Ad-G6Pase-luc and 
either Ad-Mock or Ad-SREBP1c. (C) The effect of hepatic SREBP1c overexpression 
on G6Pase promoter activity was measured by optical in vivo imaging analysis and 
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activity of the G6Pase gene in vivo (Figure 19B, 19C). These findings led us to 
investigate the effect of SREBP1c on blood glucose level in vivo. Pyruvate tolerance 
test demonstrated that the adenoviral overexpression of SREBP1c significantly 
decreased blood glucose level following pyruvate injection (Figure 20A, 20B). 
Accordingly, SREBP1c-/- mice showed higher blood glucose than SREBP1c+/+ mice 
(Figure 20C, 20D). Thus, these results suggest that hepatic SREBP1c would suppress 
gluconeogenesis, potentially by modulating gluconeogenic gene expression. 
 To examine whether CRY1, a novel target gene of SREBP1c, might 
modulate hepatic gluconeogenic gene expression, I suppressed CRY1 expression via 
siRNA in rat hepatoma H4IIE cells. Downregulation of CRY1 increased the 
expression of G6Pase and PEPCK genes (Figure 21A), which are crucial for hepatic 
gluconeogenesis. On the contrary, hepatic CRY1 overexpression decreased the 
expression of G6Pase and PEPCK genes in mouse primary hepatocytes (Figure 21B). 
To confirm these observations, I measured pyruvate-induced blood glucose level 
from CRY1+/+ and CRY1-/- mice. As shown in Figure 22A and 22B, CRY1-/- mice 
shows higher blood glucose level than CRY1+/+ mice. To test whether CRY1 could be 
a key mediator of the inhibition of hepatic gluconeogenesis by SREBP1c, I performed 
glucose production assays in primary hepatocytes. As indicated in Figure 23, 
SREBP1c overexpression significantly suppressed glucose production, while 
suppression of CRY1 with siRNA in SREBP1c-overexpressing hepatocytes rescued 







Figure 20. SREBP1c regulates pyruvate induced blood glucose level. 
(A and B) C57BL/6 mice were infected with Ad-Mock or Ad-SREBP1c and subjected 
to the PTT (A), as described in Methods. All mice were fasted at ZT10 and performed 
PTT at ZT3. The result was converted by the area-under-the curve (AUC) analysis 
(B). Data are represented as mean ±SD, N=5 for each group. *P < 0.05, **P < 0.01 
(Student’s t-test). (C and D) Pyruvate tolerance test (C) was performed in SREBP1c-
/- and SREBP1c+/+mice. All mice were fasted at ZT10 and performed PTT at ZT3. 
Results were converted to AUC values (D). Data are represented as mean ±SD, N=5 






















Figure 21. CRY1 regulates gluconeogenic gene expression. 
(A) H4IIE cells were transfected with siCON or siCRY1. Relative PEPCK and 
G6Pase mRNA levels were determined by qRT-PCR and normalized to cyclophilin 
mRNA levels. Data are represented as mean ±SD, N=3 for each group. *P < 0.05, 
**P < 0.01, ***P < 0.001 (Student’s t-test). (B) Mouse primary hepatocytes were 
infected with Ad-Mock or Ad-CRY1. Relative PEPCK and G6Pase mRNA levels 
were determined by qRT-PCR and normalized to TBP mRNA levels. Data are 




























Figure 22. CRY1-/- mice showed low level of glucose upon pyruvate challenge. 
(A and B) Pyruvate tolerance test (A) was performed in CRY1-/- and CRY1+/+ mice. 
All mice were fasted at ZT10 and performed PTT at ZT3. Results were converted to 
AUC values (B). Data are represented as mean ±SD, N=7 for each group. *P < 0.05, 




























Figure 23. The SREBP1c-CRY1 signaling pathway regulates gluconeogenesis in 
vitro.  
Mouse primary hepatocytes were infected with Ad-Mock or Ad-SREBP1c and 
transfected with either siCON or siCRY1. Relative glucose production was measured 
using a glucose oxidase (GO) kit. Data are represented as mean ±SD, N=4 for each 






















pathway could indeed repress hepatic glucose production in vivo, CRY1 was 
adenovirally overexpressed in the liver of SREBP1c-/- mice. While SREBP1c-/- mice 
showed higher blood glucose level than SREBP1c+/+ mice during the pyruvate 
tolerance test, SREBP1c-/- mice with CRY1 overexpression exhibited an attenuated 
level of blood glucose, comparable to that of WT mice (Figure 24A, 24B). These data 
strongly indicate that the SREBP1c-CRY1 signaling pathway could inhibit hepatic 
gluconeogenesis in vivo.  
 
CRY1 regulates FOXO1 protein 
 To decipher the underlying mechanism(s) by which insulin-induced CRY1 
could repress hepatic gluconeogenesis, I focused on FOXO1, as its regulatory effects 
on insulin signaling and gluconeogenesis are well established. In mouse primary 
hepatocytes, the level of the FOXO1 protein was decreased by CRY1 overexpression 
(Figure 25A) while FOXO1 mRNA levels were not altered (Figure 25B). These data 
indicated that CRY1 might modulate the level of the FOXO1 protein, probably, 
independent of the FOXO1 mRNA. Furthermore, the level of the FOXO1 protein was 
enhanced in CRY1-suppressed hepatocytes (Figure 25C, 25D). In accordance with 
these in vitro data, the FOXO1 protein level was higher in the liver of CRY1-/- mice 
than in the liver of the CRY1+/+ mice, whereas levels of the FOXO1 mRNA were not 








Figure 24. The SREBP1c-CRY1 signaling pathway regulates gluconeogenesis in 
vivo.  
(A and B) Pyruvate tolerance test (A) in SREBP1c+/+ mice injected with Ad-Mock 
and in SREBP1c-/- mice injected with either Ad-Mock or Ad-CRY1. Results were 
converted to AUC values (B) to assess the effect of CRY1 overexpression in 
SREBP1c-/- mice. All mice were fasted at ZT 10 and performed PTT at ZT 3. Data are 




























Figure 25. CRY1 regulates FOXO1 protein level in vitro. 
(A and B) Mouse primary hepatocytes were adenovirally infected with Ad-Mock or 
Ad-CRY1. The expression profiles of FOXO1 were analyzed at the protein level (A) 
using western blotting and at the mRNA level (B) using qRT-PCR. Data are 
represented as mean ±SD, N=4 for each group. *P < 0.05 (Student’s t-test). (C and D) 
H4IIE cells were transfected with siCON or siCRY1. Immunocytochemical analysis 
(C) of endogenous FOXO1. DAPI, 4’, 6-diamidino-2-phenylindole. Endogenous 
























Figure 26. FOXO1 protein level is elevated in SREBP1-/- and CRY1-/-. 
(A and B) The expression patterns of FOXO1 protein in the liver of CRY1+/+ and 
CRY1-/- mice were analyzed by western blotting (A) and qRT-PCR (B). Relative 
mRNA levels were determined using qRT-PCR and normalized to the levels of the 
TBP mRNA. Data are represented as mean ±SD, N=3 for each group. *P < 0.05, **P 
< 0.01, ***P < 0.001 (Student’s t-test). (C) Expression of CRY1 and FOXO1 proteins 























Moreover, compared to the levels of proteins observed in the livers of the SREBP1c+/+ 
mice, the amount of the FOXO1 protein was higher and the level of the CRY1 protein 
was lower in the liver of SREBP1c-/- mice (Figure 26C). To verify that CRY1 could 
inhibit hepatic gluconeogenesis via FOXO1 modulation, the effects of CRY1 and/or 
FOXO1 suppression on gluconeogenic gene expression were examined. Increased 
expression of G6Pase and PEPCK genes by CRY1 suppression was abolished when 
the FOXO1 gene was downregulated by siRNA (Figure 27), indicating that CRY1 
could alleviate hepatic gluconeogenesis via suppression of the FOXO1 protein. 
Therefore, these in vivo and in vitro data suggest that hepatic FOXO1 protein could 
be regulated by CRY1. 
  
FOXO1 protein is decreased by insulin-activated CRY1  
 FOXO1 translocation from the nucleus to the cytoplasm by AKT is a well-
known mechanism by which insulin acutely inhibits hepatic glucose production 
(Rena et al., 1999). As insulin upregulates CRY1 that, in turn, downregulates the 
FOXO1 protein (Figure 14C and 25A), I investigated the time course of these events 
by examining the expression profiles of the FOXO1 and CRY1 proteins in insulin-
treated primary hepatocytes. As shown in Figure 28A and 28B, AKT phosphorylation 
was clearly induced in cells treated with insulin for a relatively short period (0.5~4 









Figure 27. CRY1 inhibits gluconeogenesis via FOXO1 signaling pathway.  
H4IIE cells were co-transfected with siCRY1 and/or siFOXO1. Relative mRNA 
levels were normalized to the cyclophilin mRNA level. Data are represented as mean 
±SD, N=3 for each group. #P < 0.05, ##P < 0.01 versus siCRY1, *P < 0.05, **P < 




























Figure 28. CRY1 is induced in long term insulin action with inhibition of 
gluconeogenesis.  
(A, B, and C) Mouse primary hepatocytes were treated with insulin for different 
periods. Protein levels (A) were determined with western blotting and the results were 
converted to the band intensity graph (B). mRNA levels (C) were analyzed by qRT-
PCR. Data are represented as mean ±SD, N=3 for each group. *P < 0.05, **P < 0.01, 























insulin. However, phosphorylation levels of AKT and FOXO1 were gradually and 
substantially decreased by a long-term (8~12 h) incubation with insulin, implying that 
FOXO1 translocation from the nucleus to the cytoplasm by AKT might be more 
pronounced after a short exposure to insulin rather than following a long-term insulin 
treatment. Intriguingly, in hepatocytes treated with insulin for long periods, the level 
of the CRY1 protein was markedly increased, while that of the total FOXO1 protein 
was decreased, indicating that the amount of the CRY1 protein appears to be inversely 
related to the total quantity of the FOXO1 protein. Moreover, the expression of 
PEPCK and G6Pase genes was repressed after either a long-term or a short-term 
insulin treatment (Figure 28C). These data suggest that reduction in the FOXO1 
protein level might be involved in the suppression of hepatic gluconeogenesis as a 
result of a delayed effect of insulin treatment.  
 Next, I explored whether CRY1 could modulate the decrease in FOXO1 
protein in insulin-treated hepatocytes. To address this, the expression of CRY1 was 
suppressed by siRNA with or without an insulin treatment. As shown in Figure 29A, 
long-term insulin challenge led to a decrease in FOXO1 protein, while suppression 
of CRY1 protein restored the level of the FOXO1 protein. In the presence of insulin, 
decreased levels of PEPCK and G6Pase mRNA were also substantially restored by 
CRY1 knockdown in hepatocytes (Figure 29B). Together, these data indicate that 
CRY1 could repress the expression of hepatic gluconeogenic genes via reduction of 







Figure 29. Insulin sustainably suppresses gluconeogenesis via CRY1. 
(A and B) H4IIE cells were transfected with siCON or siCRY1 and treated with 10 
nM insulin for 12 h. Protein levels (A) were analyzed by western blotting and relative 
mRNA levels (B) were determined by qRT-PCR and normalized to the cyclophilin 
mRNA level. Data are represented as mean ±SD, N=3 for each group. *P < 0.05, **P 




















To test whether enhanced CRY1 could suppress hepatic gluconeogenesis 
even in the absence of a short-term insulin action, I employed AKT inhibitors. In 
primary hepatocytes, insulin increased phosphorylation levels of both AKT and 
FOXO1, while a co-treatment with the AKT inhibitor AKTVIII blocked 
phosphorylation of both proteins, as expected (Figure 30A). However, in Ad-CRY1 
overexpressing hepatocytes, the total FOXO1 level was decreased in insulin and/or 
the AKT inhibitor treated cells, implying that CRY1 could downregulate FOXO1 
protein independent of FOXO1 phosphorylation (Figure 30A). In order to confirm 
this observation in vivo, I tested another AKT inhibitor, MK2206, in mice. As 
expected, administration of MK2206 significantly increased blood glucose level upon 
pyruvate challenge; however, adenoviral CRY1 overexpression in mice significantly 
attenuated blood glucose level even in the presence of MK2206 (Figure 30B, 30C). 
It is noteworthy that the level of the FOXO1 protein was greatly augmented by 
MK2206, whereas CRY1 elevation suppressed FOXO1 protein expression in vivo 
(Figure 30D). Taken together, these data clearly indicate that CRY1-dependent 
FOXO1 reduction may contribute to the suppression of hepatic gluconeogenesis 
independent of AKT activation. 
 
CRY1 stimulates proteasomal degradation of FOXO1  







Figure 30. CRY1 suppresses FOXO1 protein level independent of AKT activity. 
(A) Mouse primary hepatocytes were infected with Ad-Mock and Ad-CRY1, and then 
treated with insulin (10 nM) or insulin (10 nM) and AKTVIII (5 µM) for 12 h. Protein 
levels were determined with western blotting. (B, C and D) C57BL/6 mice were 
infected with Ad-Mock or Ad-CRY1 and subjected to the pyruvate tolerance test (B) 
with or without the AKT inhibitor MK2206. MK2206 (30 mg/kg) was given by oral 
gavage 10 min before the pyruvate tolerance test. All mice were fasted at ZT 10 and 
performed PTT at ZT 3. Results were converted to AUC values (C). After the 
pyruvate tolerance test, hepatic protein levels (D) were analyzed by western blotting. 
Data are represented as mean ±SD, N=5-7 for each group. #P < 0.05, ##P < 0.01, 
###P < 0.001 versus Ad-Mock + vehicle control, *P < 0.05, **P < 0.01, ***P < 0.001 














protein, but not the FOXO1 mRNA, I investigated whether the downregulation of the 
FOXO1 protein proceeds via proteasomal degradation. As shown in Figure 31A, the 
reduction in the FOXO1 protein by CRY1 overexpression was alleviated by MG132 
treatment, indicating that the regulation of FOXO1 protein by CRY1 may be, at least 
in part, dependent on proteasomal degradation. When I tested physical interaction 
between FOXO1 and CRY1 proteins, co-immunoprecipitation assays revealed that 
CRY1 could associate with FOXO1 protein (Figure 31B). Then, I examined whether 
CRY1 might induce FOXO1 degradation via the ubiquitination-proteasome pathway. 
As shown in Figure 31C, CRY1 overexpression dramatically promoted FOXO1 poly-
ubiquitination, implying that CRY1 could potentiate FOXO1 degradation, probably, 
through protein-protein interactions. 
 To explore the subcellular location of FOXO1 degradation induced by 
CRY1, levels of the nuclear and cytosolic FOXO1 protein were investigated. As 
shown in Figure 31D, the nuclear fraction of the FOXO1 protein was decreased by 
CRY1 overexpression, whereas incubation with MG132 blocked this decrease. At the 
same time, levels of cytosolic FOXO1 were not altered upon CRY1 overexpression 
irrespective of the presence of MG132. Consistent with these results, poly-
ubiquitination of the nuclear form of the FOXO1 mutant protein (nFOXO1-MYC) 
was greatly augmented by CRY1 (Figure 31E). Therefore, it is plausible that the 





Figure 31. CRY1 accelerates ubiquitin-mediated FOXO1 degradation  
(A) Mouse primary hepatocytes were adenovirally infected with Ad-Mock or Ad-
CRY1. The cells were treated with 20 µM MG132 or vehicle for 4 h. Total cell lysates 
were analyzed by western blotting with indicated antibodies. (B) HEK293T cells 
were transfected with GFP-CRY1 and/or FOXO1-MYC expression vectors. Co-
immunoprecipitation with an anti-MYC antibody and western blotting were 
performed with the indicated antibodies. IP, immunoprecipitation. (C) COS-1 cells 
were co-transfected with plasmids encoding FOXO1-MYC, GFP-CRY1, and 
Ubiquitin-HA. After transfection, the cells were treated with MG132 (20 µM) for 6 h 
and then the cell lysates were subjected to immunoprecipitation with an anti-MYC 
antibody followed by western blotting with indicated antibodies. IP, 
immunoprecipitation. (D) Mouse primary hepatocytes were infected with Ad-Mock 
or Ad-CRY1. After infection, the cells were treated with MG132 (20 µM) for 4 h. 
Nuclear and cytosolic fractions were isolated and analyzed by western blotting with 
indicated antibodies. (E) COS-1 cells were co-transfected with plasmids encoding 
nFOXO1-MYC, GFP-CRY1, and Ubiquitin-HA. After transfection, the cells were 
challenged with MG132 (20 µM) for 6 h. The cell lysates were subjected to 
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CRY1 is involved in MDM2-mediated FOXO1 degradation 
 Among several ubiquitin E3 ligases of the FOXO1 protein (Fu et al., 2009; 
Kato et al., 2008), I found that the MDM2 ubiquitin E3 ligase was involved in the 
CRY1-mediated FOXO1 degradation. As shown in Figure 32A, MDM2 suppression 
markedly rescued the level of the FOXO1 protein in CRY1-overexpressing cells, 
implying that MDM2 may participate in the CRY1-dependent FOXO1 reduction. To 
study the role of CRY1 in MDM2-mediated FOXO1 degradation, I tested whether 
CRY1 might regulate the subcellular localization of MDM2. Wild type CRY1 and 
cytosolic CRY1 (∆NLS-CRY1) did not change the subcellular location of the nuclear 
MDM2 (Figure 32B). However, I revealed that CRY1 potentiates the association 
between FOXO1 and MDM2 (Figure 32C). 
 In another experiment, I explored if CRY1 could modulate MDM2-mediated 
FOXO1 degradation. As shown in Figure 33A and 33B, CRY1 overexpression 
promoted MDM2-mediated poly-ubiquitination of the nuclear form of FOXO1 
protein (Figure 33A), whereas CRY1 suppression attenuated FOXO1 poly-
ubiquitination by MDM2 (Figure 33B). These data indicate that CRY1 would 
participate in MDM2-induced FOXO1 degradation and repress FOXO1-mediated 








Figure 32. CRY1 represses FOXO1 protein through intensifying MDM2 and 
FOXO1 binding.  
(A) Mouse primary hepatocytes were infected with Ad-Mock or Ad-CRY1 and/or 
siCON or siMDM2. Total cell lysates were analyzed by western blotting with 
indicated antibodies. (B) HEK293T cells were transfected with FLAG-MDM2 with 
GFP-WT CRY1 or GFP-cytosolic CRY1 (∆NLS CRY1) and immunocytochemical 
analysis of FLAG-MDM2 and GFP was carried out. DAPI, 4’,6-diamidino-2-
phenylindole.(C) HEK293T cells were transfected with FLAG-MDM2, nFOXO1-
MYC, and GFP-CRY1 expression vectors. Total cell lysates were subjected to co-
immunoprecipitation with an anti-MYC antibody followed by western blotting with 
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Figure 33. CRY1 is involved in MDM2-mediated FOXO1 ubiquitination  
(A) COS-1 cells were co-transfected with plasmids encoding nFOXO1-MYC, 
FLAG-MDM2, FLAG-CRY1, and Ubiquitin-HA. After transfection, the cells were 
challenged with MG132 (20 µM) for 6 h. Cell lysates underwent 
immunoprecipitation with an anti-MYC antibody. IP, immunoprecipitation (B) COS-
1 cells were co-transfected with plasmids encoding nFOXO1-MYC, FLAG-MDM2, 
Ubiquitin-HA, and siCRY1. Cells were treated with MG132 (20 µM) for 6 h. Cell 
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CRY1 mitigates hyperglycemia in db/db mice 
 In the liver of obese animals such as db/db and DIO (diet-induced-obesity) 
mice, SREBP1c level is elevated while hepatic gluconeogenesis is not repressed 
(Beaven et al., 2013; Han et al., 2015; Kakuma et al., 2000; Yoon et al., 2010). To 
explore which process(es) might be dysregulated in the regulation of hepatic 
gluconeogenesis, I have examined mRNA and protein levels for SREBP1c-CRY1 
axis and gluconeogenic genes in diabetic animals. Similar to previous reports (Beaven 
et al., 2013; Han et al., 2015; Kakuma et al., 2000; Yoon et al., 2010), the mRNA 
levels of SREBP1c and gluconeogenic genes were elevated in db/db mice (Figure 
34A, 34B). However, hepatic CRY1 protein was greatly decreased in db/db mice 
(Figure 34B). Similarly, DIO mice exhibited elevated SREBP1c and gluconeogenic 
genes whereas CRY1 was not activated (Figure 34C, 34D). To test the idea that 
dysregulated CRY1 protein might mediate hyperglycemia with enhanced FOXO1 
protein in diabetic animals, CRY1 was adenovirally overexpressed in the liver of 
db/db mice. As shown in Figure 35A, the level of blood glucose was decreased by 
CRY1 overexpression. Moreover, ectopic CRY1 expression reduced the levels of 
FOXO1 protein as well as gluconeogenic gene expression in db/db mice (Figure 35B, 
35C). These results propose that CRY1 could ameliorate hyperglycemia by repressing 







Figure 34. SREBP1c is activated while CRY1 is not elevated in db/db and DIO 
mice.  
(A, and B) Ten-week-old male db/+ and db/db mice were sacrificed in fed states at 
ZT3. The relative mRNA levels of various hepatic genes (A) were determined by 
qRT-PCR analyses and normalized to the TBP mRNA level. Data are represented as 
mean ±SD, N=4 for each group. *P < 0.05 versus db/+ group. (Student’s t-test). 
Protein levels (B) were determined with western blotting. (C and D) Eight-week-old 
C57BL/6 mice were fed a NCD or HFD for 8 weeks. Hepatic gene expression levels 
(D) were determined by qRT-PCR and normalized by the level of the TBP mRNA. 


















Figure 35. CRY1 alleviates gluconeogenesis in db/db mice 
(A, B, and C) Ten-week-old male db/db mice were infected through the tail vein with 
adenovirus encoding GFP or CRY1 (adenoviral dose of 2 × 1010 viral particles per 
mouse). The blood glucose levels (A) were measured in ad libitum at ZT3. After all 
of the mice were sacrificed at ZT3, hepatic protein levels (B) were analyzed by 
western blotting, and the relative mRNA levels (C) were determined by qRT-PCR 
analyses and normalized to the TBP mRNA level. Data are represented as mean ±SD, 























 As a major anabolic hormone, insulin stimulates lipogenesis and represses 
gluconeogenesis in the liver. Following insulin exposure, lipogenesis is upregulated 
by SREBP1c, and the expression of SREBP1c target genes such as FASN, SCD and 
ELOVL6 is thus induced (Chu et al., 2013; Kim et al., 1998a; Ponugoti et al., 2010). 
In contrast, insulin blocks hepatic gluconeogenesis through AKT-mediated 
phosphorylation of FOXO1 and PGC1α (Gross et al., 2008; Li et al., 2007), both are 
major regulators of gluconeogenic genes including PEPCK and G6Pase. Here, I 
propose that the SREBP1c-CRY1 signaling pathway plays an important role to inhibit 
hepatic gluconeogenesis under anabolic state. Accumulating evidences from hepatic 
gluconeogenic gene expression, in vitro glucose output assays, time kinetics of insulin 
signaling cascades, and pyruvate tolerance test, which reflects both hepatic glucose 
output and peripheral glucose disposal, have consistently suggested the idea that 
maintenance of SREBP1c-induced CRY1 is crucial to prevent unnecessary hepatic 
gluconeogenesis during insulin action. In this regard, it has been reported that single 
nucleotide polymorphisms (SNPs) of SREBP1c and CRY1 genes are associated with 
hyperglycemia in human (Harding et al., 2006; Kelly et al., 2012). 
Similar to previous reports (Beaven et al., 2013; Han et al., 2015; Kakuma 
et al., 2000), the expression of SREBP1c and gluconeogenic genes was increased in 
the liver of diabetic db/db mice (Figure 34A, 34B, 34C). Unexpectedly, the level of 
hepatic CRY1 protein was reduced in db/db mice. In this work, I have demonstrated 
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that ectopic overexpression of CRY1 in db/db mice alleviated hepatic 
gluconeogenesis by reducing FOXO1 protein (Figure 35A, 35B, 35C). Moreover, I 
have shown that hepatic CRY1 could attenuate blood glucose level by decreasing 
FOXO1 protein, independent of AKT activity (Figure 30A, 30B, 30C, 30D). 
Although it remains to be elucidated how elevated SREBP1c fails to increase CRY1 
in the liver of db/db mice, it is very likely that increased FOXO1 protein might be 
resulted from reduced hepatic CRY1 protein in db/db mice.  
It has been reported that CRY1 seems to suppress hepatic glucose production 
through interfering glucagon signaling (Hirota et al., 2012; Zhang et al., 2010). CRY1 
interacts with GR (Lamia et al., 2011) and the α subunit of the glucagon receptor 
(Zhang et al., 2010), which are involved in the regulation of gluconeogenesis. 
Nonetheless, specific roles of CRY1 during the nutrient-rich state after exposure to 
insulin have not been clearly elucidated. To explore whether CRY1 might repress 
gluconeogenesis by inhibiting glucagon signaling, CRY1-overexpressing primary 
hepatocytes were treated with forskolin or db-cAMP to mimic the stimulation of 
glucagon signaling pathways. In primary hepatocytes, CRY1 partially repressed 
gluconeogenic gene expression in the presence of forskolin or db-cAMP (Figure 36A, 
36B), implying that in addition to the glucagon signaling pathway there may be 
another signaling cascade, regulated by CRY1, which suppresses hepatic glucose 
production. Thus, CRY1 is appears to be involved in multiple regulatory pathways 







Figure 36. Gluconeogenic gene expression is partially attenuated by CRY1 
overexpression upon incubation with forskolin and db-cAMP  
(A and B) Mouse primary hepatocytes were adenovirally infected with Ad-Mock or 
Ad-CRY1. The cells were treated with 10 µM forskolin (A), 5 µM db-cAMP (B), or 
vehicle (CON) for 4 h. PEPCK and G6Pase mRNA levels were determined using 
qRT-PCR and normalized to the level of the TBP mRNA. The values represent the 



















Activation of FOXO1-mediated gluconeogenesis is inhibited by insulin. 
AKT, a key downstream molecule of the insulin-activated signaling, phosphorylates 
FOXO1, which then is translocated from the nucleus to the cytoplasm through its 
association with the 14-3-3 protein (Zhao et al., 2004). In primary hepatocytes, 
FOXO1 phosphorylation was rapidly increased by insulin. However, hepatic 
gluconeogenic programing is persistently and efficiently suppressed regardless of the 
decreased FOXO1 phosphorylation at the late stage of insulin action. Intriguingly, 
hepatic CRY1 expression was enhanced at relatively late periods of insulin action 
(Figure 28A, 28B). Furthermore, in primary hepatocytes, a long-term insulin 
treatment downregulated FOXO1 expression, while suppression of CRY1 rescued 
FOXO1 protein levels as well as gluconeogenic gene expression (Figure 29A, 29B). 
It is noteworthy that CRY1 overexpressing mice showed a decrease of blood glucose 
level as well as of FOXO1 protein when AKT activity was pharmacologically 
repressed with AKT inhibitor MK2206 (Figure 30A, 30B, 30C, 30D). Collectively, 
our in vitro and in vivo data suggest that the CRY1-dependent FOXO1 degradation 
would be one of crucial mechanisms to attenuate hepatic gluconeogenesis for the 
long-term insulin action. Therefore, these observations prompted us to propose that 
the AKT-mediated FOXO1 phosphorylation provides an acute response during early 
insulin response, whereas SREBP1c-mediated CRY1 regulation would be a more 
durable process leading to the repression of futile hepatic gluconeogenesis throughout 
the anabolic state. 
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CRY1 is one of the key proteins in the circadian negative feedback loop. I 
observed that CRY1 levels were regulated by insulin and SREBP1c in vivo and in 
vitro. Given that hepatic circadian clock gene expression is altered in the STZ-
injected insulin-deficient rats (Yamajuku et al., 2012), I investigated circadian clock 
gene oscillations in the liver of SREBP1c+/+ and SREBP1c-/-. As shown in Figure 37, 
I did not observed any significant differences in hepatic circadian clock gene 
oscillations between SREBP1c+/+ and SREBP1c-/- mice, implying that insulin-
activated SREBP1c could stimulate CRY1 gene expression in liver, probably, 
independent of circadian clock gene oscillations. Also, I cannot exclude the 
possibility that SREBP1c-induced CRY1 might contribute to minor roles for hepatic 
circadian oscillation in SREBP1c-/- mice because it has been reported that CRY1-/- 
mice exhibit fewer changes in circadian oscillations compared to CRY1-/-CRY2-
/- double mutant mice (van der Horst et al., 1999). Furthermore, it is possible that 
remaining SREBP1a and/or SREBP2 activity in SREBP1c-/- mice might maintain 
intact circadian clock gene oscillations and this homeostatic regulation needs to be 
addressed in future studies (Im et al., 2009; Liang et al., 2002). Nonetheless, hepatic 
CRY1 gene expression is clearly upregulated by SREBP1c in the postprandial 
condition. 
  As SREBP1c could simultaneously regulate both gluconeogenesis and 
lipogenesis, it is plausible to suggest that hepatic SREBP1c would effectively 








Figure 37. Expression profiles of various genes in the liver of SREBP1c+/+ and 
SREBP1c-/- mice   
Livers were isolated every 6 h from SREBP1c+/+ and SREBP1c-/- mice fed with 
normal chow diet and kept under 12 h: dark, 12 h: dark cycle for 1 week. Relative 
mRNA levels were determined by qRT-PCR and normalized by the level of the TBP 

















downregulating glucose metabolism upon insulin signaling with different target genes. 
Our study is the first report to reveal the role of SREBP1c in CRY1 activation, which 
appears to be crucial in the regulation of hepatic glucose metabolism in the anabolic 
state. Based on the circadian oscillatory gene expression profile in SREBP1c-/- mice, 
the SREBP1c protein may not actively govern hepatic circadian clock. However, 
increased expression of hepatic CRY1 during the postprandial state is primarily 
regulated by the insulin-activated SREBP1c, which eventually leads to the 
suppression of glucose production via FOXO1 degradation (Figure 38). Although the 
roles of hepatic CRY1 in energy metabolism need to be investigated further, our data 
provide an important clue to understand the molecular mechanisms that link hepatic 





































Conclusion and perspectives 
1. Altering the hepatic circadian clock gene by feeding period restriction is 
associated with hepatic lipid and glucose metabolism, but not with body weight 
change  
The harmony of the peripheral circadian clock and the central circadian 
clock is involved in diverse metabolic homeostasis. Therefore, it is likely that 
dysregulated circadian clocks are closely linked with metabolic disorders such as 
diabetes, obesity and cardiovascular disease. The central circadian clock is regulated 
by light signal whereas the peripheral circadian clock is controlled by food intake and 
diverse hormones. Interestingly, it has been reported that shift workers are prone to 
have high body mass index and cardiovascular events, indicating that unsynchronized 
circadian clock might participate in metabolic dysregulation (Aronoff et al., 2001; 
Colles et al., 2007; Tholin et al., 2009). In this aspects, it has been proposed that 
circadian clock regulation might be a potential therapeutic approach to cure for 
obesity or metabolic disorders. 
As the prevalence of obesity continues to rise, its contribution to mortality 
increases. In particular, obesity-induced insulin resistance is one of the key factors 
for the development of metabolic diseases such as hypertension, atherosclerosis, and 
type 2 diabetes. The primary causes of obesity is simply expressed by higher energy 
intake compared to energy expenditure. To solve the relationship with 
139 
 
unsynchronized circadian clock and obesity, I analyzed two experimental groups that 
have equal amounts of energy intake with different circadian clock regulation by 
feeding period restriction.   
In chapter 1, I have demonstrated that an unsynchronized circadian clock 
with the same amounts of energy intake had no effects on body weight change. 
Because rodents, including experimental mice, are nocturnal animals who consume 
more food in night time than day time, I have provided the night time feeding group 
with the equal amounts of food as the day time feeding group. Compared to the ad 
libitum group, the day time feeding and night time feeding group are offered restricted 
calorie intake with both NCD and HFD. Intriguingly, obtained data reveal that the 
same amounts of food intake with different feeding periods do not affect the body 
weight change regardless of NCD or HFD.  
I also found out that lipid and glucose metabolisms were altered in liver upon 
feeding period restriction. The expression patterns of certain genes belonging to 
hepatic lipogenesis, gluconeogenesis, and lipid oxidation were influenced by feeding 
period alteration. Moreover, the levels of serum triacylglyceride, cholesterol, and 
glucose were changed, indicating that alteration of peripheral circadian clock genes 
is important for metabolic regulation. Although the mechanisms of how peripheral 
circadian clocks could regulate metabolic change are still to be elucidated, the results 
from chapter 1 is important for understanding the relationship between circadian 




2. Hepatic SREBP1c is a mediator of feeding dependent CRY1 gene alteration 
Accumulating evidences have suggested that key metabolic regulators are 
involved in the modulation of circadian clock gene expression. For example, PPARγ 
and its coactivator PGC1α activate BMAL1 transcription and regulate circadian 
oscillation (Lamia et al., 2009; Schmutz et al., 2010; Wang et al., 2008a). Moreover, 
RORα and Rev-erbα directly and inversely regulates BMAL1 gene expression to 
maintain circadian oscillation (Raspe et al., 2002; Tini et al., 1995). However, it has 
not been fully understood whether and how feeding or nutrient rich states might 
control circadian clock core genes in peripheral tissues.  
In chapter two, I have shown that SREBP1c activates CRY1 gene expression. 
SREBP1c is expressed in a precursor form, which is bound to the ER membrane. 
Under insulin signaling, SREBP1c precursor is processed by site 1 protease and site 
2 protease, and the truncated SREBP1c is located to the nucleus to activate its target 
gene such as FASN, SCD1 and itself. Further, SREBP1c is post-translationally 
activated with feeding signals accompanied with hormonal changes. CRY1 promoter 
contains both SRE motif and E-BOX motif which are binding motifs of SREBP1c. 
Also, E-box motif is a target element of BMAL1 and CLOCK heterodimer, which are 
the core regulators of circadian clock oscillation (Ramsey et al., 2007). I have 
demonstrated that SREBP1c stimulates CRY1 gene expression through SRE 
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sequence(s), not E-BOX motif. Luciferase assays performed with WT, 3XSRE 
mutants, and E-BOX have suggested that SRE sequences in the CRY1 promoter are 
target sites of SREBP1c. Because SREBP1c may not compete with BMAL1 and 
CLOCK at the E-box motif of CRY1 promoter, it appears that SREBP1c might have 
a little effects on circadian clock gene oscillation (Figure 37).   
 
3. SREBP1c-CRY1 axis participates in inhibition of gluconeogenesis in 
postprandial state 
SREBP1c is a well-known transcription activator that regulates lipid 
biosynthetic pathway in postprandial states. Recent data have also suggested that 
SREBP1c might participate in the suppression of hepatic gluconeogenesis (Lee et al., 
2007; Yamamoto et al., 2004). As a transcriptional activator, SREBP1c directly 
regulates lipogenesis by binding to target gene promoters. However, the molecular 
mechanism by which transcriptional activator SREBP1c may suppress gluconeogenic 
genes are not fully elucidated.  
In chapter two, I have revealed a novel signaling cascades of SREBP1c to 
mediate inhibition of hepatic gluconeogenesis. In liver, feeding or insulin mediated 
CRY1 activation by SREBP1c leads to degradation of FOXO1 protein, which is a 
crucial activator of hepatic gluconeogenesis. In primary hepatocytes, overexpression 
of SREBP1c downregulated glucose output and lowers PEPCK and G6Pase gene 
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expression. Overexpression of CRY1, as a novel target gene of SREBP1c, also 
repressed gluconeogenesis, whereas knock down of CRY1 led to increase in 
gluconeogenic gene expression. Among various signaling cascades that regulate 
gluconeogenesis, FOXO1 was regulated by CRY1. I have shown that CRY1 would 
act as a scaffold protein by binding with FOXO1 and MDM2 Ubiquitin E3 ligase 
MDM2 mediated FOXO1 ubiquitination, accompanied with FOXO1 protein 
degradation in liver. In addition, SREBP1c KO mice showed higher levels of blood 
glucose, and FOXO1 protein, compared to those of WT mice. Furthermore, CRY1 
overexpression in SREBP1c KO mice alleviated pyruvate induced blood glucose 
level. CRY1 KO mice also exhibited increased FOXO1 protein and expression of 
gluconeogenic genes, concomitant with higher blood glucose level.  
FOXO1 is a well-known transcription factor regulated by posttranslational 
modification. Under insulin signaling, insulin activated AKT phosphorylates FOXO1 
protein, which accelerates the translocation of FOXO1 into cytoplasm (Nielsen et al., 
2008; Tzivion et al., 2011; Wang et al., 2006). The key regulatory mechanism of 
insulin mediated suppression of gluconeogenesis has been reported that AKT 
mediated FOXO1 translocation. In this study, I have revealed a novel pathway that 
insulin sustainably suppresses hepatic gluconeogenesis by SREBP1c-CRY1. Insulin 
mediated FOXO1 phosphorylation occurs at an early time point whereas CRY1 is 
induced at the late stage of insulin action. I have discovered that CRY1 plays a key 
role to decrease FOXO1 protein upon insulin. To exclude the possibility that the effect 
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of AKT on FOXO1 phosphorylation, I have used AKT inhibitors. In both in vitro and 
in vivo experiments, AKT inhibitors intensified the stability of FOXO1 protein. In 
contrast, CRY1 overexpression dramatically lowers FOXO1 protein level with or 
without AKT inhibitor, implying that CRY1 would act as an inhibitor of FOXO1, 
independent of AKT activity.   
Although AKT mediated FOXO1 phosphorylation is one of the major 
inhibitory mechanisms of hepatic gluconeogenesis, here, I proposed that SREBP1c 
mediated CRY1 induction would be another crucial signaling pathways that 
participates in the suppression of gluconeogenesis in the postprandial state.  
 
4. Hyperglycemia is exacerbated by dysregulation of hepatic SREBP1c-CRY1 
signaling pathway 
Hepatic insulin signaling activates de novo lipogenesis for storage excess 
energy, and inhibits hepatic gluconeogenesis for maintaining blood glucose level. 
SREBP1c, one of key molecule in insulin signaling pathway, participates in both 
activation of de novo lipogenesis and inhibition of gluconeogenesis. Although 
hepatic SREBP1c activity is increased in obese animals, the inhibitory effect of 
SREBP1c on gluconeogenesis was not observed.  
Here, I found out that SREBP1c was increased in HFD fed mice and db/db 
mice, while CRY1 was not elevated in both obese mice models. To address the 
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question which limited CRY1 might be a cause of hyperglycemia in obesity, I have 
investigated the effects of CRY1 overexpression on glucose metabolism. In db/db 
mice CRY1 overexpression lowered blood glucose level as well as hepatic 
gluconeogenic gene expression, implying that insufficient CRY1 may not be enough 
to block FOXO1 activity for normalizing blood glucose level in obese animals. Of 
course, it is necessary to further investigate why activated SREBP1c fails to increase 
CRY1 gene expression in obese animals. Moreover, it is likely that various 
approaches with CRY1 modulation, including stability control, gene expression 
regulation, chromatin structure modulation, and epigenetic management, will be 
possible as a therapeutic target.  
Hyperglycemia is one of the many characters of obesity and diabetes. 
Lowering the blood glucose level is an important therapeutic approach for diabetes. 
Here, I have suggested that the peripheral circadian clock is important for metabolic 
regulation but not for body weight gain. Although obesity is associated with various 
metabolic complications, it appears that the primary cause of obesity is correlated 
with the amounts of food intake, but not circadian clock mediated metabolic changes. 
I have also elucidated a novel pathway that circadian clock is involved in the 
regulation of hepatic glucose metabolism. Under normal physiological condition, 
SREBP1c-CRY1 mediated FOXO1 degradation contributes to suppress 
gluconeogenesis. During this regulation, SREBP1c stimulated CRY1 expression and 
CRY1 acts as a scaffold protein by binding with MDM2 and FOXO1, leading to 
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FOXO1 degradation. Under pathophysiological conditions such as obesity, SREBP1c 
fails to activate CRY1 gene expression in liver, and as a consequence, 
gluconeogenesis is still highly activated. It is noteworthy that various approaches to 
modulate SREBP1c-CRY1 signaling pathway will give the opportunity for 
overcoming high blood glucose levels. Taken together, the characterization of the 
interaction between peripheral circadian clock and hepatic metabolism would be 
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최근 연구결과에 따르면 밤과 낮의 변화에 따라 발생하는 일주기성
은 개체의 행동 뿐 아니라 분자신호전달에도 중추적인 역할을 담당한다. 
또한, 정교하게 조절되는 일주기성은 몸의 에너지 항상성 유지에도 깊이 
연관되어 있음이 보고되었다. 이러한 측면에서 일주기성이 유지되지 못
하는 경우 포유동물은 비만 및 다양한 대사질환을 유발할 수 있다. 대표
적인 에너지 대사 조직인 지방조직, 근육조직, 간조직의 일주기성은 지방
생합성, 포도당생합성 및 지방 산화 작용 등을 조절한다. 또한, 중추조직
과 말초조직의 일주기성이 일치하지 않는 야간 근로자의 경우 대사질환
이 자주 발생하는 경향이 보고되고 있다. 그러나 일주기성의 생리적 및 
병리적 역할과 체내 에너지 대사조절과의 상호 관계에 대해서는 분자수
준의 연구가 부족한 상황이다.  
본 연구를 통해 중추조직과 말초조직의 일주기성이 일치하지 않을 
경우 간조직의 포도당 및 지방대사는 변화하는 반면 체중에는 영향을 미
치지 않음을 발견하였다. 같은 양의 음식물을 다른 시간대에 섭취하는 
조건에서 말초조직의 일주기성은 섭식 시간에 따라 변화하는 것을 관찰
한 반면, 중추조직의 일주기성은 변하지 않는다는 것을 관찰 할 수 있었
다. 간조직에서 대표적인 일주기성 유전자인 BMAL1, CLOCK, PER2는 
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음식 섭취시간대에 따라 그 발현이 변함을 관찰하였다. 간조직의 지방대
사, 포도당대사, 지방 산화에 연관된 유전자들 또한 음식섭취 시간대의 
변화에 따라 발현양상이 다르게 조절되었다. 이와 같은 현상은 저칼로리 
음식물이나 고칼로리 음식물을 섭취한 야생형 생쥐 모두에서 관찰되었다. 
본 연구를 통하여 체중증가에 있어 음식물 섭취 시간대의 변화는 보다는 
음식물의 섭취량이 핵심적임을 확인할 수 있었다.   
본 학위 논문연구 동안 본인은 음식섭취와 인슐린에 의해 증가되는 
CRY1 유전자가 포도당 생합성을 억제함을 발견하였다. 전사인자인 
SREBP1c는 음식섭취에 의해 활성화되어 간조직에서 지방생합성을 관장
하는데, 간세포의 SREBP1c가 음식섭취에 의해 CRY1의 발현을 증가 시
킴을 발견하였다. 간세포주에 CRY1을 과발현 시켰을 경우 포도당생합성 
유전자인 PEPCK, G6Pase의 발현이 억제되었고, FOXO1의 단백질량이 
감소하였다. 간세포주에서 CRY1은 인슐린을 8시간 이상 처리했을 경우 
증가되었고 이상의 연구를 통하여 CRY1은 인슐린이 지속적으로 포도당
생합성을 억제하는 과정 중 중요한 매개자의 역할을 수행하는 것으로 추
정된다. 흥미롭게도, SREBP1c에 의해 증가된 CRY1은 FOXO1의 단백질 
분해 기전을 촉진시켰으며, FOXO1의 E3 ubiquitin ligase인 MDM2와
의 결합을 강화시키는 Scaffold protein의 역할을 담당할 수 있음을 
발견하였다. 이와 관련하여, 간에서 SREBP1c가 증가되어 있음이 보고된 
163 
 
db/db 생쥐와 고지방성식이 유도 비만 생쥐 모델에서 CRY1의 발현이 
동반하여 증가하지 않았으며, 그 결과 포도당생합성이 증가될 수 있음을 
발견하였다. 그러나 db/db 생쥐에 CRY1을 과발현 시킨 경우 혈당을 낮
추는 동시에 간에서 포도당생합성 관련 유전자들의 발현이 억제됨을 관
찰하였다.  
본 연구의 결과들을 종합하여 살펴볼 때, 일주기성 유전자는 간조직
의 에너지대사를 능동적으로 조절하는 것으로 생각된다. 다양한 일주기
성 유전자 가운데 SREBP1c에 의해 증가하는 CRY1은 FOXO1의 단백질 
분해 과정 유도를 통해 간세포 내 포도당생합성 유전자의 발현을 억제할 
수 있다. 또한, 체중 증가는 말초기관의 일주기성 유전자의 발현 변화에 
의한 것이 아니라 섭취한 음식물의 에너지 양에 의해 결정되는 것으로 
추정된다. 그러므로 적절한 SREBP1c-CRY1 신호전달 경로의 조절은 체
내 에너지대사 항상성 유지에 핵심적인 신호전달 경로 중 하나임을 제안
한다. 
주요어: 비만, 당뇨, 일주기성, SREBP1c, CRY1, FOXO1, MDM2, PEPCK, 
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Roles of peripheral circadian clock in the regulation of 
hepatic energy homeostasis 
 
Hagoon Jang 
 Emerging evidence has suggested that the circadian clock is a control tower 
in the regulation of behavioral and molecular processes under day/night cycle. Also, 
precise regulation of the circadian clock is crucial for maintaining whole-body energy 
homeostasis. Thus, dysregulation of the circadian clock is closely associated with 
obesity and metabolic complications. In metabolic organs, such as adipose tissue, 
muscle and liver, the circadian clocks affect various metabolic processes including 
lipogenesis, gluconeogenesis and lipid oxidation. Moreover, unsynchronized 
cooperation between the hypothalamic central clock and the peripheral clock, in shift 
workers, is prone to occur metabolic disorders. However, the pathophysiological role 
of the circadian clock and its metabolic regulatory processes have not been 
thoroughly elucidated.  
In this study, I have demonstrated that unsynchronized circadian clock 
influences hepatic glucose and lipid metabolisms without altering body weight. With 
the same amounts of caloric intake during different time periods, the expression 
patterns of peripheral circadian clock genes showed different by day time feeding and 
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night time feeding, while that of light-regulated hypothalamic circadian clock genes 
was not affected. For instance, the expression pattern of core circadian clock genes, 
such as BMAL1, CLOCK and PER2 in peripheral tissues, was altered by different 
feeding periods. In addition, hepatic expression of lipogenic genes, gluconeogenic 
genes, and fatty acid oxidation genes was also changed by feeding periods. In 
conclusion, it is likely that the amounts of food consumed might be a crucial factor 
to induce obesity compared to feeding time because feeding period restriction has no 
effects on body weight gain either normal chow diet (NCD) or high fat diet (HFD).  
In addition, I have revealed that feeding-induced CRY1 gene expression 
leads to suppression of hepatic gluconeogenesis. Given that SREBP1c is a well-
known transcriptional activator in postprandial state for activating lipogenesis, I 
found out that SREBP1c stimulated CRY1 gene expression. CRY1 was induced by 
feeding and insulin challenge. In addition, I have shown that hepatic SREBP1c 
contributed to repress gluconeogenesis through CRY1 induction. Hepatocytes 
overexpressing CRY1 inhibited hepatic gluconeogenic genes, such as PEPCK and 
G6Pase, via lowering FOXO1 protein. Furthermore, CRY1 was elevated in long term 
insulin action for sustainable suppression of hepatic gluconeogenesis. Intriguingly, 
SREBP1c-induced CRY1 accelerated FOXO1 degradation via ubiquitination. I 
discovered that CRY1 would act as a scaffold protein by binding with MDM2, an E3 
ubiquitin ligase, and FOXO1. Although SREBP1c is increased in obese diabetic 
animals, such as db/db mice and HFD fed mice, SREBP1c failed to stimulate CRY1 
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and thereby hepatic gluconeogenesis was not suppressed in obese animals. When I 
overexpressed CRY1 in the liver of db/db mice to test the CRY1 effects on 
gluconeogenesis suppression. CRY1 overexpression reduced blood glucose level as 
well as downregulated hepatic gluconeogenic gene expression. Taken together, these 
data suggest that circadian clock genes actively and dynamically regulate energy 
metabolism in the liver. Among many circadian clock genes, SREBP1c-induced 
CRY1 especially contributes to the suppression of hepatic glucose production through 
FOXO1 degradation in liver. However, body weight gain is mainly determined by the 
amounts of calorie intake rather than alteration of peripheral circadian clock gene. 
Therefore, it is likely that appropriate regulation of SREBP1c-CRY1 signaling 
pathway would be crucial for maintaining whole-body energy homeostasis.  
 
 
Key words: Obesity, Diabetes, Circadian clock, SREBP1c, CRY1, FOXO1, MDM2, 
PEPCK, G6Pase, Hepatic gluconeogenesis, Insulin signaling  
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1. Circadian clock and metabolic regulation 
 
(1) Circadian clock 
 
Circadian clocks control behavioral and molecular processes with the day 
and night cycle. The molecular circadian clock in mammals exists within pacemaker 
neurons of the suprachiasmatic nucleus (SCN) and peripheral tissues. The central 
SCN clock regulates standard time for peripheral tissue clock (Ramsey et al., 2007). 
Various physiological changes, such as sleep-wake cycles, body temperature, blood 
pressure, and hormone secretion, are associated with the circadian clock. Molecular 
circadian oscillation is composed of transcription-translational auto-regulatory 
negative feedback loops; BMAL1, CLOCK, PER, and CRY are key circadian 
molecules that produce rhythmic oscillations in a cell-autonomous manner (Thresher 
et al., 1998; Vitaterna et al., 1999). BMAL1 and CLOCK play key roles in inducing 
PER and CRY. Induced PER and CRY then form a transcriptional repressor complex 
to suppress BMAL1 and CLOCK, which eventually leads to negative feedback 
regulation (Figure 1). In addition, BMAL1 and CLOCK also increase the mRNA 
levels of Rev-erbα and RORα, which then compete to bind to the retinoic acid-related 
orphan receptor response elements (ROREs) in BMAL1 promoter and repress or 
activate the expression of BMAL1, respectively (Raspe et al., 2002; Tini et al., 1995). 









Figure 1. Molecular clock: circadian negative feedback loop.  
CLOCK and BMAL1, heterodimer initiates transcription of target genes such ‘period’ 
genes (PER1, PER2, and PER3) and two cryptochrome genes (CRY1 and CRY2). 
Negative feedback is achieved by PER/CRY complexes which translocate into the 
nucleus to suppress their own transcription by blocking the activity of the 
























Moreover, these auto-regulatory loops are modulated by various post-
translational modifications such as phosphorylation, sumoylation, acetylation, and 
ubiquitination. For instance, casein kinase phosphorylates the PER proteins for 
degradation via the Skp1, cullin1, F-box protein (SCF)/ B-TrCP ubiquitin ligase 
complex. Adenosine monophosphate kinase (AMPK) phosphorylates CRYs and 
leads to ubiquitin-mediated proteasomal degradation via the SCF/FBXL3 ubiquitin 
ligase complex (Lamia et al., 2009; Zheng et al., 2014). In addition, cellular NAD+ 
level regulates SIRT1 activity which participates in CLOCK protein deacetylation 
(Peek et al., 2013; Ramsey et al., 2009).   
Central SCN circadian oscillation is primarily regulated by light, whereas 
peripheral circadian oscillation is affected by food intake along with hormones such 
as insulin and glucagon (Gamble et al., 2014; Hoyle and O'Neill, 2013). These clocks 
regulate biological processes to maintain whole-body homeostasis with the 
environmental changes of light and nutrients (Figure 2). Many recent studies have 
shown that numerous aspects of metabolic regulation, such as circulating hormones, 
intracellular metabolites, and feeding behaviors, exhibit daily rhythmicity 
(Brandenberger and Weibel, 2004).  
(2) Circadian clock and metabolic regulation 









Figure 2. Light-dependent central clock and feeding-mediated peripheral clock.  
The master pacemaker within SCN, although clock genes are also expressed in other 
tissues such as liver, adipose tissue, and pancreas. Emerging evidence suggests that 





















with whole-body energy homeostasis. For example, the finding that participation of 
the orphan nuclear hormone receptors, Rev-erbα and the opposing RORα, in a short 
feedback loop by controlling BMAL1 transcription provides a direct evidence for 
metabolic input into the molecular clock (Raspe et al., 2002; Tini et al., 1995). In 
addition, peroxisome proliferator-activated receptor α (PPARα) and peroxisome 
proliferator-activated receptor gamma coactivator 1 α (PGC1α) also regulate 
BMAL1 transcription via circadian core feedback loop (Liu et al., 2007). Moreover, 
microarray analysis reveals that more than half of transcripts show rhythmic gene 
oscillation, with some variation among different tissues such as liver, skeletal muscle, 
and brown and white adipose tissue (Yang et al., 2006). The numbers of transcripts 
rhythmic oscillation are up to 20%, indicating that a large proportion of the 
transcriptomes seem to be affected by circadian genes. These oscillating genes are 
involved in biosynthetic and metabolic processes such as cholesterol and lipid 
metabolism, glycolysis and gluconeogenesis, oxidative phosphorylation, and 
detoxification pathways (Akhtar et al., 2002; McCarthy et al., 2007). Interestingly, 
most rate-limiting enzymes in these metabolic pathways are regulated by circadian 
clocks, implying that the clocks could influence on biosynthetic and metabolic 
processes whole-body metabolic homeostasis 
(3) Circadian clock and metabolic disorder 
In the aspect of clinical studies, several evidences suggest that circadian 
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disruption is associated with metabolic complications across large portions of the 
human population (Karlsson et al., 2001). Cross-sectional studies have revealed an 
increased prevalence of metabolic syndrome, such as high body mass index and 
cardiovascular events, in shift workers. These observations suggest the possibility 
that chronic disharmony between central and peripheral clocks, combined with 
light/dark and fasting/feeding, might contribute to body weight gain and metabolic 
complications (Kalra and Kalra, 2004). In addition, intriguing human behavioral 
studies propose that nocturnal feeding patterns might be related with metabolic 
diseases (Ayala et al., 2009). These findings have been recapitulated by recent rodent 
experimental studies, indicating that diet-induced obesity (DIO) with HFD may lead 
to increased energy intake only in the rest/light period and not in the active/dark 
period (Kohsaka et al., 2007). In addition, several rodent models have suggested that 
circadian clock regulation is associated with metabolic disease. For example, 
CLOCK-defective mice show increased body weight and hyperphagia with disrupted 
circadian oscillation (Turek et al., 2005). HFD-fed mice become obese and diabetic 
concomitantly with altered expression of circadian clock genes (Kohsaka et al., 2007). 
BMAL1 knockout mice show dysregulation of hepatic glucose homeostasis (Rudic 
et al., 2004). Furthermore, key metabolic genes, such as PPARα, PPARγ, and AMPK, 
are involved in the regulation of circadian genes, and the circadian clocks in turn 
modulate whole-body energy metabolism (Lamia et al., 2009; Schmutz et al., 2010; 
Wang et al., 2008a). In addition to rodent studies, the control of glucose metabolism 
9 
 
by circadian oscillation in humans is a well-known aspect of clinical diabetes 
management, and a variation of the normal cyclic pattern of glucose tolerance is an 
important indicator of type 2 diabetes (Allison et al., 2007; Tasali et al., 2008).  
Unsynchronized central and peripheral clocks caused by different regulation 
of light/dark cycle and the feeding/fasting cycle have been implicated in metabolic 
disorder, along with higher calorie intake in the case of shift-workers (Ellingsen et al., 
2007; Karlsson et al., 2001). Under physiological conditions, the central and 
peripheral clocks are synchronized by the light/dark cycle and the feeding/fasting 
cycle. However, it has been also demonstrated that disharmonious signaling by these 
two cues leads to the independent regulation of each circadian oscillation. Although 
it appears that there is a close relationship between the circadian clock and metabolic 
regulation, the effects of unsynchronized SCN and peripheral-tissue circadian clocks 
on metabolic regulation are largely unknown. In addition, it is still elusive whether 
feeding period alteration might be a key determinant of body weight change without 
change of total calorie intake.   
 
2. Hepatic lipid and glucose metabolism 
(1) Lipogenesis 
In liver, synthesis of triacylglycerides in liver is nutritionally and 
hormonally regulated. The ingestion of a high-carbohydrate diet causes a marked 
elevation of enzymes involved in key metabolic pathways, including glycolysis, 
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lipogenesis, fatty acid elongation and desaturation steps, and finally triacylglyceride 
synthesis. Especially, lipogenesis is the process that converts acetyl-CoA to fatty 
acids. Acetyl-CoA is an intermediate metabolite produced from glucose, a source of 
primary energy of living organisms. Through lipogenesis and subsequent 
triacylglyceride synthesis, the excess energy can be efficiently stored in the form of 
neutral lipid metabolites (Ferre and Foufelle, 2010). Acetyl-CoA carboxylase (ACC) 
converts acetyl-CoA to malonyl-CoA, and increased malonyl-CoA level leads to 
produce long chain fatty acids. This reaction is the controlling step in fatty acid 
synthesis and takes place in the cell cytosol. The overall synthesis of fatty acids is 
catalyzed by the fatty acid synthase (FASN) complex, a single polypeptide containing 
seven distinct enzymatic activities (Griffin and Sul, 2004).  
Sterol regulatory element binding proteins (SREBPs) including SREBP1a, 
SREBP1c, and SREBP2 belong to the basic-helix-loop-helix-leucine zipper (bHLH-
LZ) transcription factor family that regulates de novo lipogenesis and cholesterol 
biosynthetic pathway (Figure 3) (Brown and Goldstein, 1997). SREBP precursor 
consists of structurally three functional domains; an NH2-terminal domain that 
contains the bHLH-LZ region for DNA binding, two hydrophobic transmembrane 
spanning domains interrupted by a short loop which are inserted into the lumen of 
ER, and COOH-terminal domain that recruits the gene regulatory machinery (Figure 








Figure 3. Structure of SREBP isotypes.  
Sterol regulatory element binding protein (SREBP) was identified as a protein that 
bound to the sterol regulatory element (SRE). SREBPs are a family of transcription 
factors that control lipid homeostasis by regulating the expression of enzymes 
required for cholesterol, fatty acid, triacylglycerol, and phospholipid synthesis. 
SREBPs are synthetized as precursor forms bound to the endoplasmic reticulum 
membranes. Upon activation, the precursor undergoes a sequential two step cleavage 























SREBP cleavage-activating protein (SCAP) is a sensor of cholesterol, and escorts the 
SREBP from the ER to the Golgi, where there are two proteases involved in the 
cleavage (DeBose-Boyd et al., 1999; Tomita et al., 1998). In the Golgi apparatus, 
SREBP is released from the Golgi membrane through cleavage by Site-1 protease 
(S1P) and Site-2 protease (S2P). The NH2-terminal domain of SREBPs is 
translocated to the nucleus, where it stimulates target gene transcription by binding 
to sterol response elements (SREs) or E-BOX in the promoter/enhancer regions of 
various target genes (Kim et al., 1995).  
SREBP1c is the master regulator of de novo lipogenesis in fat tissue and 
liver (Shimomura et al., 1999a). Insulin, which is released from pancreatic β-cells, 
stimulates, leading to fatty acid synthesis during nutrient rich status (Kim et al., 
1998a). However, glucagon, which is released from pancreatic α-cells during fasting, 
suppresses SREBP1c mediated lipogenic action (Lee et al., 2014a). SREBP1c 
regulates lipogenic pathways by stimulating the expression of fatty acid synthase 
(FASN), stearoyl-CoA desaturase 1 (SCD1) and acetyl-coenzyme A carboxylase 
(ACC) (Kim et al., 1998a; Shimomura et al., 1999b). The level of SREBP1c falls in 
streptozotocin-treated animals by accelerating pancreatic β-cell apoptosis and 
increases after insulin injection (Shimomura et al., 1999b). Moreover, overexpression 
of nuclear SREBP1c in livers of transgenic mice prevents the reduction of lipogenic 
action in fasting (Takahashi et al., 2005). Taken together, accumulating evidences 
indicate that SREBP1c is a key player in insulin-mediated lipogenic activation in liver.  
14 
 
(2) Glucose metabolism 
During fasting, most animals maintain energy balance by shifting from 
glucose utilization to fat burning. The levels of glycogenolysis and gluconeogenesis 
are increased to provide glucose as an energy source in many organs and tissues such 
as the brain and the red blood cell compartment, which are deficient in enzymes for 
burning free fatty acids (Altarejos and Montminy, 2011; Roach et al., 2012). Fasting 
also triggers elevation of circulating free amino acids, which are also major 
precursors for hepatic glucose production. When fasting is prolonged, hepatic 
gluconeogenesis is blocked to protect against excessive muscle wasting by over-
converting protein to glucose, and liver derived ketone bodies become the primary 
energy source for the brain (Morris, 2005).  
During fasting, elevated levels of circulating pancreatic glucagon stimulate 
the gluconeogenic program through the activation of the protein kinase A (PKA) 
pathway. Increased cAMP levels activate PKA, then gluconeogenic genes such as 
phosphoenol pyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase) 
are upregulated (Montminy et al., 2004). cAMP response element binding protein 
(CREB), one of major regulators of hepatic gluconeogenesis, binds to promoters for 
the PEPCK and G6Pase genes to directly stimulate the gluconeogenic program. The 
significance of CREB in the activation of hepatic gluconeogenesis has been revealed 
by a study utilizing albumin-ACREB TG mice overexpressing a dominant negative 
CREB in liver (Herzig et al., 2001). These mice show lower blood glucose levels with 
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downregulated mRNA levels for hepatic gluconeogenic genes, indicating that CREB 
is a physiological transcriptional regulator of gluconeogenesis in vivo. 
In parallel, decrement of insulin signaling upon fasting also stimulates 
gluconeogenic gene expression through dephosphorylation and nuclear translocation 
of the forkhead box (FOXO) domain proteins (Matsumoto and Accili, 2005). FOXO1 
belongs to a subclass of the forkhead family of transcription factors which have a 
forkhead box type DNA binding domain. FOXO1 recognizes insulin response 
element (IRE) located in the promoters of PEPCK and G6Pase. Regulation of 
subcellular localization of FOXO1 is one of the important regulatory pathways to 
control its activity, which is modulated by the phosphorylation status of Ser/Thr 
residues. Insulin and PI3K signaling pathway activates AKT-dependent 
phosphorylation of FOXO1 and phosphorylated FOXO1 binds with 14-3-3 shuttle 
protein to translocate to the cytoplasm (Nielsen et al., 2008; Tzivion et al., 2011; 
Wang et al., 2006). The cytoplasm-localized FOXO1 then undergoes subsequent 
degradation by an ubiquitin-proteasome pathway. Although the translocation of 
hepatic FOXO1 from the nucleus to the cytoplasm is a well-defined mechanism 
mediating a quick decrease in glucose production by insulin, it is largely unknown 
how insulin provides a sustainable inhibition of hepatic gluconeogenesis during the 
postprandial state. 
Interestingly, SREBP1c appears to be involved in hepatic carbohydrate 
metabolism. For example, SREBP1c affects the mRNA levels of PEPCK, G6Pase, 
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and IRS-2 genes and inhibits the interaction between HNF4 and PGC1α to suppress 
gluconeogenic genes (Lee et al., 2007; Yamamoto et al., 2004). Although it has been 
reported that hepatic SREBP1c suppresses hepatic glucose production, the molecular 
mechanism(s) by which SREBP1c could repress hepatic gluconeogenesis is unclear. 
(3) Selective insulin resistance in liver 
Under nutrient rich status, pancreatic β-cell secrets insulin, which is one of 
the major anabolic hormones in human body. Insulin accelerates glucose uptake in 
fat tissue and muscle as well as inhibits hepatic gluconeogenesis for lowering blood 
glucose level (Biddinger and Kahn, 2006). Moreover, insulin elevates lipogenic 
activity to store excess energy as triacylglyceride in liver and fat tissue (Kim et al., 
1998a).  
Type 2 diabetes are closely associated with hyperinsulinemia, 
hyperglycemia, and hypertriacylglyceridemia. Insulin resistance is one of the 
characteristics of type 2 diabetes. In insulin resistant animals, increased insulin is not 
enough to lower blood glucose, and consequently hyperglycemia reveals (Saltiel and 
Kahn, 2001). In diabetic subjects, liver, muscle, and adipose tissue are the major 
insulin resistant organs and the precise contributions of each organ to hyperglycemia 
and hypertriacylglyceridemia are unclear.   
Upon feeding conditions, increased plasma insulin levels elicit two key 
actions at the level of gene expression, at least, in the liver. First, insulin activates 
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transcription factor SREBP1c which enhances transcription of genes required for 
fatty acid and triacylglyceride biosynthesis such as ACC and FASN (Kim et al., 
1998a). In liver, the newly synthesized triacylglycerides are secreted in the form of 
very low density lipoproteins (VLDL), which are delivered to adipose tissues for 
storage and to muscles for fueling. The uptake of VLDL-derived fatty acids in adipose 
tissue is facilitated by insulin, which activates lipoprotein lipase on the surface of 
endothelial cells (Bourgeois et al., 1995; Lewis et al., 1994). Second, insulin 
stimulates the phosphorylation of FOXO1, a transcription factor that activates 
gluconeogenesis (Puigserver et al., 2003; Schilling et al., 2006; Xiong et al., 2013). 
Insulin-mediated FOXO1 phosphorylation prevents FOXO1 from entering the 
nucleus, which downregulates the expression of genes required for gluconeogenesis, 
including PEPCK and G6Pase. Blocking of hepatic glucose production by insulin is 
one of the crucial pathways to maintain blood glucose homeostasis. Interestingly, in 
diabetic liver, FOXO1 pathway becomes insulin resistant whereas SREBP1c-
mediated lipogenesis shows insulin sensitive (Figure 4)  (Brown and Goldstein, 
2008). Despite extremely high insulin levels, the mRNAs of PEPCK and G6Pase 
remain high, and gluconeogenesis continues in diabetic liver. Moreover, since nuclear 
SREBP1c levels are high, fatty acid synthesis is accelerated and triacylglycerides are 
accumulated, leading to hepatic steatosis (Lee et al., 2014a). Further, elevated hepatic 
triacylglycerides are secreted via VLDL, raising plasma triacylglyceride levels in 







Figure 4. Selective insulin resistance in liver.  
(A) Normal insulin response in liver. Insulin activates SERBP1c-mediated 
lipogenesis whereas inhibits gluconeogenesis. (B) Selective insulin resistance in liver 
of type 2 diabetes. Hyperinsulinemia still activates lipogenic action while is not able 
















Normal condition of insulin signaling 





aggravate insulin resistant state in muscle and adipose tissue, and the net results 
become hyperglycemia, hyperinsulinemia, and hypertriacylglyceridemia in type 2 
diabetic animals (Figure 4).  
An understanding the selective insulin resistance in diabetic liver is 
important for providing appropriate approaches to type 2 diabetes. Although it has 
been reported that hepatic SREBP1c is upregulated in obese animals, it is unknown 
why increased SREBP1c appears to fail to repress hepatic gluconeogenesis. Thus, it 
is crucial that understanding the molecular mechanisms by which SREBP1c could 
modulate gluconeogenesis under physiological and pathological conditions.   
 
 
3. Purpose of this study 
Circadian clock has a close correlation with metabolic regulation. Feeding 
is a major trigger that modulates the peripheral circadian clock while light activates 
the central circadian clock. These biological clocks are synchronized and synergically 
regulates various whole-body homeostasis including metabolism, body temperature, 
and sleep/wake cycle. Emerging evidence for the roles of circadian clock in metabolic 
tissues, such as adipose tissue, liver and muscle, proposes that the circadian clock 
actively interacts with metabolic signaling pathway to maintain the whole-body 
biological clock and energy homeostasis.  
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In this study, I have focused on body weight change according to feeding 
period restriction to investigate whether the restriction of feeding periods may affect 
body weight gain upon NCD and HFD. Whether the modulated peripheral circadian 
clock or the different amounts of food intake might be the primarily cause of obesity 
in shift workers is unclear. I have demonstrated that body weight gain in mice is not 
significantly changed by restricting feeding period to daytime or to nighttime if the 
animals take same calorie intake. On the contrary, the expression of peripheral 
circadian clock genes was altered by feeding period restriction, while the expression 
of light-regulated hypothalamic circadian clock genes was unaffected by both a NCD 
and HFD. The expression of lipogenic genes, gluconeogenic genes, and fatty acid 
oxidation related genes in the liver was also altered by feeding period restriction. 
Given that feeding period restriction does not affect body weight gain with both a 
NCD and HFD, it is likely that the amount of food consumed might be a crucial factor 
in determining body weight. In the second part, I have aimed to find out the new 
target gene of SREBP1c to find the signaling pathway that suppresses the 
gluconeogenesis. Although SREBP1c suppresses hepatic glucose production, the 
underlying molecular signaling pathway is unclear. To find out missing link between 
SREBP1c and inhibition of gluconeogenesis, I discovered CRY1 as a new target gene 
of SREBP1c. With fasting and refeeding experiment, I have shown that CRY1 is 
increased by feeding and insulin, which suppresses hepatic glucose production by 
FOXO1 degradation. Taken together, I would like to propose that the interpretation 
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of the relationship between circadian clock and hepatic glucose/lipid metabolism is 

























Feeding period restriction alters expression of 
peripheral circadian rhythm genes without body 










Accumulating evidence suggests that circadian clock is closely associated 
with metabolic regulation. However, it has not been clearly understood whether 
impaired circadian clock is a direct cause of metabolic dysregulation including body 
weight gain. In this study, I demonstrate that mice body weight gain is not 
significantly changed by feeding period restriction; ad libitum, day time feeding and 
night time feeding. Expression of peripheral circadian clock genes was altered by 
feeding period restriction, while that of light-regulated hypothalamic circadian clock 
genes was not affected with either normal chow diet (NCD) or high fat diet (HFD). 
In liver, the expression pattern of circadian clock genes including BMAL1, CLOCK, 
and PER2 was changed by different restrictions of feeding period. Moreover, the 
expression of lipogenic genes, gluconeogenic genes, and fatty acid oxidation-related 
genes was also altered in liver by feeding period restriction. Taken together, these 
data suggest that restriction of feeding period would modulate expression of 
peripheral circadian clock genes, which is uncoupled from light-sensitive 
hypothalamic circadian clock genes, even though feeding period restriction might not 
be a crucial factor to affect body weight gain under NCD or HFD, implying that the 






Various physiological and behavioral oscillations such as sleep-wake cycles, 
body temperature, blood pressure, and hormone secretion are associated with 
circadian clock (Bass and Takahashi, 2010). Circadian oscillation is composed of 
auto-regulatory negative feedback loops; BMAL1, CLOCK, PER, and CRY are key 
circadian transcription factors that determine rhythmic oscillation in a cell-
autonomous manner. BMAL1 and CLOCK play a key role to induce PER and CRY. 
Then, elevated PER and CRY form a transcriptional repressor complex to suppress 
BMAL1 and CLOCK, which eventually leads to negative feedback regulation. In 
addition to the PER and CRY targets, BMAL1 and CLOCK also activate mRNA level 
of Rev-erbα and RORα, which thereafter compete for binding to the retinoic acid 
related orphan receptor response elements (ROREs) as to repress or activate 
expression of Bmal1, respectively. This alternating promoter occupancy is due to 
rhythmic expression of Rev-erbα (Green et al., 2008). In addition, these auto-
regulatory loops are modulated by various post-translational modifications such as 
phosphorylation, sumoylation, acetylation, and ubiquitination (Lamia et al., 2009; 
Nakahata et al., 2009; Shirogane et al., 2005).  
Circadian clock exists in the hypothalamic suprachiasmatic nucleus (SCN) 
as well as peripheral tissues including liver and fat (Bass and Takahashi, 2010). SCN 
circadian oscillation is primarily regulated by light signal whereas peripheral 
circadian oscillation is affected by food intake accompanied by hormones such as 
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insulin and glucagon (Green et al., 2008). Emerging evidences have suggested that 
circadian clock is deeply associated with whole-body energy homeostasis. For 
instance, CLOCK defective mice exhibit obesity and hyperphagia with disrupted 
circadian oscillation (Turek et al., 2005). High fat diet (HFD) fed wild type mice 
become obese and show altered expression of circadian clock genes with metabolic 
dysregulation (Kohsaka et al., 2007). Further, liver specific Bmal1 knockout mice 
lose their hepatic glucose homeostasis (Canaple et al., 2006). Moreover, key 
metabolic genes such as PPARα, PPARγ, and AMPK are involved in the regulation 
of circadian genes, and circadian clocks in turn modulate whole-body energy 
metabolism (Canaple et al., 2006; Lamia et al., 2009; Wang et al., 2008b). Under 
physiological conditions, SCN clock and peripheral clock are synchronized by light-
dark cycle and feeding-fasting cycle. Nonetheless, it has been also demonstrated that 
disharmonious signaling of these two cues, light-dark cycle and feeding-fasting cycle, 
independently regulates each circadian oscillation (Damiola et al., 2000). Although it 
appears that there is a close relationship between circadian clock and metabolic 
regulation, the effects of unsynchronized circadian clocks in SCN and peripheral 
tissues on metabolic regulation are largely unknown. In addition, it is unclear whether 
alteration of feeding periods would be a major determinant of body weight change 
even when there is no change of calorie intake.  
In this study, I have investigated whether the restriction of feeding periods 
may affect body weight gain upon NCD and HFD. Also, I have analyzed gene 
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expression profiles of circadian clocks from SCN and peripheral tissue under different 
feeding periods. Our data suggest that feeding period restriction would not influence 
body weight gain whereas it would differently regulate circadian oscillations in 

















Animal care and experimental protocol 
 Four-week-old male C57BL/6N mice were obtained from SAMTAKO BIO 
KOREA Co., Ltd. Mice were maintained according to the guidelines of Seoul 
National University Animal Experiment Ethics Committee. They were housed in 
individual cages for pair feeding in 12 hr light/ 12 hr dark cycles. After a minimum 
1-week stabilization period, ad libitum group mice (5 weeks old) were exposed to 
food freely, and the night time fed mice were pair fed to match the amount of food of 
day time group with NCD and 60% HFD (Research Diets, Inc.) for 4 weeks (Figure 
5). Only those pair-fed mice (night time fed) with similar body weights as those of 
day time fed mice were subjected to the procedure from 5 weeks of age to 9 weeks of 
age. Body weight and food intake were measured daily at ZT0 (7 a.m.) and ZT12 (7 
p.m.) during the experimental protocol. The average initial body weights in each 
group of mice were not different. All mice were euthanized, and dissected tissue 
specimens were immediately stored at -80C until analysis.  
 
Quantitative real-time RT-PCR analysis 
Total RNAs were isolated from liver and hypothalamus as described 
previously (Choe et al., 2007), and cDNA was synthesized using the M-MuLV reverse 
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transcriptase kit (Fermentas, Glen Burnie, MD). The primers used for the real-time 
PCR analyses were produced in Bioneer (Korea). The primer sequences used for real-
time PCR analyses are provided in supplementary Table 1. 
  
Biochemical analysis 
The levels of plasma cholesterol and triacylglycerides were measured using 
Infinity reagents (Thermo, Melbourne, Australia). Plasma glucose levels were 























 Feeding period restriction does not change body weight gain 
  To address the question whether body weight gain is sensitively altered by 
feeding behavior, accompanied with changes of circadian clock genes, I have 
investigated the effects of feeding period restriction on body weight. Restriction of 
feeding period has been designed with the following three groups: 1) ad libitum in 
which mice were freely exposed to food, 2) restriction feeding to day time (RF Day), 
in which mice could access food only in day time, and 3) pair-feeding in night time 
(PF Night), in which mice were given the same amount of food as the RF Day group 
only in night time (Figure 5). Since mice are nocturnal animals that would take most 
food at night time than during day time, I measured the amount of food intake in day 
time, and the same amount of food was given to night time feeding (PF Night) group. 
I have designed the pair-feeding group to investigate the effect of feeding period 
variation on body weight with the same amount of calorie intake. Moreover, mice 
were fed with either normal chow diet (NCD) or high fat diet (HFD) in order to test 
the effects of different nutrition sources on body weight gain upon feeding period 
restriction. 
Interestingly, I observed that RF Day and PF Night groups revealed a similar 
pattern of body weight gain, regardless of diet source (NCD or HFD) (Figure 6A, 6B, 







Figure 5. Feeding period restriction scheme for the three feeding groups in this 
study.  
The ad libitum (AL) group was freely exposed to food; the feeding restricted to day 
time (RF Day) group could access food only during daytime; and the pair-feeding at 
night (PF Night) group was given the same amount of food as the RF Day group but 
only at night. Mice were fed with a normal chow diet (NCD) or a high-fat diet (HFD). 
The light was turned on at ZT0 and turned off at ZT12. At ZT2 and ZT14, mice were 




























Figure 6.  Feeding period restriction does not change body weight gain.  
(A and B) Body weight gain or total body weight of AL, RF Day, and PF Night NCD-
fed mice. (C) Total food intake in NCD-fed AL and RF Day mice. (D and E) Body 
weight gain or total body weight of AL, RF Day, and PF Night HFD-fed mice. (F) 
Total food intake in HFD-fed AL and RF Day mice. Each bar represents mean ±SD 
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body weight gain of ad libitum group was significantly increased with either NCD 
or HFD (Figure 6A, 6B, 6D, 6E). When the amounts of cumulative food intakes 
were measured, ad libitum group gradually consumed more food than RF Day or PF 
Night group (Figure 6C, 6F). Recently, it has been reported that circadian clock is 
disrupted by HFD (Kohsaka et al., 2007). Thus, I examined food intake patterns 
during day time (ZT0-ZT12) and night time (ZT12-ZT24) time periods in ad libitum 
group. Expectedly, mice ate more food during night time period than day time 
periods (Figure 7). Interestingly, it seemed that HFD fed mice slightly, but 
substantially, consumed more food in day time period than NCD fed mice (Figure 
7). These data suggest that the amount of food intake rather than feeding periods 
would be a major determinant of body weight gain, which is both applicable in 
different nutrition sources such as NCD and HFD.   
 
Day time feeding changes the expression of circadian clock genes in liver but 
not in hypothalamus 
I next investigated the expression of circadian clock genes upon feeding 
period restriction. In order to examine the expression profiles of circadian clock genes, 
mice were sacrificed at ZT2 and ZT14, which may reflect different expression pattern 
of circadian clock genes in 12:12 light-dark cycle. Total RNAs were isolated from 









Figure 7. Ad libitum calorie intake during day and night with NCD and HFD 
feeding.  
























respectively, and analyzed by qRT-PCR. As shown in Figure 8 and 9, the expression 
patterns of circadian clock genes such as BMAL11, PER2 and CLOCK were altered 
by feeding period restrictions in liver but not in hypothalamus with either NCD or 
HFD. Overall, ad libitum group and PF Night group showed the similar expression 
patterns of circadian clock genes in liver, which would be resulted from the behavior 
of nocturnal mice that took most food during night time. In contrast, in liver, RF Day 
group revealed distinct expression pattern of circadian genes from either ad libitum 
or PF Night group. Unlike liver, the expression patterns of hypothalamic circadian 
genes were not changed by feeding period restrictions with either NCD or HFD 
(Figure 8, 9). These data strongly indicate that feeding period restriction would 
influence expression of circadian clock genes in peripheral tissues, probably via 
modulating nutritional hormones such as insulin or glucagon, which may not affect 
expression of circadian clock genes in hypothalamus.   
 
Feeding period restriction alters expression of metabolic genes and plasma 
metabolites  
It is well known that feeding is one of important factors to regulate circadian 
clock genes as well as hepatic lipid and glucose metabolism (Kohsaka et al., 2007; 
Lamia et al., 2008). Given that RF Day changed expression patterns of hepatic 
circadian clock genes, I decided to examine whether RF Day might also influence 








Figure 8. Daytime feeding changes expression of circadian clock genes in the 
liver but not in the hypothalamus in NCD.  
Hepatic and hypothalamic BMAL1, PER2, and CLOCK gene expression profiles in 
AL, RF Day, and PF Night NCD-fed mice at ZT2 and ZT14. All RNA samples are 
normalized to TBP mRNA. Each bar represents mean ±SD of each group of mice 






















Figure 9. Daytime feeding changes expression of circadian clock genes in the 
liver but not in the hypothalamus in HFD.  
Hepatic and hypothalamic BMAL1, PER2, and CLOCK gene expression profiles in 
AL, RF Day, and PF Night HFD-fed mice at ZT2 and ZT14. All RNA samples are 
normalized to TBP mRNA. Each bar represents mean ±SD of each group of mice 
















PCR from NCD (Figure 10A, 10B, 10C) or HFD (Figure 11A, 11B, 11C) fed mice at 
ZT2 and 14. In order to conjecture key metabolic changes, I have investigated 
expression of several lipid and carbohydrate metabolism genes such as SREBP1c, 
FASN, PEPCK, G6PASE, PPARα, and CPT1. Since SREBP1c is a master 
transcription factor for lipogenesis, it regulates the expression of FASN upon 
nutritional and hormonal changes (Kim et al., 1998a; Kim and Spiegelman, 1996; 
Kim et al., 1995; Kim et al., 1998b; Kim et al., 2004). Under NCD feeding, expression 
of SREBP1c mRNA was greatly suppressed in RF Day at ZT14, while it was up-
regulated at ZT14 in PF Night (Figure 10A). Despite of this, FASN did not show 
significant change at ZT2 and 14 in RF Day and PF Night, implying that it may need 
several hours to reflect SREBP1c target gene expression in vivo. Upon HFD feeding, 
FASN was increased in RF Day at ZT2, while it was not altered in PF Night (Figure 
11A). Conversely, the expression of gluconeogenic genes such as PEPCK and G6Pase, 
which are well known as fasting-induced genes, was not changed at ZT2 and 14 both 
in RF Day and PF Night in NCD (Figure 10B). When fatty acid oxidation genes such 
as PPARα and CPT1 were analyzed, their mRNA levels were not significantly 
different in RF Day and PF Night groups (Figure 10C). These data propose that 
expression of several metabolic genes might to be partly altered by feeding period 
restriction but not as much as that of circadian clock genes in liver. 
Since feeding period restriction altered expression of subset of metabolic 







Figure 10. Feeding period restriction changes the expression of metabolic genes 
in NCD fed mice.  
(A) Expression profiles of lipogenic genes such as SREBP1c and FASN in AL, RF 
Day, and PF Night NCD-fed mice at ZT2 and ZT14. (B) Expression profiles of the 
gluconeogenic genes PEPCK and G6Pase in AL, RF Day, and PF Night NCD-fed 
mice at ZT2 and ZT14. (C) Expression profiles of the fatty acid oxidation genes 
PPARα and CPT1 in AL, RF Day, and PF Night NCD-fed mice at ZT2 and ZT14. All 
RNA samples are normalized to TBP mRNA. Each bar represents mean ± SD of each 





















Figure 11. Feeding period restriction changes the expression of metabolic genes 
in HFD fed mice.  
(A) Expression profiles of lipogenic genes such as SREBP1c and FASN in AL, RF 
Day, and PF Night HFD-fed mice at ZT2 and ZT14. (B) Expression profiles of the 
gluconeogenic genes PEPCK and G6Pase in AL, RF Day, and PF Night HFD-fed 
mice at ZT2 and ZT14. (C) Expression profiles of the fatty acid oxidation genes 
PPARa and CPT1 in AL, RF Day, and PF Night HFD-fed mice at ZT2 and ZT14. All 
RNA samples are normalized to TBP mRNA. Each bar represents mean ± SD of each 

















relevant to whole-body energy state, in different feeding period restriction groups. 
Although it has been reported that serum metabolite levels are varied throughout 
feeding-fasting cycle (Morris et al., 2012), our experimental windows limited at ZT2 
and 14 did not sensitively reflect whole-body energy state. When I measured serum 
glucose, triacylglyceride (TG), and cholesterol levels at ZT2 and 14, I failed to 
observe distinct patterns of those metabolites. Nonetheless, in PF Night group, the 
levels of serum glucose, TG, and cholesterol were higher at ZT2 than at ZT14 under 
NCD, implying that there might be a correlation between peripheral circadian 
oscillation and serum metabolites (Figure 12A, 12B, 12C). On the contrary, HFD 
challenged animals exhibited disrupted serum metabolite profiles as previously 
reported (data not shown) (Hatori et al., 2012). These data indicate that feeding period 
restriction may modulate the profiles of several serum metabolites without changes 
in body weight gain, concomitant with alteration of circadian clock genes as well as 













Figure 12. Feeding period restriction changes plasma metabolites.  
(A) Serum glucose levels in AL, RF Day, and PF Night NCD-fed mice at ZT2 and 
ZT14. (B) Serum TG levels in AL, RF Day, and PF Night NCD-fed mice at ZT2 and 
ZT14. (C) Serum cholesterol levels in AL, RF Day, and PF Night NCD-fed mice at 
























Obesity is characterized by increase of adipose tissue and lipid metabolism, 
which is caused by chronic excess of energy intake than energy expenditure. Very 
recent reports have suggested that feeding period restriction would be an important 
factor to influence body weight gain, leading to obesity (Arble et al., 2009; Hatori et 
al., 2012). Since Arble et al. have reported that day time HFD-fed mice were more 
obese than night time HFD-fed mice with no differences in calorie intake and activity 
(Arble et al., 2009), it has been proposed that change of feeding behavior by shifting 
from nigh to day time would be an important factor to regulate energy metabolism 
contribute to. In accordance with this, it has been reported that night-eating syndrome 
in human might lead to weight gain as a result of excess calories consumption at night 
(Aronoff et al., 2001; Colles et al., 2007; Tholin et al., 2009). On the contrary, several 
studies have revealed that there is no correlation of night eating syndrome and body 
weight gain in human (Gluck et al., 2008; Striegel-Moore et al., 2008; Striegel-Moore 
et al., 2004). Nonetheless, it has not been clearly understood whether dysregulation 
of any circadian clock gene expression is an essential factor to alter body weight gain.  
In the present work, I have investigated the relationship between body 
weight gain and feeding period restriction by providing the same amount of food at 
either night time or day time. I observed that feeding period restriction evidently 
altered expression pattern of peripheral circadian clock genes, provably via nutrition 
sensitive hormones. However, the expression of central circadian clock genes in 
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hypothalamus was not modulated by feeding restriction regardless of NCD or HFD. 
These data implied that central circadian clock and peripheral circadian clock would 
be independently regulated, at least, at transcriptional level, upon feeding period 
restriction (Damiola et al., 2000). Furthermore, hepatic expression of metabolic genes 
including lipogenesis, gluconeogenesis, and fatty acid oxidation were modulated 
upon feeding period restriction. Similarly, the levels of serum glucose, 
triacylglyceride, and cholesterol were also adjusted by feeding period restriction. 
Despite these changes of peripheral metabolic gene expression, there were no 
significant body weight differences between RF Day and PF Night groups with NCD 
or HFD, indicating that the change of peripheral circadian clock genes may not be a 
key factor to influence body weight. Instead of feeding behavior, it appears that the 
amount of energy intake would be a crucial factor to determine body weight, which 
might be closely linked with central circadian genes. 
It has been reported that, HFD challenge disrupts behavioral and 
physiological circadian rhythms. For instance, HFD leads to alterations in the period 
of the locomotor activity and canonical circadian clock genes (Wang et al., 2008b). 
In this study, I observed that HFD fed mice exhibited distinct expression patterns of 
subset genes in liver, including circadian clock genes and metabolic genes, compared 
with NCD fed mice. In addition, ad libitum group exhibited different food 
consumption patterns depending upon nutrition source. HFD challenged mice 
consumed more food intake in day time than NCD challenged mice, implying that 
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food intake control would be dysregulated in HFD fed group. Since fasting period of 
HFD group might be shorter than that of NCD fed group under ad libitum (Kohsaka 
et al., 2007), it appears that NCD fed group might gain less body weight compared 
with HFD fed group through activation of fasting-induced signals with SIRT1 and 
AMPK, which mediated energy expenditure to burn extra energy (Canto et al., 2010; 
Kohsaka et al., 2007). Of course, I cannot rule out the possibility that physical activity 
or body temperature may contribute to compensate for body weight gain, which will 
be investigated in further study.  
Disruption of circadian clock genes is exerted by various stimuli such as 
changes of light/dark cycle and food consumption. Interference of central circadian 
clock by light time modulation affects body weight gain (Karatsoreos et al., 2011). 
For instance, 10:10 light-dark (LD) cycle leads to body weight gain compared with 
12:12 LD cycle, and 10:10 LD cycle regime increases several metabolic parameters 
such as plasma leptin, insulin, and glucose (Karatsoreos et al., 2011). Moreover, 
circadian clock defective mice such as clock gene mutant mice and HFD fed mice 
show irregular food intake pattern, accompanied with obesity due to increased food 
intake (Damiola et al., 2000; Turek et al., 2005). In contrast, Bmal1 deficient mice 
show obese phenotype during 5 weeks of HFD, whereas they are no longer obese 
with 15 weeks of HFD (Hemmeryckx et al., 2011). However, liver-specific Bmal1 




Here, I revealed that feeding period restriction selectively alters expression 
patterns of peripheral circadian clock genes without body weight gain, concomitant 
with adjusted levels of metabolic genes and plasma profiles. Therefore, it is plausible 
to speculate that central circadian clock might play a key role to regulate body weight 
through regulation of energy intake and expenditure. Consistently, it appears the 
amounts of calorie intake would be a major factor to change body weight (Figure 13). 
On the contrary, peripheral circadian clock genes sensitively respond to changes of 
metabolic alterations upon nutrients and hormones. The exact molecular mechanism 
of central circadian clock to influence body weight gain remains to be elucidated. In 
conclusion, our data suggest that feeding period restriction would selectively 
modulate peripheral circadian clocks and metabolic regulation without a significant 









































Hyperglycemia is exacerbated by dysregulation 












SREBP1c is a key transcription factor of lipogenesis to store excess energy 
in postprandial state. Although SREBP1c appears to be involved in suppression of 
hepatic gluconeogenesis, the molecular mechanism(s) by which insulin-activated 
SREBP1c could repress hepatic gluconeogenesis is not thoroughly understood. Here, 
I demonstrate that CRY1 activation by insulin-induced SREBP1c led to decrease 
hepatic gluconeogenesis through FOXO1 degradation. In accordance with these, 
SREBP1c-/- and CRY1-/- mice showed higher blood glucose than wild type (WT) mice 
during pyruvate tolerance test, accompanied with enhanced expression of PEPCK and 
G6Pase genes. Moreover, CRY1 promoted degradation of nuclear FOXO1 by MDM2, 
one of the ubiquitin E3 ligases, by enhancing binding of FOXO1 and MDM2. 
Although hepatic SREBP1c failed to upregulate CRY1 expression in db/db mice, 
overexpression of CRY1 led to attenuate hyperglycemia through reduction of hepatic 
FOXO1 protein as well as gluconeogenic gene expression. Collectively, these data 
suggest that insulin-activated SREBP1c downregulates hepatic gluconeogenesis 
through CRY1-mediated FOXO1 degradation and thereby dysregulation of 







Insulin, which is released from pancreatic β-cells, plays a key role in the maintenance 
of the whole-body energy homeostasis by actively regulating glucose and lipid 
metabolism. In the postprandial state, insulin lowers blood glucose by stimulating 
glucose uptake in adipose tissues and muscles as well as by inhibiting hepatic glucose 
production (Puigserver et al., 2003; Summers and Birnbaum, 1997). Moreover, in the 
liver, insulin stimulates the conversion of excess glucose into glycogen (glycogenesis) 
and triacylglyceride (lipogenesis) for the long term energy storage (Moller, 2001; 
Wang et al., 2013; Wong et al., 2009).  
Suppression of hepatic gluconeogenesis by insulin is an important process 
to inhibit hyperglycemia. PEPCK and G6Pase are crucial enzymes that convert 
pyruvate to glucose, and their gene expression is regulated by several transcription 
factors such as Forkhead box O1 (FOXO1), cAMP Response Element-Binding 
protein (CREB), Hepatocyte Nuclear Factor 4 (HNF4), Glucocorticoid Receptor 
(GR), and Peroxisome proliferator-activated receptor Gamma Coactivator 1-Alpha 
(PGC1α) (Mouchiroud et al., 2014; Sugden et al., 2010; Yoon et al., 2001). In the 
liver, FOXO1 is activated upon fasting and gets inactivated by feeding, which is one 
of the essential mechanisms by which insulin rapidly and efficiently represses hepatic 
glucose production during postprandial periods (Accili and Arden, 2004; Kops et al., 
1999; Lu et al., 2012). After insulin treatment, FOXO1 protein is phosphorylated by 
AKT and then moves to the cytoplasm, resulting in the decrease of gluconeogenic 
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gene expression(Matsumoto and Accili, 2005). Although the translocation of hepatic 
FOXO1 from the nucleus to the cytoplasm is a well-defined mechanism mediating a 
quick decrease in glucose production by insulin, it is largely unknown how insulin 
endows a sustainable inhibition of hepatic gluconeogenesis during the postprandial 
state. 
 On the other hand, it has been proposed that SREBP1c might be involved in 
hepatic glucose metabolism. SREBP1c is a basic-helix-loop-helix-leucine zipper 
(bHLH-LZ) transcription factor that regulates de novo lipogenesis (Brown and 
Goldstein, 1997; Fajas et al., 1999; Moon et al., 2012; Tontonoz et al., 1993; 
Yokoyama et al., 1993). Activation of SREBP1c is mediated by AKT and mTORC1 
upon insulin signaling (Laplante and Sabatini, 2010; Peterson et al., 2011). SREBP1c 
regulates lipogenic pathways by stimulating the expression of target genes such as 
those encoding fatty acid synthase (FASN), stearoyl-CoA desaturase 1 (SCD1) and 
acetyl-coenzyme A carboxylase (ACC) (Horton et al., 2003; Kim et al., 1998a; Liang 
et al., 2002). In addition, SREBP1c appears to be involved in hepatic carbohydrate 
metabolism. For example, SREBP1c affects the mRNA levels of PEPCK, G6Pase, 
and IRS-2 genes and inhibits the interaction between HNF4 and PGC1α to suppress 
gluconeogenic genes (Becard et al., 2001; Ide et al., 2004; Lee et al., 2007; Ponugoti 
et al., 2007; Yamamoto et al., 2004). Although it has been reported that hepatic 
SREBP1c is upregulated in obese animals, it is unknown how increased SREBP1c 
fails to repress hepatic gluconeogenesis. Thus, it remains crucial to understand the 
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molecular mechanisms by which SREBP1c could modulate gluconeogenesis under 
physiological and pathological conditions.   
 CRY1 is a member of the mammalian clock transcription-translation 
feedback loop that also includes CLOCK, BMAL1, PER1, PER2, and CRY2, to 
modulate rhythmic oscillations. CLOCK and BMAL1 form a heterodimer to activate 
PER and CRY genes and then elevated PER and CRY proteins act as transcriptional 
repressors that decrease the transcriptional activity of CLOCK and BMAL1 
(Miyamoto and Sancar, 1998; Thresher et al., 1998; Vitaterna et al., 1999; Ye et al., 
2014). The hepatic circadian clock is affected by food intake as well by the expression 
of hormones such as insulin and glucagon, whereas the suprachiasmatic nucleus 
circadian clock is controlled by the light-dark cycle (Green et al., 2008). Recently, it 
has been shown that hepatic circadian clock genes also contribute to glucose 
homeostasis. For example, hepatic CRY proteins modulate glucose production by 
inhibiting the glucagon receptor signaling pathway and binding to GR (Lamia et al., 
2011; Zhang et al., 2010). In addition, an agonist of CRY proteins has been reported 
to repress the expression of hepatic gluconeogenic genes, such as PEPCK and G6Pase 
(Hirota et al., 2012). Furthermore, BMAL1-/- mice exhibited disrupted hepatic glucose 
homeostasis (Rudic et al., 2004). However, the molecular mechanisms by which 
CRY1 could repress hepatic glucose production during the postprandial state remain 
to be elucidated. 
The fact that SREBP1c downregulates hepatic gluconeogenesis prompted 
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us to investigate novel target genes of SREBP1c by comparing SREBP1c+/+ and 
SREBP1c-/- mice. Here, I demonstrate that SREBP1c attenuates hepatic glucose 
production via activation of CRY1, eventually leading to degradation of the FOXO1 
protein upon insulin signaling. While hepatic FOXO1 is rapidly translocated from the 
nucleus into the cytoplasm by AKT-mediated phosphorylation triggered by insulin, 
the SREBP1c-CRY1 signaling pathway durably represses the execution of 
gluconeogenic genes by decreasing nuclear FOXO1 protein for long term insulin 
action. Additionally, in the liver of diabetic db/db mice, overexpression of CRY1 
lowers blood glucose, accompanied with attenuated gluconeogenic genes and 
FOXO1 protein. Together, our data suggest that insulin activates the SREBP1c-CRY1 
signaling pathway, resulting in FOXO1 degradation mediated by MDM2, which is 












C57BL/6 mice were purchased from SAMTACO (Seoul, South Korea) and housed in 
colony cages. db/+ and db/db mice were obtained from Central Lab (Seoul, Korea). 
SREBP1c-/- mice were generously provided from Dr. J. Horton at the University of 
Texas Southwestern Medical Center and bred in isolated cages. All animals were 
maintained under 12 h light/ 12 h dark cycle in a pathogen-free animal facility. 
Following dissection, mouse tissue specimens were immediately stored at -80 °C 
until further analysis. All experiments with mice were approved by the Institute of 
Laboratory Animal Resources at Seoul National University and the Institutional 
Animal Care and Use Committee at the University of North Carolina.  
In vivo imaging system 
C57BL/6 mice were injected with adenoviruses encoding GFP (Ad-Mock), SREBP1c 
(Ad-SREBP1c) and G6Pase luciferase (Ad-G6Pase-luc) through the tail vein. After 
5 days, adenovirus-infected mice were injected intraperitoneally with 100 mg/kg 
sterile firefly D-luciferin. After 5 min, mice were anesthetized and imaged using an 
IVIS 100 imaging system (Xenogen, Alameda, CA, USA) as described(Lee et al., 
2014b). 
Pyruvate tolerance tests 
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For the pyruvate tolerance test, mice were fasted for 16 h and then injected 
intraperitoneally with pyruvate (2 g/kg body weight for mice). Blood glucose levels 
were measured in tail vein blood samples at the indicated time points by using a Free-
Style blood glucose meter (Therasense, Sweden).   
Antibodies, chemicals and plasmids 
MG132 was purchased from Calbiochem (San Diego, CA, USA). I used antibodies 
to the following proteins in our study: MYC, HA, FOXO1, phosphor-
FOXO1(Ser256), AKT, and phosphor-AKT(Ser473) (all purchased form Cell 
Signaling Technology, Beverly, MA, USA), FLAG, ACTIN (Sigma-Aldrich, St. 
Louis, MO, USA), G6Pase, POLII, GFP (Santa Cruz Biotechnology Santa Cruz, CA, 
USA), GAPDH (LabFrontier Co., Ltd, Seoul, Korea), SREBP1 (BD Bioscience, San 
Jose, CA, USA), MDM2 (Abcam, Cambridge, MA, USA), and CRY1 (Alpha 
Diagnostic International Inc., San Antonio, Texas, USA). GFP-CRY1 was cloned into 
the pEGFP-N1 vector and FLAG-MDM2 was cloned into pCMV-3 FLAG. Mouse 
CRY1 promoter was cloned into the pGL3-basic vector.     
Cell-based ubiquitination assays 
COS-1 cells were transfected with plasmids encoding FOXO1 WT-MYC, nFOXO1 
(ADA)-MYC, GFP-CRY1 (or FLAG-CRY1), FLAG-MDM2 and Ubiquitin-HA in 
the presence of 20 µM MG132 for 4 h. Total cell lysates were prepared using the 
TGN buffer. FOXO1 WT-MYC and nFOXO1 (ADA)-MYC were 
66 
 
immunoprecipitated with an anti-MYC antibody (Cell Signaling Technology, USA), 
and after washing in the TGN buffer, proteins were separated by SDS-PAGE followed 
by western blotting analyses with an anti-HA antibody.    
ChIP assays  
Cross-linking and chromatin immunoprecipitation assays with H4IIE cells were 
performed as described previously (Sakai et al., 2003). Extracted proteins from total 
cell lysates were immunoprecipitated with anti-SREBP1 (BD Bioscience) or IgG 
(Santa Cruz) for 2 h. Precipitated DNA fragments were analyzed by PCR using primer 
sets that encompassed the proximal (-100 to +100 base pairs) region of the rat CRY1 
promoter and negative control (+9670 to +9890 base pairs) region. The sequences of 
ChIP assay primers were as follows: sense, 5′-GTCCGAGCCAGCGTAGTAAA, 
antisense, 5′- GGATAGCGCGGGCTAGAG; negative control primer sense, 5′- 
CCAGCCACTTTGCTGAAGTT and antisense, 5′-
CTAGACAAGGCTGCCCACTC.  
Preparation of recombinant adenovirus 
The adenovirus plasmid was constructed as previously described (Lee et al., 2014a). 
rat SREBP1c and mouse CRY1 cDNAs were incorporated into the AdTrack-CMV 
shuttle vector and a recombinant vector was generated using the Ad-Easy adenoviral 
vector system. Adenoviruses were amplified in HEK293A cells and isolated by 
cesium chloride density centrifugation. The GFP was co-expressed from an 
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independent promoter with inserted cDNA. For in vivo experiments, mice were 
injected with 5 × 109 PFU of adenovirus (db/db mice, 2 × 1010 PFU) in 200 µl PBS 
through the tail vein. Empty virus expressing only the gene for GFP served as the 
control (Mock).    
Mouse primary hepatocytes cultures 
Mouse primary hepatocytes were isolated as previously described (Jo et al., 2013). 
For adenoviral infection, isolated hepatocytes were incubated for 12 h with 
adenovirus at 50 PFU/cell with the serum-free medium, which was subsequently 
replaced by the 10% FBS-containing M199 medium.  
Cell lysis and immunoprecipitation 
After washing in cold PBS, cells were treated either with the TGN buffer (50 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1% Tween-20 and 0.3% NP-40) or the SDS lysis 
buffer (200 mM Tris-HCl, pH 6.8, 10% glycerol and 4% SDS) supplemented with 
0.1% protease inhibitor cocktail (Roche, Basel, Switzerland). Total cell lysates were 
obtained by centrifugation at 12,000 rpm for 15 min at 4 °C, and 1–1.5 mg of lysates 
was used for immunoprecipitation. The lysates were incubated with primary 
antibodies for 2 h at 4 °C, followed by 1 h of further incubation with 50% slurry of 
protein A sepharose presaturated with the lysis buffer. After washing three times with 
the lysis buffer, the immunoprecipitated proteins were recovered from the beads by 




Transient transfection and luciferase assays 
HEK293T cells were transiently transfected with various DNA plasmids using the 
calcium-phosphate method described previously (Seo et al., 2004). After incubation 
for 36 h, transfected cells were harvested with the lysis buffer (25 mM Tris-phosphate 
pH 7.8, 10% glycerol, 2 mM EDTA, 2 mM DTT and 1% Triton X-100) and the 
activities of luciferase and β-galactosidase were measured according to the 
manufacturer’s protocol (Promega, Madison, WI, USA). The relative luciferase 
activity was normalized to β-galactosidase activity in each sample.  
RNA preparation and q-RT-PCR analyses 
RNA was prepared as previously described (Kim et al., 2010). Briefly, total RNA was 
isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Subsequently, 
equal amounts of RNA were subjected to cDNA synthesis using the RevertAid M-
MuLV reverse transcriptase (Fermentas, Canada). The relative amount of mRNA was 
evaluated by using a CFX real-time quantitative PCR detection system (Bio-Rad 
Laboratories, Hercules, CA, USA) and calculated following normalization to the 
level of TBP or cyclophilin mRNA. The primer sequences used for the real-time 










siRNA duplexes for CRY1, MDM2, and FOXO1 were purchased from the Bioneer 
Inc. (Daejeon, South Korea). Primary hepatocytes were transiently transfected with 
the Lipofectamine RNAi MAX reagent (Invitrogen, Carlsbad, CA, USA) according 
to the manufacturer’s protocol. The sequence information for siRNA is described in 
the Supplementary Table 3.  
Glucose production assays 
Glucose production by mouse primary hepatocytes was measured according to the 
manufacturer’s protocol using a glucose oxidase assay (Sigma-Aldrich, St. Louis, 
MO, USA). Briefly, the cells were incubated for 6 h at 37 °C and 5% CO2 in the 
Krebs-Ringer buffer (115 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 1.2 mM 
NaH2PO4, 2.5 mM CaCl2, 25 mM NaHCO3, 10 mM lactate and 2 mM pyruvate, pH 
7.4). The glucose production assays were performed in triplicate.  
Statistical analysis 
Data were compared using a paired Student’s t test or analysis of variance as 
appropriate and are represented as the mean ± standard deviation (SD). Values of P 





















CRY1 is promoted by feeding and insulin 
 In the liver, peripheral circadian clock genes are regulated by various 
nutritional and hormonal changes (Jang et al., 2012). Given that circadian clock genes 
are closely associated with energy homeostasis, I sought to investigate which 
circadian clock genes could affect feeding-dependent hepatic lipid and glucose 
metabolism. Since the expression of most circadian clock genes is oscillated in a time 
dependent manner, the end points of the fasting and/or refeeding experiment were 
fixed at ZT 3. Upon refeeding, the expression of most lipogenic genes including 
SREBP1c, FASN, and ACC was upregulated in the liver. In accordance with previous 
reports (McNeill et al., 1982; Oh et al., 2013; Pilkis et al., 1988), the expression of 
gluconeogenic genes such as PEPCK and G6Pase was downregulated in the 
postprandial state (Figure 14A). Interestingly, the level of hepatic CRY1 mRNA was 
selectively elevated in refed mice, while the expression of other circadian clock genes 
such as PER2, CRY2, CLOCK, and BMAL1 was not significantly altered after 
nutritional changes (Figure 14A). Moreover, the expression of the CRY1 protein was 
markedly increased in the liver of refed mice (Figure 14B). These findings prompted 
us to test whether insulin might elevate hepatic CRY1 gene expression. In primary 
hepatocytes, the level of CRY1 mRNA was increased by insulin, similar to SREBP1c 
mRNA (Figure 14C). These data indicate that hepatic CRY1 expression is 







Figure 14. CRY1 is stimulated by feeding and exposure to insulin 
(A and B) C57BL/6 mice were fasted for 24 h and then refed for 12 h. Both fasted 
and refed mice were sacrificed at ZT3.In the liver, levels of the CRY1 mRNA (A) and 
CRY1 protein (B) were determined using qRT-PCR with normalization to TBP 
mRNA levels and western blotting, respectively. Data are represented as mean ±SD, 
N=4 for each group. *P < 0.05, **P < 0.01 (Student’s t-test). (C) CRY1 gene 
expression was measured in mouse primary hepatocytes following 12 h of insulin 
exposure and in control conditions using qRT-PCR. The level of the TBP mRNA was 
used for the qRT-PCR normalization. Data are represented as mean ±SD, N=3 for 




















dependent energy metabolism. 
 
SREBP1c regulates CRY1 gene expression  
 To investigate which transcription factors regulate insulin-dependent CRY1 
gene expression, I analyzed CRY1 promoters in several species including monkey, 
cow, sheep, human, rat and mouse (Figure 16A). In the proximal CRY1 promoter, 
there are several sterol regulatory element (SRE) motifs as well as an E-BOX 
(CANNTG) motif, which is also a target motif for BMAL1 and CLOCK, the core 
circadian clock proteins (Figure 16A). Both SRE and E-BOX motifs are well known 
binding targets of SREBP1c with its dual DNA binding specificity (Griffin et al., 
2007; Kim et al., 1995). To examine whether SREBP1c could regulate CRY1 gene 
expression, SREBP1c was overexpressed in mouse primary hepatocytes. As shown 
in Figure 15A and 15B, the levels of hepatic CRY1 mRNA and CRY1 protein were 
increased by SREBP1c overexpression (Figure 15A, 15B), implying that SREBP1c 
may be a key transcription factor that upregulates hepatic CRY1 gene expression in 
the postprandial state. Next, the effect of ectopic expression of SREBP1c on the 
CRY1 promoter activity was examined. Expression of luciferase from a wild-type 
CRY1 promoter was compared with expression from a promoter with mutated SRE 
motifs (3XSRE) in HEK293T cells (Figure 16B). I observed substantial loss of 








Figure 15. SREBP1c directly activates CRY1 gene expression  
(A and B) Mouse primary hepatocytes were adenovirally infected with Ad-Mock or 
Ad-SREBP1c, as indicated. The levels of the CRY1 mRNA (A) and CRY1 protein 
(B) were determined using qRT-PCR with normalization to TBP mRNA levels and 
western blotting, respectively. Data are represented as mean ±SD, N=3 for each group. 

























Figure 16. SREBP1c binds to SRE sequence in CRY1 promoter. 
(A) SRE motifs and E-BOX sequences in the CRY1 promoter from various species. 
(B) Luciferase activity of the WT CRY1 promoter and 3XSRE mutant promoter were 
measured following co-transfection with expression plasmids encoding either 
SREBP1c or Mock in HEK293T cells. Luciferase activity was normalized by β-gal 
activity. Data are represented as mean ±SD, N=5 for each group. *P < 0.05, **P < 
0.01 (Student’s t-test). (C) HEK293T cells were co-transfected with a reporter 
plasmid containing the WT or E-BOX mutant mouse CRY1 promoter along with 
expression plasmids encoding either Mock or SREBP1c. The values represent the 















(Figure 16B, 16C). In addition, SREBP1c binding to the CRY1 promoter was 
confirmed by a ChIP assay (Figure 17). Meanwhile, consistent with previous reports 
(Becard et al., 2001; Ide et al., 2004; Lee et al., 2007), hepatic SREBP1c reduced 
G6Pase expression (Figure 15A, 15B). 
 To verify whether SREBP1c could modulate hepatic CRY1 gene expression 
in vivo, SREBP1c adenovirus was injected into mice via the tail vein and hepatic gene 
expression was investigated. As expected, hepatic SREBP1c overexpression 
increased the expression of lipogenic genes such as FASN, SCD1 and ELOVL6 
(Figure 18A). As in the case with primary hepatocytes, the level of hepatic CRY1 
mRNA was enhanced by SREBP1c in vivo (Figure 18A). Moreover, in contrast to 
SREBP1c+/+ mice, refeeding failed to increase hepatic CRY1 gene expression in 
SREBP1c-/- mice (Figure 18B). This observation indicates that SREBP1c is an 
essential factor for the upregulation of hepatic CRY1 gene expression in the 
postprandial state. 
 
SREBP1c-CRY1 pathway inhibits hepatic gluconeogenesis 
 Consistent with previous reports (Becard et al., 2001; Lamia et al., 2011; 
Zhang et al., 2010), SREBP1c overexpression decreased glucose production in mouse 
primary hepatocytes (Figure 19A). In addition, the optical in vivo imaging analysis 









Figure 17. SREBP1c directly binds to CRY1 promoter. 
ChIP assay, performed as described in Methods, showing CRY1 promoter occupancy 































Figure 18. CRY1 regulation in SREBP1c modulated mice.  
(A) C57BL/6 mice were infected with adenoviruses encoding either a Mock or 
SREBP1c (adenoviral dose of 5×109 viral particles per mouse) through the tail vein. 
Mice were sacrificed 5 days following the injection of adenoviruses and relative 
mRNA levels were determined by qRT-PCR and normalized to the TBP mRNA signal. 
Data are represented as mean ±SD, N=3-4 for each group. *P < 0.05, **P < 0.01 
(Student’s t-test). (B) SREBP1c-/- and SREBP1c+/+ mice were fasted for 24 h and then 
refed for 12 h. Both fasted and refed mice were sacrificed at ZT3. The levels of 
SREBP1c and CRY1 mRNAs were determined by qRT-PCR and normalized to TBP 
mRNA levels. Data are represented as mean ±SD, N=3-4 for each group. *P < 0.05, 





















Figure 19. SREBP1c suppresses hepatic gluconeogenesis 
(A) Mouse primary hepatocytes were adenovirally infected with Ad-Mock or Ad-
SREBP1c. Relative glucose secretion was measured using a glucose oxidase (GO) kit 
as described in Methods. Data are represented as mean ±SD, N=3 for each group. *P 
< 0.05 (Student’s t-test). (B) C57BL/6 mice were infected with Ad-G6Pase-luc and 
either Ad-Mock or Ad-SREBP1c. (C) The effect of hepatic SREBP1c overexpression 
on G6Pase promoter activity was measured by optical in vivo imaging analysis and 
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activity of the G6Pase gene in vivo (Figure 19B, 19C). These findings led us to 
investigate the effect of SREBP1c on blood glucose level in vivo. Pyruvate tolerance 
test demonstrated that the adenoviral overexpression of SREBP1c significantly 
decreased blood glucose level following pyruvate injection (Figure 20A, 20B). 
Accordingly, SREBP1c-/- mice showed higher blood glucose than SREBP1c+/+ mice 
(Figure 20C, 20D). Thus, these results suggest that hepatic SREBP1c would suppress 
gluconeogenesis, potentially by modulating gluconeogenic gene expression. 
 To examine whether CRY1, a novel target gene of SREBP1c, might 
modulate hepatic gluconeogenic gene expression, I suppressed CRY1 expression via 
siRNA in rat hepatoma H4IIE cells. Downregulation of CRY1 increased the 
expression of G6Pase and PEPCK genes (Figure 21A), which are crucial for hepatic 
gluconeogenesis. On the contrary, hepatic CRY1 overexpression decreased the 
expression of G6Pase and PEPCK genes in mouse primary hepatocytes (Figure 21B). 
To confirm these observations, I measured pyruvate-induced blood glucose level 
from CRY1+/+ and CRY1-/- mice. As shown in Figure 22A and 22B, CRY1-/- mice 
shows higher blood glucose level than CRY1+/+ mice. To test whether CRY1 could be 
a key mediator of the inhibition of hepatic gluconeogenesis by SREBP1c, I performed 
glucose production assays in primary hepatocytes. As indicated in Figure 23, 
SREBP1c overexpression significantly suppressed glucose production, while 
suppression of CRY1 with siRNA in SREBP1c-overexpressing hepatocytes rescued 







Figure 20. SREBP1c regulates pyruvate induced blood glucose level. 
(A and B) C57BL/6 mice were infected with Ad-Mock or Ad-SREBP1c and subjected 
to the PTT (A), as described in Methods. All mice were fasted at ZT10 and performed 
PTT at ZT3. The result was converted by the area-under-the curve (AUC) analysis 
(B). Data are represented as mean ±SD, N=5 for each group. *P < 0.05, **P < 0.01 
(Student’s t-test). (C and D) Pyruvate tolerance test (C) was performed in SREBP1c-
/- and SREBP1c+/+mice. All mice were fasted at ZT10 and performed PTT at ZT3. 
Results were converted to AUC values (D). Data are represented as mean ±SD, N=5 






















Figure 21. CRY1 regulates gluconeogenic gene expression. 
(A) H4IIE cells were transfected with siCON or siCRY1. Relative PEPCK and 
G6Pase mRNA levels were determined by qRT-PCR and normalized to cyclophilin 
mRNA levels. Data are represented as mean ±SD, N=3 for each group. *P < 0.05, 
**P < 0.01, ***P < 0.001 (Student’s t-test). (B) Mouse primary hepatocytes were 
infected with Ad-Mock or Ad-CRY1. Relative PEPCK and G6Pase mRNA levels 
were determined by qRT-PCR and normalized to TBP mRNA levels. Data are 




























Figure 22. CRY1-/- mice showed low level of glucose upon pyruvate challenge. 
(A and B) Pyruvate tolerance test (A) was performed in CRY1-/- and CRY1+/+ mice. 
All mice were fasted at ZT10 and performed PTT at ZT3. Results were converted to 
AUC values (B). Data are represented as mean ±SD, N=7 for each group. *P < 0.05, 




























Figure 23. The SREBP1c-CRY1 signaling pathway regulates gluconeogenesis in 
vitro.  
Mouse primary hepatocytes were infected with Ad-Mock or Ad-SREBP1c and 
transfected with either siCON or siCRY1. Relative glucose production was measured 
using a glucose oxidase (GO) kit. Data are represented as mean ±SD, N=4 for each 






















pathway could indeed repress hepatic glucose production in vivo, CRY1 was 
adenovirally overexpressed in the liver of SREBP1c-/- mice. While SREBP1c-/- mice 
showed higher blood glucose level than SREBP1c+/+ mice during the pyruvate 
tolerance test, SREBP1c-/- mice with CRY1 overexpression exhibited an attenuated 
level of blood glucose, comparable to that of WT mice (Figure 24A, 24B). These data 
strongly indicate that the SREBP1c-CRY1 signaling pathway could inhibit hepatic 
gluconeogenesis in vivo.  
 
CRY1 regulates FOXO1 protein 
 To decipher the underlying mechanism(s) by which insulin-induced CRY1 
could repress hepatic gluconeogenesis, I focused on FOXO1, as its regulatory effects 
on insulin signaling and gluconeogenesis are well established. In mouse primary 
hepatocytes, the level of the FOXO1 protein was decreased by CRY1 overexpression 
(Figure 25A) while FOXO1 mRNA levels were not altered (Figure 25B). These data 
indicated that CRY1 might modulate the level of the FOXO1 protein, probably, 
independent of the FOXO1 mRNA. Furthermore, the level of the FOXO1 protein was 
enhanced in CRY1-suppressed hepatocytes (Figure 25C, 25D). In accordance with 
these in vitro data, the FOXO1 protein level was higher in the liver of CRY1-/- mice 
than in the liver of the CRY1+/+ mice, whereas levels of the FOXO1 mRNA were not 








Figure 24. The SREBP1c-CRY1 signaling pathway regulates gluconeogenesis in 
vivo.  
(A and B) Pyruvate tolerance test (A) in SREBP1c+/+ mice injected with Ad-Mock 
and in SREBP1c-/- mice injected with either Ad-Mock or Ad-CRY1. Results were 
converted to AUC values (B) to assess the effect of CRY1 overexpression in 
SREBP1c-/- mice. All mice were fasted at ZT 10 and performed PTT at ZT 3. Data are 




























Figure 25. CRY1 regulates FOXO1 protein level in vitro. 
(A and B) Mouse primary hepatocytes were adenovirally infected with Ad-Mock or 
Ad-CRY1. The expression profiles of FOXO1 were analyzed at the protein level (A) 
using western blotting and at the mRNA level (B) using qRT-PCR. Data are 
represented as mean ±SD, N=4 for each group. *P < 0.05 (Student’s t-test). (C and D) 
H4IIE cells were transfected with siCON or siCRY1. Immunocytochemical analysis 
(C) of endogenous FOXO1. DAPI, 4’, 6-diamidino-2-phenylindole. Endogenous 
























Figure 26. FOXO1 protein level is elevated in SREBP1-/- and CRY1-/-. 
(A and B) The expression patterns of FOXO1 protein in the liver of CRY1+/+ and 
CRY1-/- mice were analyzed by western blotting (A) and qRT-PCR (B). Relative 
mRNA levels were determined using qRT-PCR and normalized to the levels of the 
TBP mRNA. Data are represented as mean ±SD, N=3 for each group. *P < 0.05, **P 
< 0.01, ***P < 0.001 (Student’s t-test). (C) Expression of CRY1 and FOXO1 proteins 























Moreover, compared to the levels of proteins observed in the livers of the SREBP1c+/+ 
mice, the amount of the FOXO1 protein was higher and the level of the CRY1 protein 
was lower in the liver of SREBP1c-/- mice (Figure 26C). To verify that CRY1 could 
inhibit hepatic gluconeogenesis via FOXO1 modulation, the effects of CRY1 and/or 
FOXO1 suppression on gluconeogenic gene expression were examined. Increased 
expression of G6Pase and PEPCK genes by CRY1 suppression was abolished when 
the FOXO1 gene was downregulated by siRNA (Figure 27), indicating that CRY1 
could alleviate hepatic gluconeogenesis via suppression of the FOXO1 protein. 
Therefore, these in vivo and in vitro data suggest that hepatic FOXO1 protein could 
be regulated by CRY1. 
  
FOXO1 protein is decreased by insulin-activated CRY1  
 FOXO1 translocation from the nucleus to the cytoplasm by AKT is a well-
known mechanism by which insulin acutely inhibits hepatic glucose production 
(Rena et al., 1999). As insulin upregulates CRY1 that, in turn, downregulates the 
FOXO1 protein (Figure 14C and 25A), I investigated the time course of these events 
by examining the expression profiles of the FOXO1 and CRY1 proteins in insulin-
treated primary hepatocytes. As shown in Figure 28A and 28B, AKT phosphorylation 
was clearly induced in cells treated with insulin for a relatively short period (0.5~4 









Figure 27. CRY1 inhibits gluconeogenesis via FOXO1 signaling pathway.  
H4IIE cells were co-transfected with siCRY1 and/or siFOXO1. Relative mRNA 
levels were normalized to the cyclophilin mRNA level. Data are represented as mean 
±SD, N=3 for each group. #P < 0.05, ##P < 0.01 versus siCRY1, *P < 0.05, **P < 




























Figure 28. CRY1 is induced in long term insulin action with inhibition of 
gluconeogenesis.  
(A, B, and C) Mouse primary hepatocytes were treated with insulin for different 
periods. Protein levels (A) were determined with western blotting and the results were 
converted to the band intensity graph (B). mRNA levels (C) were analyzed by qRT-
PCR. Data are represented as mean ±SD, N=3 for each group. *P < 0.05, **P < 0.01, 























insulin. However, phosphorylation levels of AKT and FOXO1 were gradually and 
substantially decreased by a long-term (8~12 h) incubation with insulin, implying that 
FOXO1 translocation from the nucleus to the cytoplasm by AKT might be more 
pronounced after a short exposure to insulin rather than following a long-term insulin 
treatment. Intriguingly, in hepatocytes treated with insulin for long periods, the level 
of the CRY1 protein was markedly increased, while that of the total FOXO1 protein 
was decreased, indicating that the amount of the CRY1 protein appears to be inversely 
related to the total quantity of the FOXO1 protein. Moreover, the expression of 
PEPCK and G6Pase genes was repressed after either a long-term or a short-term 
insulin treatment (Figure 28C). These data suggest that reduction in the FOXO1 
protein level might be involved in the suppression of hepatic gluconeogenesis as a 
result of a delayed effect of insulin treatment.  
 Next, I explored whether CRY1 could modulate the decrease in FOXO1 
protein in insulin-treated hepatocytes. To address this, the expression of CRY1 was 
suppressed by siRNA with or without an insulin treatment. As shown in Figure 29A, 
long-term insulin challenge led to a decrease in FOXO1 protein, while suppression 
of CRY1 protein restored the level of the FOXO1 protein. In the presence of insulin, 
decreased levels of PEPCK and G6Pase mRNA were also substantially restored by 
CRY1 knockdown in hepatocytes (Figure 29B). Together, these data indicate that 
CRY1 could repress the expression of hepatic gluconeogenic genes via reduction of 







Figure 29. Insulin sustainably suppresses gluconeogenesis via CRY1. 
(A and B) H4IIE cells were transfected with siCON or siCRY1 and treated with 10 
nM insulin for 12 h. Protein levels (A) were analyzed by western blotting and relative 
mRNA levels (B) were determined by qRT-PCR and normalized to the cyclophilin 
mRNA level. Data are represented as mean ±SD, N=3 for each group. *P < 0.05, **P 




















To test whether enhanced CRY1 could suppress hepatic gluconeogenesis 
even in the absence of a short-term insulin action, I employed AKT inhibitors. In 
primary hepatocytes, insulin increased phosphorylation levels of both AKT and 
FOXO1, while a co-treatment with the AKT inhibitor AKTVIII blocked 
phosphorylation of both proteins, as expected (Figure 30A). However, in Ad-CRY1 
overexpressing hepatocytes, the total FOXO1 level was decreased in insulin and/or 
the AKT inhibitor treated cells, implying that CRY1 could downregulate FOXO1 
protein independent of FOXO1 phosphorylation (Figure 30A). In order to confirm 
this observation in vivo, I tested another AKT inhibitor, MK2206, in mice. As 
expected, administration of MK2206 significantly increased blood glucose level upon 
pyruvate challenge; however, adenoviral CRY1 overexpression in mice significantly 
attenuated blood glucose level even in the presence of MK2206 (Figure 30B, 30C). 
It is noteworthy that the level of the FOXO1 protein was greatly augmented by 
MK2206, whereas CRY1 elevation suppressed FOXO1 protein expression in vivo 
(Figure 30D). Taken together, these data clearly indicate that CRY1-dependent 
FOXO1 reduction may contribute to the suppression of hepatic gluconeogenesis 
independent of AKT activation. 
 
CRY1 stimulates proteasomal degradation of FOXO1  







Figure 30. CRY1 suppresses FOXO1 protein level independent of AKT activity. 
(A) Mouse primary hepatocytes were infected with Ad-Mock and Ad-CRY1, and then 
treated with insulin (10 nM) or insulin (10 nM) and AKTVIII (5 µM) for 12 h. Protein 
levels were determined with western blotting. (B, C and D) C57BL/6 mice were 
infected with Ad-Mock or Ad-CRY1 and subjected to the pyruvate tolerance test (B) 
with or without the AKT inhibitor MK2206. MK2206 (30 mg/kg) was given by oral 
gavage 10 min before the pyruvate tolerance test. All mice were fasted at ZT 10 and 
performed PTT at ZT 3. Results were converted to AUC values (C). After the 
pyruvate tolerance test, hepatic protein levels (D) were analyzed by western blotting. 
Data are represented as mean ±SD, N=5-7 for each group. #P < 0.05, ##P < 0.01, 
###P < 0.001 versus Ad-Mock + vehicle control, *P < 0.05, **P < 0.01, ***P < 0.001 














protein, but not the FOXO1 mRNA, I investigated whether the downregulation of the 
FOXO1 protein proceeds via proteasomal degradation. As shown in Figure 31A, the 
reduction in the FOXO1 protein by CRY1 overexpression was alleviated by MG132 
treatment, indicating that the regulation of FOXO1 protein by CRY1 may be, at least 
in part, dependent on proteasomal degradation. When I tested physical interaction 
between FOXO1 and CRY1 proteins, co-immunoprecipitation assays revealed that 
CRY1 could associate with FOXO1 protein (Figure 31B). Then, I examined whether 
CRY1 might induce FOXO1 degradation via the ubiquitination-proteasome pathway. 
As shown in Figure 31C, CRY1 overexpression dramatically promoted FOXO1 poly-
ubiquitination, implying that CRY1 could potentiate FOXO1 degradation, probably, 
through protein-protein interactions. 
 To explore the subcellular location of FOXO1 degradation induced by 
CRY1, levels of the nuclear and cytosolic FOXO1 protein were investigated. As 
shown in Figure 31D, the nuclear fraction of the FOXO1 protein was decreased by 
CRY1 overexpression, whereas incubation with MG132 blocked this decrease. At the 
same time, levels of cytosolic FOXO1 were not altered upon CRY1 overexpression 
irrespective of the presence of MG132. Consistent with these results, poly-
ubiquitination of the nuclear form of the FOXO1 mutant protein (nFOXO1-MYC) 
was greatly augmented by CRY1 (Figure 31E). Therefore, it is plausible that the 





Figure 31. CRY1 accelerates ubiquitin-mediated FOXO1 degradation  
(A) Mouse primary hepatocytes were adenovirally infected with Ad-Mock or Ad-
CRY1. The cells were treated with 20 µM MG132 or vehicle for 4 h. Total cell lysates 
were analyzed by western blotting with indicated antibodies. (B) HEK293T cells 
were transfected with GFP-CRY1 and/or FOXO1-MYC expression vectors. Co-
immunoprecipitation with an anti-MYC antibody and western blotting were 
performed with the indicated antibodies. IP, immunoprecipitation. (C) COS-1 cells 
were co-transfected with plasmids encoding FOXO1-MYC, GFP-CRY1, and 
Ubiquitin-HA. After transfection, the cells were treated with MG132 (20 µM) for 6 h 
and then the cell lysates were subjected to immunoprecipitation with an anti-MYC 
antibody followed by western blotting with indicated antibodies. IP, 
immunoprecipitation. (D) Mouse primary hepatocytes were infected with Ad-Mock 
or Ad-CRY1. After infection, the cells were treated with MG132 (20 µM) for 4 h. 
Nuclear and cytosolic fractions were isolated and analyzed by western blotting with 
indicated antibodies. (E) COS-1 cells were co-transfected with plasmids encoding 
nFOXO1-MYC, GFP-CRY1, and Ubiquitin-HA. After transfection, the cells were 
challenged with MG132 (20 µM) for 6 h. The cell lysates were subjected to 
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CRY1 is involved in MDM2-mediated FOXO1 degradation 
 Among several ubiquitin E3 ligases of the FOXO1 protein (Fu et al., 2009; 
Kato et al., 2008), I found that the MDM2 ubiquitin E3 ligase was involved in the 
CRY1-mediated FOXO1 degradation. As shown in Figure 32A, MDM2 suppression 
markedly rescued the level of the FOXO1 protein in CRY1-overexpressing cells, 
implying that MDM2 may participate in the CRY1-dependent FOXO1 reduction. To 
study the role of CRY1 in MDM2-mediated FOXO1 degradation, I tested whether 
CRY1 might regulate the subcellular localization of MDM2. Wild type CRY1 and 
cytosolic CRY1 (∆NLS-CRY1) did not change the subcellular location of the nuclear 
MDM2 (Figure 32B). However, I revealed that CRY1 potentiates the association 
between FOXO1 and MDM2 (Figure 32C). 
 In another experiment, I explored if CRY1 could modulate MDM2-mediated 
FOXO1 degradation. As shown in Figure 33A and 33B, CRY1 overexpression 
promoted MDM2-mediated poly-ubiquitination of the nuclear form of FOXO1 
protein (Figure 33A), whereas CRY1 suppression attenuated FOXO1 poly-
ubiquitination by MDM2 (Figure 33B). These data indicate that CRY1 would 
participate in MDM2-induced FOXO1 degradation and repress FOXO1-mediated 








Figure 32. CRY1 represses FOXO1 protein through intensifying MDM2 and 
FOXO1 binding.  
(A) Mouse primary hepatocytes were infected with Ad-Mock or Ad-CRY1 and/or 
siCON or siMDM2. Total cell lysates were analyzed by western blotting with 
indicated antibodies. (B) HEK293T cells were transfected with FLAG-MDM2 with 
GFP-WT CRY1 or GFP-cytosolic CRY1 (∆NLS CRY1) and immunocytochemical 
analysis of FLAG-MDM2 and GFP was carried out. DAPI, 4’,6-diamidino-2-
phenylindole.(C) HEK293T cells were transfected with FLAG-MDM2, nFOXO1-
MYC, and GFP-CRY1 expression vectors. Total cell lysates were subjected to co-
immunoprecipitation with an anti-MYC antibody followed by western blotting with 
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Figure 33. CRY1 is involved in MDM2-mediated FOXO1 ubiquitination  
(A) COS-1 cells were co-transfected with plasmids encoding nFOXO1-MYC, 
FLAG-MDM2, FLAG-CRY1, and Ubiquitin-HA. After transfection, the cells were 
challenged with MG132 (20 µM) for 6 h. Cell lysates underwent 
immunoprecipitation with an anti-MYC antibody. IP, immunoprecipitation (B) COS-
1 cells were co-transfected with plasmids encoding nFOXO1-MYC, FLAG-MDM2, 
Ubiquitin-HA, and siCRY1. Cells were treated with MG132 (20 µM) for 6 h. Cell 
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CRY1 mitigates hyperglycemia in db/db mice 
 In the liver of obese animals such as db/db and DIO (diet-induced-obesity) 
mice, SREBP1c level is elevated while hepatic gluconeogenesis is not repressed 
(Beaven et al., 2013; Han et al., 2015; Kakuma et al., 2000; Yoon et al., 2010). To 
explore which process(es) might be dysregulated in the regulation of hepatic 
gluconeogenesis, I have examined mRNA and protein levels for SREBP1c-CRY1 
axis and gluconeogenic genes in diabetic animals. Similar to previous reports (Beaven 
et al., 2013; Han et al., 2015; Kakuma et al., 2000; Yoon et al., 2010), the mRNA 
levels of SREBP1c and gluconeogenic genes were elevated in db/db mice (Figure 
34A, 34B). However, hepatic CRY1 protein was greatly decreased in db/db mice 
(Figure 34B). Similarly, DIO mice exhibited elevated SREBP1c and gluconeogenic 
genes whereas CRY1 was not activated (Figure 34C, 34D). To test the idea that 
dysregulated CRY1 protein might mediate hyperglycemia with enhanced FOXO1 
protein in diabetic animals, CRY1 was adenovirally overexpressed in the liver of 
db/db mice. As shown in Figure 35A, the level of blood glucose was decreased by 
CRY1 overexpression. Moreover, ectopic CRY1 expression reduced the levels of 
FOXO1 protein as well as gluconeogenic gene expression in db/db mice (Figure 35B, 
35C). These results propose that CRY1 could ameliorate hyperglycemia by repressing 







Figure 34. SREBP1c is activated while CRY1 is not elevated in db/db and DIO 
mice.  
(A, and B) Ten-week-old male db/+ and db/db mice were sacrificed in fed states at 
ZT3. The relative mRNA levels of various hepatic genes (A) were determined by 
qRT-PCR analyses and normalized to the TBP mRNA level. Data are represented as 
mean ±SD, N=4 for each group. *P < 0.05 versus db/+ group. (Student’s t-test). 
Protein levels (B) were determined with western blotting. (C and D) Eight-week-old 
C57BL/6 mice were fed a NCD or HFD for 8 weeks. Hepatic gene expression levels 
(D) were determined by qRT-PCR and normalized by the level of the TBP mRNA. 


















Figure 35. CRY1 alleviates gluconeogenesis in db/db mice 
(A, B, and C) Ten-week-old male db/db mice were infected through the tail vein with 
adenovirus encoding GFP or CRY1 (adenoviral dose of 2 × 1010 viral particles per 
mouse). The blood glucose levels (A) were measured in ad libitum at ZT3. After all 
of the mice were sacrificed at ZT3, hepatic protein levels (B) were analyzed by 
western blotting, and the relative mRNA levels (C) were determined by qRT-PCR 
analyses and normalized to the TBP mRNA level. Data are represented as mean ±SD, 























 As a major anabolic hormone, insulin stimulates lipogenesis and represses 
gluconeogenesis in the liver. Following insulin exposure, lipogenesis is upregulated 
by SREBP1c, and the expression of SREBP1c target genes such as FASN, SCD and 
ELOVL6 is thus induced (Chu et al., 2013; Kim et al., 1998a; Ponugoti et al., 2010). 
In contrast, insulin blocks hepatic gluconeogenesis through AKT-mediated 
phosphorylation of FOXO1 and PGC1α (Gross et al., 2008; Li et al., 2007), both are 
major regulators of gluconeogenic genes including PEPCK and G6Pase. Here, I 
propose that the SREBP1c-CRY1 signaling pathway plays an important role to inhibit 
hepatic gluconeogenesis under anabolic state. Accumulating evidences from hepatic 
gluconeogenic gene expression, in vitro glucose output assays, time kinetics of insulin 
signaling cascades, and pyruvate tolerance test, which reflects both hepatic glucose 
output and peripheral glucose disposal, have consistently suggested the idea that 
maintenance of SREBP1c-induced CRY1 is crucial to prevent unnecessary hepatic 
gluconeogenesis during insulin action. In this regard, it has been reported that single 
nucleotide polymorphisms (SNPs) of SREBP1c and CRY1 genes are associated with 
hyperglycemia in human (Harding et al., 2006; Kelly et al., 2012). 
Similar to previous reports (Beaven et al., 2013; Han et al., 2015; Kakuma 
et al., 2000), the expression of SREBP1c and gluconeogenic genes was increased in 
the liver of diabetic db/db mice (Figure 34A, 34B, 34C). Unexpectedly, the level of 
hepatic CRY1 protein was reduced in db/db mice. In this work, I have demonstrated 
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that ectopic overexpression of CRY1 in db/db mice alleviated hepatic 
gluconeogenesis by reducing FOXO1 protein (Figure 35A, 35B, 35C). Moreover, I 
have shown that hepatic CRY1 could attenuate blood glucose level by decreasing 
FOXO1 protein, independent of AKT activity (Figure 30A, 30B, 30C, 30D). 
Although it remains to be elucidated how elevated SREBP1c fails to increase CRY1 
in the liver of db/db mice, it is very likely that increased FOXO1 protein might be 
resulted from reduced hepatic CRY1 protein in db/db mice.  
It has been reported that CRY1 seems to suppress hepatic glucose production 
through interfering glucagon signaling (Hirota et al., 2012; Zhang et al., 2010). CRY1 
interacts with GR (Lamia et al., 2011) and the α subunit of the glucagon receptor 
(Zhang et al., 2010), which are involved in the regulation of gluconeogenesis. 
Nonetheless, specific roles of CRY1 during the nutrient-rich state after exposure to 
insulin have not been clearly elucidated. To explore whether CRY1 might repress 
gluconeogenesis by inhibiting glucagon signaling, CRY1-overexpressing primary 
hepatocytes were treated with forskolin or db-cAMP to mimic the stimulation of 
glucagon signaling pathways. In primary hepatocytes, CRY1 partially repressed 
gluconeogenic gene expression in the presence of forskolin or db-cAMP (Figure 36A, 
36B), implying that in addition to the glucagon signaling pathway there may be 
another signaling cascade, regulated by CRY1, which suppresses hepatic glucose 
production. Thus, CRY1 is appears to be involved in multiple regulatory pathways 







Figure 36. Gluconeogenic gene expression is partially attenuated by CRY1 
overexpression upon incubation with forskolin and db-cAMP  
(A and B) Mouse primary hepatocytes were adenovirally infected with Ad-Mock or 
Ad-CRY1. The cells were treated with 10 µM forskolin (A), 5 µM db-cAMP (B), or 
vehicle (CON) for 4 h. PEPCK and G6Pase mRNA levels were determined using 
qRT-PCR and normalized to the level of the TBP mRNA. The values represent the 



















Activation of FOXO1-mediated gluconeogenesis is inhibited by insulin. 
AKT, a key downstream molecule of the insulin-activated signaling, phosphorylates 
FOXO1, which then is translocated from the nucleus to the cytoplasm through its 
association with the 14-3-3 protein (Zhao et al., 2004). In primary hepatocytes, 
FOXO1 phosphorylation was rapidly increased by insulin. However, hepatic 
gluconeogenic programing is persistently and efficiently suppressed regardless of the 
decreased FOXO1 phosphorylation at the late stage of insulin action. Intriguingly, 
hepatic CRY1 expression was enhanced at relatively late periods of insulin action 
(Figure 28A, 28B). Furthermore, in primary hepatocytes, a long-term insulin 
treatment downregulated FOXO1 expression, while suppression of CRY1 rescued 
FOXO1 protein levels as well as gluconeogenic gene expression (Figure 29A, 29B). 
It is noteworthy that CRY1 overexpressing mice showed a decrease of blood glucose 
level as well as of FOXO1 protein when AKT activity was pharmacologically 
repressed with AKT inhibitor MK2206 (Figure 30A, 30B, 30C, 30D). Collectively, 
our in vitro and in vivo data suggest that the CRY1-dependent FOXO1 degradation 
would be one of crucial mechanisms to attenuate hepatic gluconeogenesis for the 
long-term insulin action. Therefore, these observations prompted us to propose that 
the AKT-mediated FOXO1 phosphorylation provides an acute response during early 
insulin response, whereas SREBP1c-mediated CRY1 regulation would be a more 
durable process leading to the repression of futile hepatic gluconeogenesis throughout 
the anabolic state. 
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CRY1 is one of the key proteins in the circadian negative feedback loop. I 
observed that CRY1 levels were regulated by insulin and SREBP1c in vivo and in 
vitro. Given that hepatic circadian clock gene expression is altered in the STZ-
injected insulin-deficient rats (Yamajuku et al., 2012), I investigated circadian clock 
gene oscillations in the liver of SREBP1c+/+ and SREBP1c-/-. As shown in Figure 37, 
I did not observed any significant differences in hepatic circadian clock gene 
oscillations between SREBP1c+/+ and SREBP1c-/- mice, implying that insulin-
activated SREBP1c could stimulate CRY1 gene expression in liver, probably, 
independent of circadian clock gene oscillations. Also, I cannot exclude the 
possibility that SREBP1c-induced CRY1 might contribute to minor roles for hepatic 
circadian oscillation in SREBP1c-/- mice because it has been reported that CRY1-/- 
mice exhibit fewer changes in circadian oscillations compared to CRY1-/-CRY2-
/- double mutant mice (van der Horst et al., 1999). Furthermore, it is possible that 
remaining SREBP1a and/or SREBP2 activity in SREBP1c-/- mice might maintain 
intact circadian clock gene oscillations and this homeostatic regulation needs to be 
addressed in future studies (Im et al., 2009; Liang et al., 2002). Nonetheless, hepatic 
CRY1 gene expression is clearly upregulated by SREBP1c in the postprandial 
condition. 
  As SREBP1c could simultaneously regulate both gluconeogenesis and 
lipogenesis, it is plausible to suggest that hepatic SREBP1c would effectively 








Figure 37. Expression profiles of various genes in the liver of SREBP1c+/+ and 
SREBP1c-/- mice   
Livers were isolated every 6 h from SREBP1c+/+ and SREBP1c-/- mice fed with 
normal chow diet and kept under 12 h: dark, 12 h: dark cycle for 1 week. Relative 
mRNA levels were determined by qRT-PCR and normalized by the level of the TBP 

















downregulating glucose metabolism upon insulin signaling with different target genes. 
Our study is the first report to reveal the role of SREBP1c in CRY1 activation, which 
appears to be crucial in the regulation of hepatic glucose metabolism in the anabolic 
state. Based on the circadian oscillatory gene expression profile in SREBP1c-/- mice, 
the SREBP1c protein may not actively govern hepatic circadian clock. However, 
increased expression of hepatic CRY1 during the postprandial state is primarily 
regulated by the insulin-activated SREBP1c, which eventually leads to the 
suppression of glucose production via FOXO1 degradation (Figure 38). Although the 
roles of hepatic CRY1 in energy metabolism need to be investigated further, our data 
provide an important clue to understand the molecular mechanisms that link hepatic 





































Conclusion and perspectives 
1. Altering the hepatic circadian clock gene by feeding period restriction is 
associated with hepatic lipid and glucose metabolism, but not with body weight 
change  
The harmony of the peripheral circadian clock and the central circadian 
clock is involved in diverse metabolic homeostasis. Therefore, it is likely that 
dysregulated circadian clocks are closely linked with metabolic disorders such as 
diabetes, obesity and cardiovascular disease. The central circadian clock is regulated 
by light signal whereas the peripheral circadian clock is controlled by food intake and 
diverse hormones. Interestingly, it has been reported that shift workers are prone to 
have high body mass index and cardiovascular events, indicating that unsynchronized 
circadian clock might participate in metabolic dysregulation (Aronoff et al., 2001; 
Colles et al., 2007; Tholin et al., 2009). In this aspects, it has been proposed that 
circadian clock regulation might be a potential therapeutic approach to cure for 
obesity or metabolic disorders. 
As the prevalence of obesity continues to rise, its contribution to mortality 
increases. In particular, obesity-induced insulin resistance is one of the key factors 
for the development of metabolic diseases such as hypertension, atherosclerosis, and 
type 2 diabetes. The primary causes of obesity is simply expressed by higher energy 
intake compared to energy expenditure. To solve the relationship with 
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unsynchronized circadian clock and obesity, I analyzed two experimental groups that 
have equal amounts of energy intake with different circadian clock regulation by 
feeding period restriction.   
In chapter 1, I have demonstrated that an unsynchronized circadian clock 
with the same amounts of energy intake had no effects on body weight change. 
Because rodents, including experimental mice, are nocturnal animals who consume 
more food in night time than day time, I have provided the night time feeding group 
with the equal amounts of food as the day time feeding group. Compared to the ad 
libitum group, the day time feeding and night time feeding group are offered restricted 
calorie intake with both NCD and HFD. Intriguingly, obtained data reveal that the 
same amounts of food intake with different feeding periods do not affect the body 
weight change regardless of NCD or HFD.  
I also found out that lipid and glucose metabolisms were altered in liver upon 
feeding period restriction. The expression patterns of certain genes belonging to 
hepatic lipogenesis, gluconeogenesis, and lipid oxidation were influenced by feeding 
period alteration. Moreover, the levels of serum triacylglyceride, cholesterol, and 
glucose were changed, indicating that alteration of peripheral circadian clock genes 
is important for metabolic regulation. Although the mechanisms of how peripheral 
circadian clocks could regulate metabolic change are still to be elucidated, the results 
from chapter 1 is important for understanding the relationship between circadian 




2. Hepatic SREBP1c is a mediator of feeding dependent CRY1 gene alteration 
Accumulating evidences have suggested that key metabolic regulators are 
involved in the modulation of circadian clock gene expression. For example, PPARγ 
and its coactivator PGC1α activate BMAL1 transcription and regulate circadian 
oscillation (Lamia et al., 2009; Schmutz et al., 2010; Wang et al., 2008a). Moreover, 
RORα and Rev-erbα directly and inversely regulates BMAL1 gene expression to 
maintain circadian oscillation (Raspe et al., 2002; Tini et al., 1995). However, it has 
not been fully understood whether and how feeding or nutrient rich states might 
control circadian clock core genes in peripheral tissues.  
In chapter two, I have shown that SREBP1c activates CRY1 gene expression. 
SREBP1c is expressed in a precursor form, which is bound to the ER membrane. 
Under insulin signaling, SREBP1c precursor is processed by site 1 protease and site 
2 protease, and the truncated SREBP1c is located to the nucleus to activate its target 
gene such as FASN, SCD1 and itself. Further, SREBP1c is post-translationally 
activated with feeding signals accompanied with hormonal changes. CRY1 promoter 
contains both SRE motif and E-BOX motif which are binding motifs of SREBP1c. 
Also, E-box motif is a target element of BMAL1 and CLOCK heterodimer, which are 
the core regulators of circadian clock oscillation (Ramsey et al., 2007). I have 
demonstrated that SREBP1c stimulates CRY1 gene expression through SRE 
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sequence(s), not E-BOX motif. Luciferase assays performed with WT, 3XSRE 
mutants, and E-BOX have suggested that SRE sequences in the CRY1 promoter are 
target sites of SREBP1c. Because SREBP1c may not compete with BMAL1 and 
CLOCK at the E-box motif of CRY1 promoter, it appears that SREBP1c might have 
a little effects on circadian clock gene oscillation (Figure 37).   
 
3. SREBP1c-CRY1 axis participates in inhibition of gluconeogenesis in 
postprandial state 
SREBP1c is a well-known transcription activator that regulates lipid 
biosynthetic pathway in postprandial states. Recent data have also suggested that 
SREBP1c might participate in the suppression of hepatic gluconeogenesis (Lee et al., 
2007; Yamamoto et al., 2004). As a transcriptional activator, SREBP1c directly 
regulates lipogenesis by binding to target gene promoters. However, the molecular 
mechanism by which transcriptional activator SREBP1c may suppress gluconeogenic 
genes are not fully elucidated.  
In chapter two, I have revealed a novel signaling cascades of SREBP1c to 
mediate inhibition of hepatic gluconeogenesis. In liver, feeding or insulin mediated 
CRY1 activation by SREBP1c leads to degradation of FOXO1 protein, which is a 
crucial activator of hepatic gluconeogenesis. In primary hepatocytes, overexpression 
of SREBP1c downregulated glucose output and lowers PEPCK and G6Pase gene 
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expression. Overexpression of CRY1, as a novel target gene of SREBP1c, also 
repressed gluconeogenesis, whereas knock down of CRY1 led to increase in 
gluconeogenic gene expression. Among various signaling cascades that regulate 
gluconeogenesis, FOXO1 was regulated by CRY1. I have shown that CRY1 would 
act as a scaffold protein by binding with FOXO1 and MDM2 Ubiquitin E3 ligase 
MDM2 mediated FOXO1 ubiquitination, accompanied with FOXO1 protein 
degradation in liver. In addition, SREBP1c KO mice showed higher levels of blood 
glucose, and FOXO1 protein, compared to those of WT mice. Furthermore, CRY1 
overexpression in SREBP1c KO mice alleviated pyruvate induced blood glucose 
level. CRY1 KO mice also exhibited increased FOXO1 protein and expression of 
gluconeogenic genes, concomitant with higher blood glucose level.  
FOXO1 is a well-known transcription factor regulated by posttranslational 
modification. Under insulin signaling, insulin activated AKT phosphorylates FOXO1 
protein, which accelerates the translocation of FOXO1 into cytoplasm (Nielsen et al., 
2008; Tzivion et al., 2011; Wang et al., 2006). The key regulatory mechanism of 
insulin mediated suppression of gluconeogenesis has been reported that AKT 
mediated FOXO1 translocation. In this study, I have revealed a novel pathway that 
insulin sustainably suppresses hepatic gluconeogenesis by SREBP1c-CRY1. Insulin 
mediated FOXO1 phosphorylation occurs at an early time point whereas CRY1 is 
induced at the late stage of insulin action. I have discovered that CRY1 plays a key 
role to decrease FOXO1 protein upon insulin. To exclude the possibility that the effect 
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of AKT on FOXO1 phosphorylation, I have used AKT inhibitors. In both in vitro and 
in vivo experiments, AKT inhibitors intensified the stability of FOXO1 protein. In 
contrast, CRY1 overexpression dramatically lowers FOXO1 protein level with or 
without AKT inhibitor, implying that CRY1 would act as an inhibitor of FOXO1, 
independent of AKT activity.   
Although AKT mediated FOXO1 phosphorylation is one of the major 
inhibitory mechanisms of hepatic gluconeogenesis, here, I proposed that SREBP1c 
mediated CRY1 induction would be another crucial signaling pathways that 
participates in the suppression of gluconeogenesis in the postprandial state.  
 
4. Hyperglycemia is exacerbated by dysregulation of hepatic SREBP1c-CRY1 
signaling pathway 
Hepatic insulin signaling activates de novo lipogenesis for storage excess 
energy, and inhibits hepatic gluconeogenesis for maintaining blood glucose level. 
SREBP1c, one of key molecule in insulin signaling pathway, participates in both 
activation of de novo lipogenesis and inhibition of gluconeogenesis. Although 
hepatic SREBP1c activity is increased in obese animals, the inhibitory effect of 
SREBP1c on gluconeogenesis was not observed.  
Here, I found out that SREBP1c was increased in HFD fed mice and db/db 
mice, while CRY1 was not elevated in both obese mice models. To address the 
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question which limited CRY1 might be a cause of hyperglycemia in obesity, I have 
investigated the effects of CRY1 overexpression on glucose metabolism. In db/db 
mice CRY1 overexpression lowered blood glucose level as well as hepatic 
gluconeogenic gene expression, implying that insufficient CRY1 may not be enough 
to block FOXO1 activity for normalizing blood glucose level in obese animals. Of 
course, it is necessary to further investigate why activated SREBP1c fails to increase 
CRY1 gene expression in obese animals. Moreover, it is likely that various 
approaches with CRY1 modulation, including stability control, gene expression 
regulation, chromatin structure modulation, and epigenetic management, will be 
possible as a therapeutic target.  
Hyperglycemia is one of the many characters of obesity and diabetes. 
Lowering the blood glucose level is an important therapeutic approach for diabetes. 
Here, I have suggested that the peripheral circadian clock is important for metabolic 
regulation but not for body weight gain. Although obesity is associated with various 
metabolic complications, it appears that the primary cause of obesity is correlated 
with the amounts of food intake, but not circadian clock mediated metabolic changes. 
I have also elucidated a novel pathway that circadian clock is involved in the 
regulation of hepatic glucose metabolism. Under normal physiological condition, 
SREBP1c-CRY1 mediated FOXO1 degradation contributes to suppress 
gluconeogenesis. During this regulation, SREBP1c stimulated CRY1 expression and 
CRY1 acts as a scaffold protein by binding with MDM2 and FOXO1, leading to 
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FOXO1 degradation. Under pathophysiological conditions such as obesity, SREBP1c 
fails to activate CRY1 gene expression in liver, and as a consequence, 
gluconeogenesis is still highly activated. It is noteworthy that various approaches to 
modulate SREBP1c-CRY1 signaling pathway will give the opportunity for 
overcoming high blood glucose levels. Taken together, the characterization of the 
interaction between peripheral circadian clock and hepatic metabolism would be 
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최근 연구결과에 따르면 밤과 낮의 변화에 따라 발생하는 일주기성
은 개체의 행동 뿐 아니라 분자신호전달에도 중추적인 역할을 담당한다. 
또한, 정교하게 조절되는 일주기성은 몸의 에너지 항상성 유지에도 깊이 
연관되어 있음이 보고되었다. 이러한 측면에서 일주기성이 유지되지 못
하는 경우 포유동물은 비만 및 다양한 대사질환을 유발할 수 있다. 대표
적인 에너지 대사 조직인 지방조직, 근육조직, 간조직의 일주기성은 지방
생합성, 포도당생합성 및 지방 산화 작용 등을 조절한다. 또한, 중추조직
과 말초조직의 일주기성이 일치하지 않는 야간 근로자의 경우 대사질환
이 자주 발생하는 경향이 보고되고 있다. 그러나 일주기성의 생리적 및 
병리적 역할과 체내 에너지 대사조절과의 상호 관계에 대해서는 분자수
준의 연구가 부족한 상황이다.  
본 연구를 통해 중추조직과 말초조직의 일주기성이 일치하지 않을 
경우 간조직의 포도당 및 지방대사는 변화하는 반면 체중에는 영향을 미
치지 않음을 발견하였다. 같은 양의 음식물을 다른 시간대에 섭취하는 
조건에서 말초조직의 일주기성은 섭식 시간에 따라 변화하는 것을 관찰
한 반면, 중추조직의 일주기성은 변하지 않는다는 것을 관찰 할 수 있었
다. 간조직에서 대표적인 일주기성 유전자인 BMAL1, CLOCK, PER2는 
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음식 섭취시간대에 따라 그 발현이 변함을 관찰하였다. 간조직의 지방대
사, 포도당대사, 지방 산화에 연관된 유전자들 또한 음식섭취 시간대의 
변화에 따라 발현양상이 다르게 조절되었다. 이와 같은 현상은 저칼로리 
음식물이나 고칼로리 음식물을 섭취한 야생형 생쥐 모두에서 관찰되었다. 
본 연구를 통하여 체중증가에 있어 음식물 섭취 시간대의 변화는 보다는 
음식물의 섭취량이 핵심적임을 확인할 수 있었다.   
본 학위 논문연구 동안 본인은 음식섭취와 인슐린에 의해 증가되는 
CRY1 유전자가 포도당 생합성을 억제함을 발견하였다. 전사인자인 
SREBP1c는 음식섭취에 의해 활성화되어 간조직에서 지방생합성을 관장
하는데, 간세포의 SREBP1c가 음식섭취에 의해 CRY1의 발현을 증가 시
킴을 발견하였다. 간세포주에 CRY1을 과발현 시켰을 경우 포도당생합성 
유전자인 PEPCK, G6Pase의 발현이 억제되었고, FOXO1의 단백질량이 
감소하였다. 간세포주에서 CRY1은 인슐린을 8시간 이상 처리했을 경우 
증가되었고 이상의 연구를 통하여 CRY1은 인슐린이 지속적으로 포도당
생합성을 억제하는 과정 중 중요한 매개자의 역할을 수행하는 것으로 추
정된다. 흥미롭게도, SREBP1c에 의해 증가된 CRY1은 FOXO1의 단백질 
분해 기전을 촉진시켰으며, FOXO1의 E3 ubiquitin ligase인 MDM2와
의 결합을 강화시키는 Scaffold protein의 역할을 담당할 수 있음을 
발견하였다. 이와 관련하여, 간에서 SREBP1c가 증가되어 있음이 보고된 
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db/db 생쥐와 고지방성식이 유도 비만 생쥐 모델에서 CRY1의 발현이 
동반하여 증가하지 않았으며, 그 결과 포도당생합성이 증가될 수 있음을 
발견하였다. 그러나 db/db 생쥐에 CRY1을 과발현 시킨 경우 혈당을 낮
추는 동시에 간에서 포도당생합성 관련 유전자들의 발현이 억제됨을 관
찰하였다.  
본 연구의 결과들을 종합하여 살펴볼 때, 일주기성 유전자는 간조직
의 에너지대사를 능동적으로 조절하는 것으로 생각된다. 다양한 일주기
성 유전자 가운데 SREBP1c에 의해 증가하는 CRY1은 FOXO1의 단백질 
분해 과정 유도를 통해 간세포 내 포도당생합성 유전자의 발현을 억제할 
수 있다. 또한, 체중 증가는 말초기관의 일주기성 유전자의 발현 변화에 
의한 것이 아니라 섭취한 음식물의 에너지 양에 의해 결정되는 것으로 
추정된다. 그러므로 적절한 SREBP1c-CRY1 신호전달 경로의 조절은 체
내 에너지대사 항상성 유지에 핵심적인 신호전달 경로 중 하나임을 제안
한다. 
주요어: 비만, 당뇨, 일주기성, SREBP1c, CRY1, FOXO1, MDM2, PEPCK, 
G6Pase, 포도당생합성, 인슐린 신호전달경로 
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